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CHAPTER 1 
INTRODUCTION 
 The Center for Disease Control (CDC) HIV/AIDS Surveillance Report 2011 (2013) 
estimates that African Americans, who make up 12-14% of the US population, now account for 
approximately half of the populace living with HIV and half of the upsurge of all new HIV 
diagnoses. Early in the epidemic, relatively few African American (AA) women contracted the 
disease, but today their prevalence rate (40.0 per 100,000) is alarmingly one of the highest of all 
groups. In fact, 64% of all new female infections identified themselves as African American, as 
compared to 17% Caucasian. While among other ethnicities and cultures infection has decreased 
significantly, HIV has been reported as the leading cause of death among AA women ages 25-34 
years, third among those ages 35-44 years, and fourth among ages 45-54 years (CDC, 2008). 
There is no doubt that the disparity of HIV has affected AA women the hardest; HIV-related 
sleep disruption seems to be no different (Hand, Phillips, Sowell, Rojas, & Becker, 2003; Marion 
et al., 2009; Phillips, Sowell, et al., 2005). HIV-related sleep disruption places many AA women 
with HIV disease at risk for exacerbation of existing stressors, having assiduous ramifications on 
their health and wellbeing. 
HIV-related sleep disruption is a well-documented debilitating phenomenon that dates 
back to the earliest clinical reports of HIV infection (Norman, Resnick, et al., 1988). Prevalence 
rates of sleep disruption range from 73 to 100% in those who are HIV-seropositive (Dreher, 
2003; Hand et al., 2003). Individuals experiencing sleep disruption may complain of a greater 
delay in sleep onset, earlier morning awakenings, more frequent arousals during the night, 
reduced total sleep time, unrefreshing sleep, and a decreased feeling of wellbeing upon 
awakening (Edinger et al., 2004; Jean-Louis et al., 2012; Omonuwa, Goforth, Preud’homme, & 
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Krystal, 2009). Such disturbances have been reported early in the infection, during clinical 
latency or the asymptomatic phase of the disease progression (Chen et al., 2012; Robbins, 
Phillips, Dudgeon, & Hand, 2004). The asymptomatic phase is a long chronic period, just after 
an acute seroconversion, when the immune system gradually deteriorates but presents with little 
to no clinical signs and symptoms suspicious of HIV infection or immunocompromise. However, 
due to suspected changes in the central nervous system, sleep disturbances are likely to manifest 
throughout all phases of the disease, progressing to more than just minor aberrations (Hand et al., 
2003; Reid & Dwyer, 2005). In fact, HIV-related sleep disruption has been reported to be of the 
more intense and distressful symptoms of HIV, leading to excessive daytime sleepiness, 
antiretroviral nonadherence, reduced neurocognitive functioning, increased comorbidity, 
untoward effects on one’s quality of life and wellbeing, and eventually increased risk for all-
cause mortality (Hudson, Kirksey, & Holzemer, 2004; Lee et al., 2012; Phillips, Sowell, et al., 
2005; Robbins et al., 2004; Saberi, Neilands, & Johnson, 2011; Vance & Burrage, 2005; Webel 
et al., 2013).  
Just as the course of disease progression in HIV may vary from individual to individual, 
it is expected that HIV-related sleep disruption may also differ. The dynamics of sleep in HIV 
disease are influenced by a myriad of physiological, psychological, and sociological factors 
(Phillips & Skelton, 2001). Antiretroviral medications, notably efavirenz, have been found to 
bear a certain risk for physiological side effects that are disruptive to sleep (Gallego et al., 2004; 
Nunez et al., 2001). And despite some conflicting evidence, CD4+ lymphocyte cell count and 
HIV RNA viral load are explained by researchers to have a great impact on sleep quality, 
especially with the derangement of immune system functioning seen late in the progression of 
the disease (Ferreira & Ceolim, 2012; Lee, Portillo, & Miramontes, 2001; Okocha et al., 2009; 
	  	  
	  
3 
Robbins et al., 2004). Several investigators have focused on various psychological correlates, 
such as feelings of anxiety, stress, and depression, and their negative consequence to sleep 
among those infected (Jean-Louis et al., 2012; Marion et al., 2009; Mock, Phillips, & Sowell, 
2002). Meanwhile, others have demonstrated differential effects of social engagement, such as 
social support on HIV-related sleep disturbance (Friedman et al., 2005; Vosvick et al., 2004). 
Remarkably, perceived social support has even been implicated in affecting one’s ability to self-
estimate sleep efficiency (Jackowska, Dockray, Hendrickx, & Steptoe, 2011).  
 Reports of distorted sleep physiology in response to HIV infection date back to the late 
1980’s (Darko et al., 1992; Norman & Chediak, 1992; Norman, Nay, & Cohn, 1988; 
Rothenberg, Zozula, Funesti, & McAuliffe, 1990). The HIV-diseased biological processes of the 
central nervous system (CNS) were postulated to cause the alterations in sleep architecture, even 
before HIV-immunosuppression could be detected (Norman, Shaukat, Nay, Cohn, & Resnick, 
1987). The CNS involvement manifested as anomalies in the NREM/REM sleep periods. The 
most salient of these findings was a significant increase in NREM slow wave sleep (SWS), 
which extended late into the second half of the night, when normally it predominates in the first 
few hours of sleep and then tapers rapidly (Norman, Chediak, Kiel, & Cohn, 1990; Norman, 
Demirozu, & Chediak, 1990; Norman, Resnick, et al., 1988; White et al., 1995). Cytokine 
dysregulation, a direct physiologic effect of the HIV virus, has gained a recent spotlight as a 
major contributor to the disruption of sleep generation and sleep patterns (Foster et al., 2008). 
The HIV envelope glycoproteins and infected immune cells were found to induce altered 
secretion of various inflammatory cytokines, such as IL-1, TNF-α, & IL-6 (Gemma & Opp, 
1999; Opp et al., 1996), which are known for their influence in the initiating, maintaining, and 
ending of sleep (Chrousos, 1995). The resulting cytokine imbalance (dysregulation) has been 
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highly correlated with the subjective complaints related to these pathophysiologic aberrations of 
sleep parameters (Norman, Chediak, Kiel, & Cohn, 1990; Norman, Chediak, Kiel, Gazeroglu, et 
al., 1990; Norman, Resnick, et al., 1988; Vgontzas et al., 1999).  
 As the scientific trends evolved, studies noted interleukin-6 (IL-6), a putative ‘sleep 
factor’, as elemental in sleep research given its apparent relation with sleep quality and its 
association with disorders of excessive daytime sleepiness (Bovbjerg, 2003; Morrow & Opp, 
2005; Vgontzas & Chrousos, 2002; Vgontzas et al., 2005). IL-6 is an inflammatory cytokine 
ranging from 2-29 pg/mL and exhibiting a biphasic circadian pattern, having two nadirs (8am 
and 9pm) and two zeniths (about 7pm and 5am, Burgos et al., 2006; Vgontzas et al., 1999). 
Nevertheless, daytime IL-6 levels are sensitive, inversely influenced by the quantity and quality 
of the previous night’s sleep (Irwin, 2002; Mills et al., 2007; Vgnotzas, Zoumakis, et al., 2002). 
Generally, lower IL-6 levels are associated with better sleep and a good sense of wellbeing the 
next day, and higher IL-6 levels are associated with poor or disrupted sleep and an increase in 
SWS the second half of the next night (Vgontzas & Chrousos, 2002; Vgontzas et al., 2003). Data 
from studies on disorders of excessive daytime sleepiness, exogenous administration, and 
experimentally induced hypersecretion of IL-6 (via sleep-deprivation) concurrently reflect its 
homeostatic drive for sleep and its direct action on CNS sleep mechanisms (Friedman et al., 
2005; Mills et al., 2007; Vgontzas et al., 2005). Therefore, the dramatic increase in IL-6 levels 
seen in past HIV studies appropriately fits amid the complaints of poor sleep and the CNS-
related alterations in sleep architecture (Breen et al., 1990; Honda et al., 1990).  
 IL-6 is also known as a pleiotropic cytokine with its wide variety of biological effects 
causing ‘sickness manifestations’ that may also affect sleep, including symptoms of anorexia, 
fatigue, somnolence, fever, malaise, listlessness, and hyperalgesia to name a few (Breen et al., 
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1990; Chrousos, 1995; Vgontzas et al., 1999; Vollmer-Conna et al., 2004). Average IL-6 plasma 
levels correspond with overall health outcomes and general wellbeing; with inflammatory 
conditions, immune-related diseases, and chronic pain syndromes negatively influencing its 
overall secretion (Friedman et al., 2005; Vgontzas et al., 2003). Prolonged dysregulation or shifts 
in the IL-6 circadian rhythm are consistent with reports of increased morbidity and mortality 
(Bovbjerg, 2003; Mills et al., 2007). Consequently, daytime dysfunction, viral replication, and 
inappropriate apoptosis seen in HIV is congruent with data suggesting that IL-6 is a highly 
valuable predictor of morbidity and mortality in HIV disease (Fumaz et al., 2012; Míguez, 
Rosenberg, Burbano-Levy, Carmona, & Malow, 2012). 
Research has played a vital role in the formation of treatment modalities for HIV. HIV 
care has evolved from an acute medically-based treatment model to a more holistic chronic-
illness approach, which demands investigations into the integrative factors which influence the 
promotion of health, quality of life, and wellbeing (Mock et al., 2002). The World Health 
Organization (WHO) defined health as “a state of complete physical, mental, and social 
wellbeing and not merely the absence of disease or infirmity” (http://www.who.int/about/ 
definition/en/print.html). Quality of life is a broad concept often used to portray all aspects of an 
individual’s wellbeing. It has also been described as a dynamic, multidimensional reflection of 
the internal satisfaction or happiness with how life is going compared to some aplombed 
conjecture of how life should be (Cella & Tulsky, 1990; Lutgendorf, Antoni, Schneiderman, & 
Fletcher, 1994). Thus, quality of life is the degree to which an individual perceives that life is 
worth living. Within the past decade, the measurement of quality of life has grown in recognition 
as a critical outcome measure in research, used to determine whether or not an individual is 
living better not just longer (Hays et al., 2000). This becomes particularly relevant when 
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assessing the burden incurred from chronic illnesses, especially those with a debilitating course 
and aggressive treatment modalities, such as HIV. HIV is a chronic disease haunted by an 
uncertain trajectory of life-threatening physical decline, a lifestyle full of stigma and redress, and 
an ever increasing reliance on healthcare services and medical adeptness (Lutendorf et al., 1994). 
Such burdens tend to challenge every aspect of an individual’s life and wellbeing. So, whether it 
is viewed from the looking-glass of a philosopher captivated in the nature of human existence 
(Faden & LePlège, 1992), an ethicist concerned for the sanctity of life and social utility (Edlund 
& Tancredi, 1985), an economist interested in the efficient allocation of resources needed to 
achieve goals (Grabowski & Hansen, 1990), a physician focused on disease–related variables 
(Pearlman & Uhlmann, 1988), or a nurse keeping in a holistic approach (Ferrans, 1990), quality 
of life has established priority in HIV care and remains a key element in HIV research (Phillips, 
Mock, Bopp, Dudgeon, & Hand, 2006).  
An association between sleep quality and quality of life was found in HIV-seropositive 
African American women, when “good” sleepers reported significantly higher levels of quality 
of life (Phillips, Sowell, et al., 2005). Sleep, which was originally depicted as a passive, dormant 
part of our daily life, has since been recognized as a very active and dynamic time of growth, 
healing, and rejuvenation for many body systems (National Institute of Neurological Disorders 
and Stroke [NINDS], 2007; Wilson; 2010).  In fact, chronic disruptions in this time of healing 
and rejuvenation are now recognized as major risk factors for all-cause mortality (Alvarez & 
Ayas, 2004, Reid & Dwyer, 2005, Webel et al., 2013). Therefore, sleep should not be perceived 
as a luxury, but as a basic need that must be satisfied in order to lead an optimal, healthy, and 
productive life (Alvarez & Ayas, 2004; Edéll-Gustafsson & Ek, 1992). As such, health 
maintenance is consistent with the science of nursing; it creates a great opportunity for nurse 
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researchers to explore the interplay of biophysical research on the nature of sleep, health, and 
wellness. 
Statement of Problem 
 With the demographical shifts, African American women of childbearing age have now 
emerged as one of the fastest growing HIV populations today, and confirmed that HIV exhibits 
differential patterns of influence on different groups of people. Despite the gender and racial 
differences known to influence the hormonal and metabolic effects of HIV and HIV treatments 
(Cargill & Stone, 2005), surprisingly, this relevant group (AA women) remains a vulnerable and 
underrepresented population in the sleep literature. With no published works found to describe 
objective assessments of sleep parameters and relatively few subjective assessments, sleep 
researchers have only an elusive idea of what HIV-related sleep disruption looks like specific to 
HIV-seropositive AA women. With sparse data, development of sleep-related treatment 
modalities specific to the needs of young minority women becomes a guessing game; incoherent, 
unfounded in research, and lacking a scientific foundational base. Additionally, with the majority 
of the research still focusing primarily on men, there remains paucity as to the various impacts of 
HIV-related sleep disruption on AA women’s wellbeing. 
Statement of Purpose 
The purpose of this pilot study was to examine the dynamics of HIV-related sleep 
disruption and wellbeing in asymptomatic HIV-seropositive AA women of childbearing age 
within the context of a holistic, theoretical substruction from Myra Levine’s Conservation Model 
(1967). The rationale for the proposed study was to provide a foundation of both the objective 
and subjective experience of HIV-related sleep disruption, which as a stressor can affect 
wellbeing in HIV-seropositive AA women.  
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Specific Aims and Research Questions 
The specific aims and research questions in this study are as follows: 
Specific Aim 1: To describe sleep homeodynamics of HIV-related sleep disruption in 
asymptomatic HIV-seropositive African American women of childbearing age, as evidenced by 
sleep/wake rhythm, sleep quality, daytime sleepiness, and interleukin-6 rhythm. 
Research Question 1(A): What are the characteristics of the sleep/wake rhythm, as 
measured by actigraphic estimates of sleep/wake minutes, sleep/wake episodes, minutes 
before sleep onset, sleep percentage, sleep efficiency, sleep fragmentation index, activity 
mean, activity index, and acceleration index? 
Research Question 1(B): What is the perception of sleep quality, as measured by the 
Pittsburgh Sleep Quality Index (PSQI) and the Subjective Sleep Quality Questionnaire 
(SSQ)? 
Research Question 1(C): What is the perception of daytime sleepiness, as measured by 
the Epworth Sleepiness Scale (ESS) and the Stanford Sleepiness Scale (SSS)? 
Research Question 1(D): What are the characteristics of the interleukin-6 rhythm, as 
measured by four time-specific plasma interleukin-6 levels? 
Specific Aim 2: To describe wellbeing in asymptomatic HIV-seropositive African American 
women of childbearing age experiencing HIV-related sleep disruption, as evidenced by quality 
of life. 
Research Question 2: What is the perception of quality of life, as measured by the 
Quality of Life Index (QLI) and the Quality of Life Visual Analogue Scale (VAS-Q)? 
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Specific Aim 3: To determine the relationship between variables of sleep homeodynamics and 
wellbeing in asymptomatic HIV-seropositive African American women of childbearing age 
experiencing HIV-related sleep disruption. 
Research Question 3(A): What is the strength and direction of the correlation between the 
sleep/wake rhythm and wellbeing, as measured by sleep efficiency and the Quality of 
Life Visual Analogue Scale (VAS-Q)?  
Research Question 3(B): What is the strength and direction of the correlation between 
sleep quality and wellbeing, as measured by the Subjective Sleep Quality Questionnaire 
(SSQ) and the Quality of Life Visual Analogue Scale (VAS-Q)?    
Research Question 3(C): What is the strength and direction of the correlation between 
daytime sleepiness and wellbeing, as measured by the Stanford Sleepiness Scale (SSS) 
and the Quality of Life Visual Analogue Scale (VAS-Q)?   
Research Question 3(D): What is the strength and direction of the correlation between the 
interleukin-6 rhythm and wellbeing, as measured by the average interleukin-6 level and 
the Quality of Life Visual Analogue Scale (VAS-Q)?   
Specific Aim 4: To determine the agreement between the quality of life measurements in 
asymptomatic HIV-seropositive African American women of childbearing age experiencing 
HIV-related sleep disruption. 
Research Question 4: What is the agreement between the Quality of Life Index (QLI) and 
the Quality of Life Visual Analogue Scale (VAS-Q)? 
Significance 
One of the major challenges in HIV care, besides viral suppression, is effective symptom 
management in order to maintain an optimal state of health and quality of life (Hudson et al., 
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2004). Although many acquiesce to the significance of this phenomenon, there remains no 
standard criterion for the diagnosis or management of HIV-related sleep disruption. In fact, a 
recent study demonstrated the significant impact of underdiagnosed HIV-related sleep disorders 
on quality of life and daytime functioning (Gamaldo et al., 2013). Despite the growing body of 
sleep literature considering IL-6, as a biological marker of health and wellbeing (Friedman et al., 
2005), the connection with IL-6 remains scarce in the HIV-related sleep research literature. 
Elevated IL-6 plasma levels have undoubtedly been seen in HIV infection, with HIV envelope 
glycoproteins and infected monocytes being the primary source of HIV-induced IL-6 
hypersecretion (Breen et al., 1990; Honda et al., 1990). By considering IL-6 as a common link 
between HIV-related sleep disruption, progression of disease, and quality of life, this pilot study 
will contribute substantially to mainstream biobehavioral research by describing a key biological 
measure inherent in the nature of health and wellbeing seen in HIV disease. Such inquiry 
responds to the growing interest into the many facets that may prevent or delay the damaging 
nature of HIV infection, and to the call for integrative studies that combine influences on health 
across multiple domains. 
HIV-sleep literature has followed a gender and ethnicity trend dictated by the evolution 
of national incidence rates, starting with the classics, whose primary focus was on homosexual 
Caucasian men. As with most chronic diseases of premature mortality, HIV is known to exhibit 
differential patterns of impact across racial/ethnic and gender groups (Míguez et al., 2012). This 
current study wishes to contribute to the progression of the literature by exploring HIV-related 
sleep disruption in one of the most clinically relevant HIV populations today, asymptomatic 
African American women of childbearing age. The Healthy People 2020 public health goals, 
sponsored by the United States Department of Health and Human Services 
	  	  
	  
11 
(http://www.healthypeople.gov/2020/about/), renewed their focus on exploring ways to improve 
quality of life and to eliminate health disparities among divergent segments of the population. 
The 10-year agenda for improving the Nation’s health continues to target HIV as it has done in 
the past, however, several new focus areas have been added, sleep health being one of them. The 
goal to increase the awareness and treatment of poor sleep health, acknowledges sleep as a basic 
requirement and a critical determinant of health and wellbeing. Having emerged as a major 
subgroup and incurred such a disproportionate burden related to HIV infection, each piece of 
research regarding AA women becomes imperative in meeting the goals put forth. 
Characterizing the various features of sleep homeodynamics and wellbeing in HIV-seropositive 
AA women will add a more accurate assessment of sleep health in this population and potential 
clarification to the understanding of the conundrum of group differences found in people at risk 
for negative health outcomes.  
Significance to Nursing 
Nursing’s social mandate is to pursue the enhancement of health, quality of life, and 
wellbeing, and its domain of inquiry should be reflective of its nature of service and social 
accountability (Parse, 2006). Nursing’s holistic nature is found within its unique process, 
manifested by complexity and integration that generates wellbeing through health promotion 
(Reed, 1995). A commitment to the development of nursing knowledge aims to explain the 
relationships between and among concepts specific to nursing, and provide the grounds for 
designing interventions congruent within nursing’s nature (Fawcett, 1991). HIV has been and 
continues to be one of the leading health concerns in today’s society. The noxious insult of HIV-
related sleep disruption, which only serves to exaggerate the progression of disease and ravage 
quality of life, demands further scientific inquiry. The goal is to advance nursing knowledge by 
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providing an extended understanding of the complexity of HIV-related sleep disruption 
experienced by HIV-seropositive AA women. Such inquiry will document key biological 
measures along with various psychosociobehavioral factors to join a growing literature that is 
mapping diverse pathways to be utilized in the formulation of innovative health-promoting 
interventions in this population. 
 Even though early nurse theorists laid the groundwork for the inclusion of sleep research 
in their conceptual frameworks, the literature fails to depict much advancement of nursing 
science in this area (Mornhinweg & Voignier, 1996). A commitment to the development of 
nursing science includes examining explicit exemplars guided by a nursing conceptual 
framework, in order to establish the underlying validity of the framework (Fawcett, 1999; Silva, 
1986). With a program of study that is focused on the advancement of nursing science in the area 
of sleep research through the application and testing of Levine’s Conservation Model, this pilot 
study serves as a preliminary investigation for the utilization of the Conservation Model as an 
organizing framework for examining HIV-related sleep disruption and wellbeing in 
asymptomatic HIV-seropositive AA women.  
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CHAPTER 2 
THEORETICAL FRAMEWORK 
 Myra Levine (1967), developed the Conservation Model as a “generalization of nursing” 
in order to provide the “whys” of nursing activities. Levine characterized the conceptual model, 
more specifically, as an interaction model of the complex relationship between an ever-changing 
person and the ever-changing environment. With a unique focus on conservation or the “keeping 
together” of a person’s wholeness, Levine recognized the process of adaptation as the essential 
component in defining one’s lifecourse, in that it bridges the gap between the person and the 
environment (Levine, 1967, 1969).  
Threats are experienced from the internal and external environments with which the 
person is connected. This can cause perturbation in the homeostasis (static state) and/or 
homeorhesis (stabilized flow) of various systems within the person. Consequently, an adaptation 
process of integrative organismic responses, such as fight or flight, inflammatory or immune, 
stress, and perceptual awareness, is evoked. Conservation is the natural law governing the self-
sustaining conditions and the cascade of adaptive changes initiated by the assiduous 
encroachment of noxious influences, which may arise. Survival depends on the frugal use of 
resources in effort to spare one’s integrity from these life-threatening implications. Making the 
ultimate purpose of conservation; be it conservation of energy, structural integrity, personal 
integrity, and/or social integrity, to defend the system for which it functions. If the person can 
retain integrity while faced with the dynamic exchange of threatening realities of the 
environment, then adaptation is said to be successful. Environmental congruency, integrity, 
health, and wholeness (all of which are used interchangeably) are maintained (Levine, 1969, 
1989, 1991, 1996).  
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Levine presented the Conservation Model to provide a unifying structure for 
understanding the person as an active holistic being with an enduring concern to pursue 
wholeness and integrity. Wholeness is achieved through the life process of adaptation and 
safeguarded by the essence of conservation. Life testifies to the ever-present nature of this 
biological wisdom that seeks, sorts, selects, and acts on behalf of communal wellbeing (Levine, 
1967, 1969, 1971). An initial linear sketch of a scholarly interpretation of this dynamic and fluid 
person-environment interaction has been constructed in Figure 2.1.  
 
 
 
Conceptual Level Concepts 
 Conservation. Levine conceptualized conservation as the “keeping together” function or 
guardian activity over the achievement of adaptation that defends and protects an individual’s 
wholeness. Conservation is a consequence of numerous, synchronized feedback systems which 
interact and enable the adjustment and stabilizing of living organisms. More specifically, 
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conservation is the fundamental biological ability to weigh the resources against the demands 
and allow the body to thrive with the most economic, frugal, and energy-sparing use of resources 
needed for effective functioning. This sparing (conserving) of the individual’s expense, Levine 
described, is of crucial importance to defend, sustain, maintain, define, and reclaim the person’s 
health and wholeness. Conservation is the process of successful adaption; which assumes unity 
and integrity (Levine, 1967, 1989, 1991).  
To Levine, the concept of conservation breaks down into four dimensions, which she 
called “the principles of conservation”. There is conservation of energy, structural integrity, 
personal integrity, and social integrity. Each conservation principle is constant, in that the 
process cannot be turned on and off, and that it begins with birth and does not end until death. 
Each principle may be examined separately in order to focus on discrete issues. However, when 
speaking of the integrity of the whole person, the influences of all four principles must be 
acknowledged (Levine, 1969, 1991). An illustration of Levine’s Conservation Model has been 
constructed at a conceptual level in Figure 2.2.  
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 Energy. Energy is the provenance of life; a life source if you will. For life is dependent 
on the production, exchange, and expenditure of energy. Energy is not directly observable, but 
the consequences of it can be quantified, predicted, and, thus, managed (Levine, 1991, p. 7). The 
resources of energy are finite. When energy is exhausted, so is the ability to adapt. Therefore, 
energy should be spent carefully, with priority given to life-sustaining activities. In other words, 
one’s energy consumption related to body functions, repair, and healing should never outweigh 
one’s energy potential gained from proper rest, nutrition, and exercise. Conservation of energy 
expresses that the use of energy should be only for as long as it is needed. Not limited to minimal 
activity, conservation of energy also means the proper disbursement of energy expense for life to 
flourish. The rationale is a natural defense to maintain sufficient resources necessary for free 
participation in an active life, which is essential to the wholeness of the individual (Levine, 1967, 
1971, 1991).  
 Structural Integrity. Structural integrity refers to the wholeness of a person’s structure 
and function, or the architectural balance which allows the body to move and choose activities 
freely. Structural integrity is maintained and restored by preventing physical breakdown and 
promoting timely repair and healing when needed. If the remarkable design of biological 
structures determines optimum function, then with structural changes comes debilitation or 
restriction of function. Conservation of structural integrity is the body’s defense against the insult 
of environmental hazards, which emphasizes biological priority, as well as, the most economical 
and restorative expense of healing efforts. The rationales behind conservation of structural 
integrity is to minimize the functional tissue that is sacrificed due to trauma or disease and/or 
limit the aberration of the adjacent structures (Levine, 1967, 1971, 1991). 
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Personal Integrity. Personal integrity refers to the wholeness of a person’s self-identity as 
a unique and cherished personhood. The knowledge of such an inner, most-private self conveys 
much more than just physical realities. It conveys an awareness of self-worth, self-respect, being 
intact, independent, and always unique. Realizations of a person’s own self-definition is 
fundamental to the acceptance, confidence, security, and cultivation of self. Loss of personal 
validity can have a tremendous impact on the life experience, for the sense of self is indelibly 
written on every choice. Conservation of personal integrity is the recognition of the value of 
privacy, independence, and the secret knowledge of inner-self, which defines the person. The 
rationale behind conservation of personal integrity is to minimize vulnerability of dependence, 
loss of freedom, and loss of self, all of which only produce anxiety, low self-esteem, and a 
negative influence on every choice a person makes (Levine 1967, 1989, 1991, 1996).  
 Social Integrity. Social Integrity is the wholeness of the person’s interactions as a social 
being, for the essence of humanity is seen in the reflection from others. Each person is affected 
by the dynamics of an interwoven social context, including their family, friends, workplace, 
community, religion, education, culture, and ethnic heritage. Social norms mediate the specific 
interactions, roles, and lifestyles in which the individual chooses to participate. Conservation of 
social integrity involves the recognition of the need for definition of self that extends far beyond 
the individual. The rationale behind conservation of social integrity is that a satisfying and 
fulfilled life depends on the ability to develop behaviors that allow for participation and 
acceptance in many social relationships and settings (Levine, 1967, 1989, 1991, 1996). 
 Wholeness. “Wholeness emphasizes a sound, organic, progressive mutuality between the 
diversified functions and parts within an entirety, the boundaries of which are open and fluid” 
(Erikson, 1968, as cited by Levine, 1996). Wholeness speaks to the universal idea of completion 
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and the longing for unity. Wholeness accounts for the multi-dimensions of the complete and total 
person as a bio-psycho-social-spiritual being. Wholeness, a function of the harmonious 
interaction between the internal environment and the external environment, is what each 
individual cherishes and defends throughout the entire life process. It represents the 
uninterrupted continuity of energy, structural integrity, personal integrity, and social integrity. 
Wholeness is integrity, and infers health, healing, and wellbeing. Because such terms are known 
to stem from the Anglo-Saxon word for “whole”, they are commonly used interchangeably 
within Levine’s writings. Wholeness is maintained and reclaimed through conservation, which is 
a process of successful adaptation (Levine, 1969, 1989, 1991, 1996).  
Substruction of the Theoretical Framework 
 The Sleep Conservation Model represents a vertical descent or a substruction of a less-
abstract form of the Conservation Model described above. The Sleep Conservation Model is the 
theoretical framework or the middle range theory guiding the present study. The components of 
the Sleep Conservation Model include theoretical concepts, theoretical variables, and relational 
propositions.  
Theoretical Level Concepts 
The theoretical concepts of the Sleep Conservation Model represent a vertical descent or 
a substruction of a less-abstract form of the conceptual concepts of the Conservation Model. An 
illustration of the substruction to the theoretical concepts of the Sleep Conservation Model has 
been provided in Figure 2.3. Note, the causal arrow of successful adaptation at the conceptual 
level has been modified to a dotted line in the theoretical model to denote a possible relationship 
between conservation of sleep and wellbeing. The reason for the modification is that there is not 
enough data in this field to establish or test cause and effect. Therefore, the goal of this 
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preliminary project was to provide base-level data toward identifying relationships between the 
study variables. Cause and effect will be tested in future higher-level studies in this program of 
research. 
 
 
 
Conservation of Sleep. Conservation of sleep is the guardian activity required for the 
maintenance and restoration of one’s physical, mental, and emotional wellbeing. Conservation of 
sleep governs over the biological processes of adaptation, in order to achieve the adequate 
quantity and quality of sleep, necessary to defend and protect the individual’s wellbeing. It is a 
consequence of many feedback systems of the hypothalamic-pituitary-adrenal axis, cytokines, 
hormones, and circadian effects allowing for the frugal or energy-sparing adjustments that 
facilitate and stabilize sleep (Vgontzas & Chrousos, 2002). Conservation of sleep allows for the 
sparing of an individual’s expense of sleep homeodynamics, immunological integrity, 
psychological integrity, and relational integrity. This sparing of expense is of crucial importance 
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to defend, sustain, maintain, define, and reclaim the person’s adaptive wellbeing. Conservation 
of sleep is the process of successful adaptation; which assumes wellbeing.  
 Sleep Homeodynamics. Sleep homeodynamics refers to processes, or biofields of change 
or activities, which are in constant interaction with each other, in order to self-regulate the 
energy source sleep. Biofields, such as sleep-wake behaviors and IL-6 production/secretion, 
manifest objective patterns or rhythms from sleep-related energy interactions, which become 
quantifiable measures of sleep energy (Rubik, 2002; Schaefer, 1991). Biofields, such as sleep 
quality and daytime sleepiness, manifest subjective patterns or rhythms from sleep-related 
energy interactions, which also become quantifiable measures of sleep energy. Sleep 
conservation related to sleep homeodynamics is successful adaptation towards achieving sleep 
homeorhesis.  
 Immunological Integrity. Immunological integrity refers to an unimpaired condition or 
free movement through the cascading activities of cells involved in the innate and adaptive 
subdivisions of the immune system. An intact or uninterrupted immune system is essential to the 
body’s defense against the hazards in the environment, and to the healing processes necessary to 
overcome insult and injury (Levine, 1991). Sleep conservation related to immunological integrity 
recognizes the need for adequate sleep to allow the body to rebuild the immune system and 
combat infection effectively, which are indicators of successful adaptation (Bryant, Trinder, & 
Curtis, 2004). 
 Psychological Integrity. Psychological integrity refers to stable or unimpaired cognitive 
evaluation and the well adjustment of ongoing emotional reactions. Alterations or interruptions 
in one’s affect and/or judgment of life satisfaction, compromise the mind’s defense against the 
stressors of life, creating a catalyst for anxiety, stress, and depression (Levine, 1996; Nathawat, 
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1996). Sleep conservation related to psychological integrity recognizes the need for adequate 
sleep to allow for the restoration and rebalancing of emotion and reason, necessary for inner 
peace and a productive lifestyle (Gorman, 2004).  
 Relational Integrity. Relational integrity refers to adequate or unimpaired perception of 
social support gained from both emotional (non-tangible) and instrumental (tangible) support of 
earlier and present-day relationships. Disruption or interference in the consanguinity of 
supportive feedback and/or behaviors from significant relationships affects a person’s sense of 
acceptance, and ultimately, the ability to cope or respond to stress successfully (Sarason & 
Sarason, 1994; Young, 2006). Sleep conservation related to relational integrity recognizes the 
need for adequate sleep to reduce irritability, crankiness, and preventable frustration (NINDS, 
n.d.), all of which are major threats to social interaction and the perception of social support. 
 Wellbeing. Wellbeing is a sense or awareness of the internal feelings of satisfaction or 
dissatisfaction with how life is going. Wellbeing is multidimensional and encompasses aspects 
related to physical, psychological, and social status. Myra Levine (1991) describes wellbeing as 
the end product of successful adaptation. Levine asserts that wellbeing depends on every activity 
respecting the structural wholeness of the individual (1996, p. 10), and the pursuit of health 
offers the promise of wellbeing (p. 3). A “good” sense of wellbeing is what one cherishes and 
strives for throughout life (Levine, 1991). 
Theoretical Level Variables 
Within the theoretical level there is a further descent to measurable theoretical variables, 
which are used to define the theoretical concepts of this study. The theoretical variables are even 
less abstract than the theoretical concepts, and from these variables analyses were done 
according to the study-specific aims. The variables chosen to represent the concepts were based 
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on their significance in the literature; especially those with consequence in both the sleep and 
HIV literature. An illustration of the substruction to the theoretical variables of the Sleep 
Conservation Model has been provided in Figure 2.4. 
  
 
 
Sleep Homeodynamics. The phenomenon known as sleep homeodynamics encompasses 
quantifiable manifestations of multiple processes or biofields of change or activity which are in 
constant interaction with each other, in order to self-regulate sleep. The manifestations of interest 
in this study are expressed as the sleep/wake rhythm, sleep quality, daytime sleepiness, and the 
interleukin-6 (IL-6) rhythm. 
Immunological Integrity. The phenomenon known as immunological integrity 
encompasses quantifiable manifestations of an intact or freely moving system of cascading cells 
involved in the body’s defense against physical hazards of the environment (internal and 
external). The variable set of immunological consequence in this study is expressed as CD4+ 
lymphocyte cell count and HIV RNA viral load. 
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Psychological Integrity. The phenomenon known as psychological integrity encompasses 
quantifiable manifestations of unimpaired cognitive evaluations and the well adjustment of 
ongoing emotional reactions involved in the mind’s defense (ability to cope or respond 
successfully) against the psychological hazards of the environment (stressors of life). The 
variable set of psychological consequence might include variables such as anxiety, stress, 
depression, coping, and hopefulness; nonetheless, this theoretical concept requires further 
development and will not be addressed in this study.  
Relational Integrity. The phenomenon known as relational integrity encompasses 
quantifiable manifestations of adequate or unimpaired emotional (non-tangible) and instrumental 
(tangible) social support of both earlier and present-day relationships that are involved in the 
mind’s defense (sense of acceptance, self-worth, or belonging) against the sociological hazards 
of the environment (social conflicts). The variable set of relational consequence might include 
the variable social support; nonetheless, this theoretical concept requires further development 
and will not be addressed in this study. 
Wellbeing. The phenomenon known as wellbeing encompasses quantifiable 
manifestations of the sense or awareness of the internal feelings of satisfaction or dissatisfaction 
with how life is going compared to some self-actualized idea of how life should be. Wellbeing is 
multidimensional and takes into account the influences of a physical, psychological, social, and 
spiritual nature. In this study, wellbeing is expressed as quality of life.  
Relational Propositions of the Sleep Conservation Model 
The Sleep Conservation Model is also horizontally congruent with Levine’s Conservation 
Model, in that the primary and secondary relational propositions flow from that of the conceptual 
level. Study Proposition: The phenomenon known as conservation of sleep is a process of 
	  	  
	  
24 
adaptation that occurs in effort to maintain and/or restore sleep homeodynamics, immunological 
integrity, psychological integrity, and relational integrity, which assumes wellbeing. 
Primary Relational Proposition. The primary relational proposition of the Sleep 
Conservation Model is a substitutive relationship of three concepts; where if concept X 
(conservation of sleep) occurs, the other concept Y (wellbeing) will occur. However, if some 
similar concept S (successful adaptation) occurs, the second concept Y (wellbeing) also will 
occur. Simply stated as:  
If X, but also if S, then Y. 
 Conservation of sleep or successful adaptation is related to wellbeing.  
Because conservation of sleep influences four very specific concepts: X1 (sleep 
homeodynamics), X2 (immunological integrity), X3 (psychological integrity), and 4X (relational 
integrity), the primary relational proposition can be more specifically stated as: 
 If [X1 + X2 + X3 + X4], but also if S, then Y. 
 Conservation of sleep as it relates to sleep homeodynamics, immunological integrity,  
psychological integrity, and relational integrity or successful adaptation is related to 
wellbeing.  
The concept map of the primary relational proposition of the Sleep Conservation Model is shown 
below in Figure 2.5. 
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Secondary Relational Propositions. The secondary relational propositions of the Sleep 
Conservation Model are symmetrical relationships between the aforementioned four concepts 
influenced by the conservation of sleep: X1 (sleep homeodynamics), X2 (immunological 
integrity), X3 (psychological integrity), and 4X (relational integrity). Simply stated as: 
 X1 is related to X2; and X2 is related to X1 
X2 is related to X3; and X3 is related to X2 
 X3 is related to X4; and X4 is related to X3 
 X1 is related to X3; and X3 is related to X1 
 X1 is related to X4; and X4 is related to X4 
 X2 is related to X4; and X4 is related to X2 
 Sleep homeodynamics, immunological integrity, psychological integrity, and relational  
integrity all have a reciprocal relationship with each other. 
The concept map of the secondary relational propositions of the Sleep Conservation Model is 
shown below in Figure 2.6. 
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Operational Level of the Substruction 
From the theoretical level, there was one final vertical descent or substruction to the 
operational level variables which are the specific instruments used in the measurement of the 
theoretical variables in the present study. An illustration of the substruction to the operational 
level from the Sleep Conservation Model has been substructed in Figure 2.7. The operational 
variables of this study are discussed in detail in the “Study Variables and Measurements” section 
of Chapter 4. Note, the arrangement of the theoretical level concepts and variables in Figure 2.7 
have been modified to help distinguish what was and was not examined in this present study. 
Psychological integrity and relational integrity were grayed out in Figure 2.7, as they were the 
theoretical concepts excluded from this study and require further development that will be 
forthcoming within my program of research. As will the testing of the various relational 
propositions of this model.   
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  Concepts/variables and relationships included in this study are in white and black.         
  Concepts/variables and relationships not included in this study are grayed out. 
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CHAPTER 3 
LITERATURE REVIEW 
The goal of the current study was to extend the understanding of disrupted sleep 
homeodynamics among asymptomatic HIV-seropositive African American women as it relates 
to their immunological integrity and their experience of wellbeing. The following literature 
review provides a systematic overview of the relevant empirical research related to the study 
variables explored: CD4+ cell count, HIV viral load, sleep/wake rhythm, sleep quality, daytime 
sleepiness, interleukin-6 rhythm, and quality of life. 
Study Variables 
CD4+ Cell Count and HIV Viral Load  
HIV infection sets the context for this inquiry, along with the unique challenges and 
vulnerabilities it creates as a result of the derangement of the immune system. HIV disease is a 
continuum of progressive immunologic damage that begins with a chronic asymptomatic state 
and over time evolves to an ever-increasing symptomatic quandary of susceptibility to 
opportunistic infections, neoplasms, wasting, acquired immunodeficiency syndrome (AIDS), and 
eventually death (Osmond, 1998). A deteriorating CD4+ lymphocyte cell count and a 
propagating HIV RNA viral load are indicators of the natural history or progression of the 
disease (Cohen, Ferrans, Vizgirda, Kunkle, & Cloninger, 1996). Because the virus targets and 
kills CD4+ lymphocytes in particular, it has become the hallmark laboratory marker used to 
assess the level of immunosuppression and susceptibility to specific HIV-related conditions (Call 
et al., 2000, Honda et al., 1990; Osmond, 1998; Phillips et al., 1994). Depending on the 
laboratory, normal CD4+ lymphocyte cell counts, also known as T-helper cell counts, range from 
500 cells/mm3 to 1000 cells/mm3. The HIV RNA viral load has also become an important 
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laboratory marker in assessing the extent of viral proliferation, related symptomology, and 
effectiveness of antiviral therapies in controlling viral replication. Since there is no true normal 
range for the virus, the objective of treatment is undetectable levels less than 20 copies/mL, 
depending on the type and sensitivity of the test. In general, the lower the CD4+ cell count and 
the higher the HIV viral load, the more likely an individual is to experience HIV-related 
symptomologies and opportunistic infections (Osmond, 1998). These aversive events, ultimately, 
become disruptive and incompatible with normal restorative sleep profiles (Robbins et al., 2004).  
Numerous historical studies found an inverse relationship between the frequency of sleep 
complaints and CD4+ cell counts, suggesting that sleep disturbances increase as the disease 
progresses and the immune system deteriorates (Brown et al., 1991; Nuñes et al., 2001; Wheatley 
& Smith, 1994; Rothenberg et al., 1990). Funesti and coworkers (1991) found that CD4+ counts 
had an intense relationship with both sleep onset and sleep maintenance problems in 
asymptomatic subjects with sleep complaints. White and colleagues (1995) found a specific 
architectural correlation related to CD4+ counts; uniquely, those with a CD4+ greater than 400 
cells/mm3 demonstrated a significant increase in SWS in the middle and final third of the night, 
along with significantly fewer awakenings during the night when compared to controls. The 
length of time infected and antiviral medications were of no consequence in White’s study. Lee’s 
cohort (2001) duplicated the inverse relationship between CD4+ cell count and the number of 
awakenings throughout the night, but found nothing significant with sleep efficiency or with 
daytime activity in this study. Later, Lee and associates (2012) were able to establish a 
relationship between short sleep (< 6 hours) and lower CD4+ counts. In a pediatric trial, both 
decreasing CD4+ counts and increasing viral loads were associated with increased nocturnal 
sleep, daytime sleep, and overall total 24-hour sleep time (Okocha et al., 2009).  
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Sleep disruptions of varying kinds have been demonstrated in multiple age groups and 
stages of HIV disease, but the advanced stage of the infection, in particular, tends to elicit 
significant increases in the frequency and intensity of the disruptions (Darko et al., 1992, Möeller 
et al., 1991; Okocha et al., 2009; Reid & Dwyer, 2005). As a result, those with progressive 
disease were found to have a tendency to use sleep medications more often than not (Möeller et 
al., 1991). It is important to note that not only have studies shown immune status to have 
profound effects on sleep, but the data has also demonstrated that sleep disturbance can further 
impair immune functioning beyond the damage caused by the virus (Moldofsky, Lue, Eisen, 
Keyston, & Gorczynski, 1986; Wheatley & Smith, 1994). This downward spiral between cause 
and consequence supports a reciprocal link between sleep regulating hormones and immune cells 
(Darko et al., 1992). 
To the contrary, several investigators found no correlation between sleep measures and 
CD4+ cell counts (Cohen et al., 1996; Cruess et al., 2003; Rubinstein & Selwyn, 1998; Nokes & 
Kendrew, 2001, Saberi et al., 2011). Saberi and researchers (2011) analyzed data from a sample 
of 2845 HIV-positive adults, and although they found no correlation with CD4+, every tenfold 
increase in viral load was independently related to a pattern of heightened sleep problems. In a 
Brazil study, most subjects who described a good experience in quality of sleep were those with 
undetectable viral loads (Ferreira & Ceolim, 2012).  
Sleep/Wake Rhythm 
Polysomnography Studies. Initial scientific and clinical investigations into sleep 
disruption experienced in HIV disease began in the late 1980’s, soon after researchers had 
isolated the human immunodeficiency virus in the cerebrospinal fluid. This confirmed that HIV 
infects the CNS, and thus, the sleep-regulating mechanisms located therein (Norman, Chediak, 
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Kiel, & Cohn, 1990). Focus was placed on laboratory-based analyses of sleep physiology 
through the use of polysomnography. Polysomnography (PSG), the gold standard of sleep 
assessment, allowed for the objective exploration into the circadian rhythm of sleep and its 
dynamic architecture. Alterations in nocturnal architectural patterns demonstrated the subtle 
CNS manifestations postulated to be directly related to HIV infection and altered immune 
responses (Reid & Dwyer, 2005).   
Dr. Suzan Norman and her colleagues were of the first to pioneer evaluations into 
distorted sleep physiology related to HIV infection. Focus was initially placed on the associated 
sleep changes experienced during the asymptomatic phase of the illness. Preliminary studies of 
asymptomatic homosexual men demonstrated various architectural changes, such as decreased 
sleep efficiency and increases in sleep fragmentation and the amount of SWS pathologically 
shifting to the second half of the night (Norman et al., 1987; Norman, Resnick, et al., 1988). 
Trials using similar samples were able to reaffirm the SWS anomaly, noting that persistent SWS 
occurring in the later sleep cycles may be a physiological feature consistent with early HIV 
infection (Norman et al., 1989; Norman, Chediak, Freeman, et al., 1992; Norman, Chediak, Kiel, 
& Cohn, 1990; Norman, Chediak, Kiel, Gazeroglu, et al., 1990; Norman, Nay, et al., 1988). 
Findings excluded the influences of azidothymidine (AZT) antiretroviral medication use, 
anxiety, and depression (Norman, Chediak, Kiel, Gazeroglu, et al., 1990). Also noteworthy, 
PSG-derived sleep measures were found to lack correlation with subjective sleep complaints 
(Norman, Chediak, Freeman, et al., 1992).  
Animal models using domestic cats infected with feline immunodeficiency virus (FIV) 
demonstrated similar abnormalities to those seen in HIV-seropositive humans, including the 
increased SWS structures appearing throughout the latter parts of the night (Prospero-Garcia et 
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al., 1994). Researchers concluded that FIV mimics HIV in its invasion of the CNS, producing 
sleep alterations that are apparently reflective of changes in immune system functioning soon 
after infection (Darko, Mitler, & Henriksen, 1995; Prospero-Garcia et al., 1994). Such findings 
were somewhat challenged by Ferini-Stambi and associates (1995), who found that 
asymptomatic HIV-infected men had difficulty achieving deeper levels of sleep as evidenced by 
a reduced percentage of SWS compared to matched controls. Seemingly dependent on severe 
immune dysregulation, such a reduction in SWS had previously only been reported in patients in 
advanced stages of their HIV disease progression (Norman & Chediak, 1992; Wiegand et al., 
1991). Ferini-Stambi’s group specifically explored the microstructures of sleep, and found a 
significant difference in the rate of cyclic alternating pattern (CAP) cycles in 9 asymptomatic 
seropositive men without sleep complaints as compared to 9 age-matched seronegative 
counterparts. Thus, suggesting dynamic HIV-related alterations in fine sleep stability even prior 
to sleep complaints or PSG detection. Additional abnormalities seen in other studies, enrolling 
asymptomatic males, included alpha-intrusions and altered NREM/REM patterns, such as 
increased number of REM periods and decreased total REM percentage (Norman, Chediak, Kiel, 
Gazeroglu, et al., 1990; Norman et al., 1989). When compared to published normative data, 
HIV+ subjects demonstrated increases in the number of awakenings, stage 1 shifts, alpha-NREM 
anomalies, total percent of SWS attributed to its presence in the second half of the night, and 
number of REM periods. HIV-subjects also demonstrated decreased stage 2 sleep, sleep latency, 
and average REM durations (Norman Chediak, Freeman, et al., 1992; Norman, Chediak, Kiel, & 
Cohn, 1990). In contrast, however, White and co-investigators (1995) evaluated 23 
asymptomatic seropositive and 13 seronegative men, finding only a significant difference in 
REM latency between the groups.  
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Evaluations of symptomatic stages of the illness, including AIDS, demonstrated an 
exacerbation of fragmented sleep and markedly reduced percentage of both REM and SWS 
(Norman & Chediak, 1992; Norman, Nay, et al., 1988). Kubicki and fellows (1988) evaluated a 
small group of AIDS patients who demonstrated consistent findings, including a reduced total 
sleep time, more time awake in stage 1, and less SWS and REM sleep. Additionally, they found 
increases in REM latency, SWS latency, and length of NREM period; and decreases in 
percentage of stage 2 sleep, K complexes, and extremely low sleep spindle density. Results were 
confirmed in a later study with a much larger sample of AIDS patients (Kubicki et al., 1989). 
Wiegand and researchers (1991) also reported comparable findings of longer sleep latency, 
reduced total sleep time, reduced sleep efficiency, increased awake time, and more stage 1 and 
stage 2 than deeper sleep stages in symptomatic HIV patients. However, they did not find a 
significant difference in percentage of REM sleep, REM density, or SWS when compared to 
healthy matched controls.  
Wrist Actigraphy Studies. Following the hallmark PSG studies, measurement of HIV-
sleep profiles progressed to a more feasible and subject-friendly method of assessment via wrist 
actigraphy. Although actigraphy does not allow for the precise assessment of sleep architecture 
or sleep stages, it is another valid option to objectively explore the circadian nature of sleep and 
activity patterns with minimal restrictions on normal routines. As a result, investigators have 
been able to monitor sleep-wake activity rhythms in virtually any sample and environment. By 
scoring the data, researchers are able to estimate a variety of sleep-wake variables related to 
nocturnal sleep patterns and daytime functioning.  
Lee, Portillo, & Miramontes (2001) used wrist actigraphy to describe sleep and activity 
patterns in relation to HIV status and fatigue. This was one of the first HIV-actigraphic studies 
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published, and its sample included 100 women of mixed ethnicity in various stages of their 
illness. Sleep, in terms of total sleep time (6.5 hours + 1.95) and sleep efficiency (74.7%), was 
poor; resulting in more frequent naps (45%) in comparison to previous reports of healthy women 
in the community. However, women with high fatigue demonstrated more difficulty falling 
asleep, more nocturnal awakenings, and poorer daytime functioning compared to those with low 
fatigue. Phillips & Skelton (2001) were of the first to objectively test the significance of an HIV-
related sleep disruption intervention (a 5-week course of acupuncture) in 21 HIV+ men and 
women using actigraphy. Post-intervention results demonstrated significant improvement in total 
sleep time, sleep latency, number of awakenings, number of minutes spent awake, sleep 
percentage, wake percentage, and sleep ratio. Hudson, Portillo, & Lee (2008) also made use of 
actigraphic data to pilot test a tailored sleep promotion intervention in 30 women recruited from 
Lee’s 2001 study. This sub-group showed post-intervention improvement with a significant 
decrease in the percentage of nappers. When separated out, poor sleepers were the only ones to 
demonstrate significant improvement in their post-intervention actigraphic measurements of 
initiation insomnia and maintenance insomnia. Actigraphic methodologies were also successful 
in evaluating sleep characteristics in HIV-infected children. Unlike adult assessments, Foster and 
investigators found that overall, HIV-infected children slept more and longer than controls 
(Foster et al., 2007), and that children with viremia had an even higher increase in sleep duration 
and sleep efficiency relative to HIV-infected children with undetectable viral loads and controls 
(Foster et al., 2008).  
More recently, Lee and coworkers (2012) utilized actigraphic estimates of nocturnal sleep 
time, wake after sleep onset, and daytime sleep to characterize specific types of sleep problems 
in 290 adult men and women with HIV. Nearly half (45%) of the sample slept less than 6 hours 
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per night (mean 6.2 hours + 1.6) and over half (56%) demonstrated fragmented sleep throughout 
the night. Results supported the need for continued efforts to improve both sleep initiation and 
sleep maintenance difficulties in the majority of adults living with HIV/AIDS, regardless of 
clinical and demographic profiles. Chen and partners (2012) employed a dual qualitative and 
biomedical approach to examine HIV-related sleep disturbance in a subgroup of 9 Chinese 
women from a larger parent-study in Shanghai. Although the study did not report actigraphic 
sleep time, collectively, participants cognitively set aside less than 7.5 hours for sleep (from the 
time they laid down until they got up). Those who demonstrated fragmented sleep showed 
increased daytime sleep, as evidenced by longer nap times (average 3.15 hours). Objective data 
also implied that these women maintained the normal activity levels of their healthy 
counterparts. In a sample of eight HIV+ men and women of varying ethnicities, Taibi, Price, and 
Voss (2012) described comparable actigraphic outcomes (mean total sleep time = 6.1 + 1.6 hours 
and sleep efficiency = 72.4 + 12.6%) first reported by Lee’s group more than 10 years prior (Lee 
et al., 2001). Wake time in bed averaged 142.2 minutes (2.37 hours), however, data showed lack 
of napping as participants were engaged in a program of activities throughout the day. In this 
study, objective sleep data presented more severe than the subjective data reported on sleep 
diaries, again corroborating the objective-subjective sleep measure discrepancies seen in prior 
studies (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989; Norman, Chediak, Freeman, et al., 
1992). Gamaldo and investigators (2013) conducted a comparative multi-method assessment of 
sleep, function and HIV in an all-Black male sample (25 HIV-positive and 19 HIV-negative). 
Similar actigraphic measures included sleep times less than 6 hours and sleep efficiencies less 
than 70%. Sleep latency periods, however, were longer in the HIV+ group and were correlated 
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with lower quality of life scores. The difference between sleep latency scores was statistically 
significant until they were adjusted for education and trait anxiety. 
Conclusion. A review of each of the 13 classic PSG studies found clear abnormalities in 
nocturnal sleep physiology, which suggests that CNS sleep-structure distortion is one of the 
earliest and most consistent signs of HIV infection (White et al., 1995). The attenuations in sleep 
architecture varied with the progression of disease; however, severe destruction of sleep 
structures was only evident in the late-stages of AIDS. Wrist actigraphy studies were supportive, 
in that they provided additional objective findings of distorted sleep-wake patterns, consistent 
with that of HIV-related CNS sleep disruption. The use of wrist actigraphy made way for 
feasible evaluation of sleep intervention and the exploration of more diverse populations, 
including children. Progressively, researchers have tried to exclude known primary sleep 
disorders, first night effect, medications, drug use, anxiety, depression, and other 
psychopathologies as major contributors of the aberrations seen in HIV.  Based on the studies 
reviewed, it is probable that the decay of healthy sleep profiles associated with early HIV 
infection could be primarily pathophysiological in origin with few psychosocial causes, except 
perhaps for the frequent arousals which are also seen as sequelae of stress and anxiety (Darko et 
al., 1995; Norman, Resnick, et al., 1988).  
Many of the objective sleep studies reviewed were wrought with limitations. PSG studies 
are extremely costly and usually very limited in the number of nights available for data 
collection, making longitudinal studies almost nonexistent. Sleep-laboratories are endowed with 
foreign conditions, which tend to facilitate a false representation of typical sleep patterns. Type II 
errors are notable in studies with such small sample sizes. Very few of these studies used 
controls with a sufficient number of participants or matched variables in each group. 
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Methodologies were highly selective and controlled, thus, limited in their consideration of 
various lifestyles and environmental confounders. Documentation or potential exclusion of 
preexisting sleep conditions prior to HIV infection was lacking, and normative data used for 
comparisons were from results published over 15 years prior, before a diagnosis of HIV even 
existed. Lastly, the many variations in definitions, methodologies, and sub-populations utilized 
in these inquiries may account for some of the conflicting results reported between studies. 
Sleep Quality 
Manifestations of HIV-related sleep disruption were not only observed through objective 
measures of the sleep/wake rhythm, but interest quickly grew in the subjective experience of 
sleep quality as well. Participants clearly articulated a noticeable change in sleep for the worse 
with their diagnosis (Portillo, Tom, Lee, & Miramontes, 2003). Poor sleep quality was found to 
include any self-reports of difficulty initiating sleep, difficulty maintaining sleep, waking up too 
early, and sleep that was chronically nonrestorative, poor in quality and/or quantity (Edinger et 
al., 2004; Phillips & Branson, 2009). Once subjects equated the experience of a good night’s rest 
to a sense of normalcy and a happier life, quality of sleep soon proved to be just as important as 
the quantity and physiology of sleep (Nokes & Kendrew, 2001; Portillo et al., 2003). As a result, 
HIV-sleep researchers over the past several years have focused much of their attention on the 
self-reported experiences of disrupted sleep quality. 
Historically, disturbances in sleep quality has been a common complication associated 
with HIV infection, and to the trained professional eye, a potential predictor of the disease 
(Cohen et al., 1996; Nokes & Kendrew, 1996; Nokes, Chidekel, & Kendrew, 1999; Norman, 
Chediak, Kiel, & Cohn, 1990; Norman, Chediak, Freeman, et al., 1992; Ragsdale & Morrow, 
1990; Reid & Dwyer, 2005; Rubinstein & Selwyn, 1998; Saberi et al., 2011). While the general 
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population has demonstrated anywhere from 10% to 40% prevalence of poor sleep quality, this 
remains significantly lower than that reported in the context of HIV disease (Lee et al., 2001; 
Omonuwa et al., 2009; Reid & Dwyer, 2005). In fact, reports of HIV-related sleep quality 
disturbances have surpassed those of other chronic diseases, such as cancer and renal failure (Lee 
et al., 2001; Rubinstein & Selwyn, 1998). Despite the high prevalence, most subjects reported 
little or no use of sleeping aids, and physician-guided intervention was almost nonexistent 
(Gamaldo et al., 2013; Phillips & Sowell, 2005; Robbins et al, 2004).  
In 1992, Norman, Chediak, Freeman, and other partners proposed that HIV-seropositive 
individuals had a greater perception of sleep disturbance and a significant increase in sleep-
related complaints than their seronegative counterparts. Supporting such claims, Lee, Portillo, & 
Miramontes (2001) and Nokes & Kendrew (2001) established PSQI scores of 9.9 (SD = 4.4) and 
10 (SD = 5), respectively. Hand and partners (2003) found that 100% of their African American 
sample experienced some type of sleep disturbance, and their PSQI group mean was 12.4 (SD = 
3.9). Age and gender were not shown to be factors in this study. Robbins and associates (2004) 
and Phillips and associates (2006), independently, confirmed that 100% of their samples self-
reported poor sleep quality with PSQI means remaining stable at 12.3 (SD = 3.9). More recently, 
Salahuddin and comrades (2009) reported an 80% prevalence of substantial sleep complaints in a 
sample of 128 participants, most of which were African American men at varying stages of HIV 
disease. Their PSQI group mean was 9.4 (SD = 4.4). Lee and colleagues (2012) reported an 
average PSQI of 7.7 (SD = 3.8) in short sleepers (those routinely sleeping < 6 hours). Wibbeler 
and researchers (2012) compared sleep quality in 180 infected subjects against 120 controls, 
finding increased prevalence rates (63.9% vs. 21.0%) and increased scores (8.0 + 4.4 vs. 4.1 + 
2.5) in the infected group. In Brazil, however, participants (N=122) reported a lower prevalence 
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of poor sleep quality (46.7%); their mean PSQI score was 6.1 (SD = 4.1) and the median was 5.0 
(Ferreira & Ceolim, 2012). Discordantly, comparable sleep quality scores between HIV and non-
HIV groups have been observed in a few studies (Crum-Cianflone et al., 2012; Vance & 
Burrage, 2005; White et al., 1995).  
Hypotheses of a direct connection with immune function led some investigators to 
explore poor sleep quality early in the asymptomatic phase of HIV disease, while others focused 
more of their attention on its ubiquitous nature throughout the symptomatic phases. Although 
disturbances in sleep quality have been clearly described in each phase since the early ‘90s, the 
underlying pathophysiology of the disturbances remains unclear and the data regarding the 
association between sleep quality and the phase of illness inconsistent. (Reid & Dwyer, 2005). 
To further explore possible causal factors, qualitative interviews conveying noticeable changes in 
sleep quality with HIV infection, exposed issues of subsequent health problems, decreased 
productivity, increased psychosocial problems, addictions, and accidental deaths (Nokes & 
Kendrew, 2001; Portillo et al., 2003; vanServellen, Sarna, & Jablonski, 1998). Researchers noted 
that such changes in sleep quality were generally entwined with numerous disease-specific and 
non-disease-related correlates of influence including immunological, neurological and cognitive 
dysfunction, opportunistic infections, psychosocial circumstances, environment, lifestyle 
choices, and side effects of the various treatments (Hand et al., 2003; Hand, Phillips, & 
Dudgeon, 2006; Robbins et al., 2004; Vosvick et al, 2004).  
In an exploratory study by Nokes and Kendrew (2001), 58 subject’s sleep quality was 
linked to employment status, general wellbeing, trait anxiety, sleeping arrangements, addictive 
substances (cigarettes, caffeine, marijuana, and alcohol), symptom severity, depressive 
symptoms, daytime sleepiness, functional status, state anxiety, length of time living with HIV, 
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and antiretroviral medications. Of that list, depressive symptoms, daytime sleepiness, symptom 
severity, state anxiety, and functional status, collectively, explained 43% of the variance found in 
sleep quality (F= 7.93, p= .000). Moreover, worst sleep was correlated with a noisy bedroom, 
impaired functional status, and a longer duration of HIV disease. No relationships were found 
related to age, intravenous drug use, AIDS diagnosis, CD4+ cell count, or HIV viral load. Several 
studies explored HIV-related fatigue and its association with sleep quality (Marion et al., 2009; 
Phillips et al, 2004; Robbins et al., 2004). Lee’s cohort (2001) demonstrated that high levels of 
fatigue, depression, poor sleep quality, and poor daytime functioning were all associated. 
Robbins and fellows (2004) concluded HIV symptoms, total pain, fatigue, depression, state 
anxiety, and number of adults in the household were related to sleep quality.  
Through time, investigators continued to examine correlates such as pain (Phillips & 
Skelton, 2001; Vosvick, et al., 2004), existential wellbeing and total spiritual wellbeing (Phillips 
et al., 2006), number of HIV symptoms and poor adherence with antiretroviral therapy (Minarik, 
Portillo, & Lee, 2007; Phillips, Moneyham, et al., 2005; Saberi et al., 2011), lack of employment 
(Phillips, Sowell et al., 2005), viral load and CD4+ cell count (Ferreira & Ceolim, 2012; Okocha, 
et al, 2009), cognitive impairment (Gallego et al, 2004; Hand et al., 2003), caffeine intake 
(Dreher, 2003), living space (Nokes & Kendrew, 2001), sexual quality of life (Rose, Peake, 
Ennis, Pereira, & Antoni, 2005), social support (Vosvick et al., 2004), maintenance of risk 
behaviors (Ferreira & Ceolim, 2012), and various sleep-related behaviors (Hudson et al., 2008), 
just to name a few. Given the dominance of anxiety, stress, and depression experienced in HIV 
disease, numerous studies supported the significant impact psychological correlates have on 
sleep quality (Jean-Louis et al., 2012; Junqueira, Bellucci, Rossini, & Reimao, 2008; Lee et al., 
2001; Mello, Segurado, & Malbergier, 2010; Mock et al., 2002; Nokes & Kendrew, 2001; 
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Phillips, Moneyham, et al., 2005; Robbins et al., 2004). Cruess and researchers (2003) concluded 
that sleep quality was the mediator between psychological distress and immune status.  
A few studies have explored the use of antiretroviral therapy (ART) as it relates to sleep 
quality in HIV disease. Despite the fact that insomnia is almost always listed as an adverse effect 
of most drugs, early studies seem less than supportive (Möeller et al., 1991; Rubenstein & 
Selwyn, 1998; Wheatley & Smith, 1994). In 2001, Nokes’ group found that antiretroviral therapy 
did correlate significantly with poor sleep quality. Seventy-two percent of their sample reported 
zidovudine, didanosine, zalcitabine, stavudine, or lamivudine use. Nuñez and associates (2001) 
demonstrated a significant difference in sleep quality when comparing 51 patients receiving 
efavirenz to case-controls. Elevated plasma levels were associated with extended abnormal 
dreams, increased awakenings, and trouble falling asleep. An efavirenz plasma level over 3.5 
ug/mL was found to be an independent predictor of poor sleep quality. Gallego and partners 
(2004) also supported efavirenz-related sleep quality disruptions via PSQI data. A recent study 
noted the contrary, with no associations with HAART use or long-term efavirenz use found 
(Crum-Cianflone et al, 2012).  
Conclusion. In summary, the exploration of such a complex and subjective experience 
has led to some elusiveness throughout the literature. Authors made reference to a wide array of 
terminology, such as insomnia, dysfunctional sleep, distorted sleep, nonrestorative sleep, or 
simply just poor sleep. Methodologies and working definitions were incoherent between studies. 
For example, progression of disease, which can be defined in terms of CD4+ cell count, CDC 
staging, or by WHO staging varied by study. Together with small sample sizes, data seemed 
inconsistent making it hard to draw firm conclusions. However, regardless of the terms or 
definitions used, one can agree that sleep quality is dynamic, highly individual, and influenced 
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by a multitude of physiological, psychological, psychosocial, and pharmacological factors 
(Phillips & Skelton, 2001).  
Daytime Sleepiness 
HIV-related sleep disruption often manifests in the daytime as a functional impairment 
known as excessive daytime sleepiness (Darko et al., 1995; Nokes & Kendrew, 2001; Wibbeler 
et al., 2012). Daytime sleepiness can have a profound effect on an individual’s important 
activities of daily living, such as self-care practices, work performance, and interpersonal 
relationships (Lee et al, 2001; Nokes & Kendrew, 2001; Perkins et al., 1995; Wheatley & Smith, 
1994). Even modest levels of sleepiness have been noted to have substantial adverse influences 
on everyday life (Briones et al., 1996). Subjectively, one might express the experience in terms 
of drowsiness, lethargy, tiredness, somnolence, malaise, and/or fatigue. Such dysfunction usually 
entails physiological and psychological components that tend to translate into a propensity 
toward excessive daytime napping, reduced cognition and reflexes, irritability, curtailed social 
activities, depression, and even exaggerated perceptions of illness (Hand et al., 2006; Wheatley 
& Smith, 1994). Given the important role that each of these may play in terms of general health 
and quality of life, the research on the prominence of excessive daytime sleepiness associated 
with HIV disease remains particularly modest in quantity. (Lee, Portillo, & Miramontes, 1999; 
Wheatley & Smith, 1994).  
Increased rates of daytime sleepiness, secondary to HIV-related sleep disruption, have 
readily been found in HIV-infected patients upon assessment and even reported as a typical 
presenting symptom of HIV infection (Aldrich et al., 1988; Epstein et al., 1995; Hand et al., 
2006). More than just a physiological or behavioral propensity to fall asleep, sleepiness has been 
further described as an encompassing phenomenological experience of subjective feelings 
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associated with alterations or imbalances in sleep/wake mechanisms (Shen, Barbera, & Shapiro, 
2006). In a study conducted by Cohen and co-investigators (1996), HIV-positive women 
reported feeling very tired in the morning (40%) more than HIV-positive men (13.3%), yet no 
statistical difference was demonstrated in the number of naps between men and women. 
Interestingly, national polls, sponsored by the National Sleep Foundation (n.d.), support such 
findings that women generally are more likely than men to experience symptoms of sleep 
disruption, including daytime sleepiness. Subjects in symptomatic CDC stages III and IV have 
been noted to complain of sleeping more, napping more, and having diminished midmorning 
alertness (Nokes & Kendrew, 2001; Robbins et al., 2004). Lee and coworkers (2001) established 
that HIV-positive women with lower rhythm strength on wrist actigraphic assessment (indicative 
of irregularities in their sleep/activity patterns), perceived more daytime dysfunction and spent 
more time napping during the day as compared to those with higher rhythm strength (indicative 
of stable sleep/activity pattern). Salahuddin and researchers (2009) analyzed 128 HIV-positive 
individuals and found a high prevalence of sleep-related daytime dysfunction (42%) and feelings 
of excessive daytime sleepiness (55%). The sample mean on the Epworth Sleepiness Scale (ESS) 
was 11 (SD = 5.2), ten indicating pathology. Uniquely, Salahuddin’s group also examined 
daytime sleepiness in context of fatigue, finding a significant correlation between the ESS and 
the HIV-Related Fatigue Scale (HRFS). In a multiple regression model, daytime sleepiness did 
not explain the association between stress and fatigue intensity, however, it did marginally 
explain the association between stress and fatigue-related impairment of functioning. In a 
controlled study, Wibbeler and associates (2012) demonstrated a significant increase in daytime 
sleepiness in HIV-infected participants (46.6%) verses the control group (19.4%). Mean ESS 
scores differed significantly as well, 9.4 (SD = 4.9) in the infected group and 6.5 (SD = 3.2) in 
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the non-infected group. They observed a trend where those with a significantly higher percentage 
of HAART intake and lower viral loads were more likely to report increased daytime sleepiness.  
Incongruously, Crum-Cianflone and colleagues (2012) detected no significant difference in ESS 
scores among a group of 193 early-treated HIV infected participants (7.5 + 4.4) and 50 
uninfected controls (6.6 + 3.6).  Gamaldo and co-investigators (2013) supported the lack of 
significance in an all-Black controlled study, however, ESS results were listed in a table and no 
discussion was provided related to ESS scores.   
In summary, those experiencing HIV-related sleep disruption are also predisposed to 
experience excessive daytime sleepiness. Nonetheless, there seems to be some ambiguity in the 
HIV-sleep literature regarding the conceptual distinctions, particularly between fatigue and 
daytime sleepiness. The two are often used interchangeably, and there is no established 
consensus on what the universal experience of ‘sleepiness’ actually entails or what is considered 
to be ‘excessive’ sleepiness (Shen et al., 2006). Very few studies were found that assessed 
daytime sleepiness at length. The ESS was utilized the most, however, some described sleepiness 
within the context of their assessment of sleep quality via PSQI, and others may have simply 
misclassified it or included it in with fatigue.  
For clarification purposes, it is this investigator’s scholarly opinion that daytime 
sleepiness is a manifestation of sleep disruption, contradistinguished from fatigue. Fatigue 
denotes a much broader construct of HIV-symptomology related to the many infectious 
processes involved in HIV infection, which may or may not include sleep/wake alterations and 
an increased sleep propensity (Shen et al., 2006; Vgontaz et al, 2002). This may explain why Lee 
and colleagues (2001) found that fatigue was not associated with total sleep time at night, 
circadian rhythm parameters, or napping behaviors during the day. Likewise, Mock and fellows 
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(2002) found that sleep dysfunction accounted little for the variation in fatigue, and thus, 
hypothesized physiological and pathophysiological processes of the disease instead.  
IL-6 Rhythm.  
Interleukin-6 (IL-6) is an inflammatory cytokine produced by many different cells in the 
body, such as T-lymphocyte cells, monocytes, macrophages, osteoblasts, bone marrow stromal 
cells, intestinal epithelial cells, and cells of the testis, pituitary, endometrial, and vascular smooth 
muscle (Babakhanian, 1995; Papanicolaou, Wilder, Manolagas, & Chrousos, 1998). IL-6 is a 
pleiotrophic cytokine, in that the immune system uses it to communicate and orchestrate specific 
responses related to inflammatory, endocrine, neurologic, and metabolic functioning 
(Babakhanian, 1995; Kishimoto & Hirano, 1988; Papanicolaou et al., 1998; Späth-Schwalbe et 
al., 1998; Vgontzas et al., 2005). As a result, IL-6 plays a role in a broad array of biological 
activities: stimulates the secretion of growth hormone, inhibits thyroid-stimulating hormone 
secretions, suppresses serum lipid concentrations, plays a central role in the pathogenesis of 
osteoporosis related to bone resorption conditions, stimulates energy mobilization which leads to 
increased body temperature and resting metabolic rates, inhibits secretion of TNFα and IL-1, 
synergistic with glucocorticoids activates the production of acute phase reactants from the liver 
(C-reactive protein, haptglobin, fibrinogen), stimulates the hypothalamic-pituitary-adrenal axis 
(HPA), activates B-cell differentiation and maturation, activates T-cell proliferation and 
differentiation, and helps control various inflammatory, stress, and immune responses (Chrousos, 
1995; Kishimoto & Hirano, 1988; Papanicolaou et al., 1998). IL-6 normally circulates in the 
blood at levels ranging from 5 to 15 pg/mL (Honda et al., 1990). Honda and comrades (1990) 
described these values as being reflective of the minimal activation required for normal-everyday 
functioning of the immune system, absent of major injury, sickness, or stress. Secretion of IL-6 
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is positively influenced by body mass index, catecholamines, IL-1, and TNFα; and negatively 
influenced by glucocorticoids, estrogen, and androgen (Chrousos, 1995; Papanicolaou et al., 
1998). Elevated levels of IL-6 are seen in many severe inflammatory, infectious, stressful, and 
traumatic states, such as pain, obesity, major depression, chronic insomnia, nightshift workers, 
steroid withdrawal syndrome, alcoholism, rheumatoid arthritis, and systemic erythematous lupus 
(Alesci et al., 2005; Bovbjerg, 2003; Chrousos, 1995; Friedman et al., 2005; Krueger et al., 1995, 
Papanicolaou et al., 1998; Redwine, Dang, Hall, & Irwin, 2003; Vgontzas et al., 2003; Vgontzas 
et al., 2002). Overproduction may contribute to illness by causing reciprocal sickness behaviors 
including symptoms of anorexia, fatigue, somnolence, inability to concentrate, sleepiness, fever, 
decreased motivation, joint and muscle pain, malaise, headaches, listlessness, social withdrawal, 
and hyperalgesia (Alesci et al, 2005; Breen et al., 1990; Chrousos, 1995; Dantzer, 2004; 
Papanicolaou et al., 1998; Vgontzas et al., 1999; Vollmer-Conna et al., 2004). With such a bi-
directional relationship, it is not hard to understand how average IL-6 plasma levels correspond 
with overall health outcomes and general wellbeing (Friedman et al., 2005; Vgontzas et al., 
2003).  
In addition to all the immunomodulating of the complex networks listed above, IL-6 has 
shown to be a somnogentic cytokine, a putative ‘sleep factor’, elemental in sleep research 
because of its apparent association with sleep architecture, sleep quality, and disorders of 
excessive daytime sleepiness (Bovbjerg, 2003; Vgontzas et al., 2005; Vgontzas & Chrousos, 
2002). Along with other somnogenic cytokines, namely IL-1 and TNFα, IL-6 plays a major role 
in the neural-biochemical interactions of the central nervous system responsible for the 
regulation of sleep (Chrousos, 1995; Gemma & Opp et al., 1999; Opp et al., 1996; Redwine et 
al., 2003; Redwine, Hauger, Gillin, & Irwin, 2000).  Investigators have described both a 
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circadian rhythm and a homeostatic component in the IL-6 signaling related to sleep (Krueger et 
al., 1998; Opp et al., 1996; Vgontzas et al., 1999). Generally, increasing levels of IL-6 
correspond with sleep onset, and tend to peak sometime in the latter part of normal sleep (Bauer 
et al., 1994; Friedman et al., 2005; Redwine et al., 2000). Daytime levels, which are inversely 
influenced by the previous night’s sleep, normally decrease and tend to be influenced by daily 
temporal patterns of sleepiness (Friedman et al., 2005; Irwin, 2002; Mills et al., 2007; Vgnotzas 
et al., 2005; Vgnotzas et al., 2002). In fact, lower daytime IL-6 concentrations are reflective of 
better sleep the night before and a good sense of wellbeing upon awakening (Miller, Cohen, & 
Ritchey, 2002; Späth-Schwalbe et al., 1998; Vgontzas et al., 1999, 2003; Vgontzas & Chrousos, 
2002). Extensive investigations into IL-6 levels throughout the day have revealed a naturally 
occurring biphasic circadian rhythm with two nadirs (troughs) around 0800 and 2100 hours and 
two zeniths (peaks) approximately 1900 and 0500 hours (Honda et al., 1990; Vgontzas et al., 
1999). The 0500 zenith has been noted to be the stronger of the two peaks (Vgontzas et al., 1999, 
2005). Another source reported a similar circadian periodicity in healthy individuals with a 
primary zenith during the night between 0100 and 0500 hours, a nadir in the morning between 
0800 and 1000, and a secondary zenith between 1700 and 1900 hours (Alesci et al., 2005).  
Poor or disrupted sleep is known to result in a subsequent elevation of daytime IL-6 
levels (Irwin, 2001; Miller et al., 2002; Redwine et al., 2003; Shearer et al., 2001; Vgontzas et 
al., 1999, 2002, 2003). Data from experimentally-induced hypersecretion of IL-6 (by either 
exogenous administration or sleep-deprivation studies) concurrently reflect that IL-6 has direct 
effects on sleep progression through feedback mechanisms of the HPA axis, which are thought to 
trigger the restorative homeostatic drive for sleep (Bollinger et al., 2009; Friedman et al., 2005; 
Mills et al., 2007; Shearer et al., 2001; Späth-Schwalbe et al., 1998; Vgontzas et al., 1999, 2005). 
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Participants experienced an ensuing somnolence, mental and physical weariness with a 
propensity for sleep during the day, delays or shifts in their IL-6 rhythm zeniths (from nighttime 
to daytime), and architectural changes, such as prolonged sleep latency, deeper sleep, decreased 
REM, and shifted SWS into the second half of the following night (Miller et al., 2002; Redwine 
et al., 2003; Späth-Schwalbe et al., 1998; Vgontzas et al., 1999, 2002, 2003). Interestingly, those 
naturally prone to increased SWS, exhibited an inherent ability to tolerate sleep loss, seemingly 
protective against IL-6 hypersecretion (Papanicolaou et al., 1998; Shearer et al., 2001; Vgontzas 
et al., 1999). Progressive age-related increases in IL-6 secretion explained the dawdling 
decreases in the quantity and quality of sleep, as well as other common ailments associated with 
aging (Okun et al., 2011; Vgontzas et al., 2003). Regardless of the reason, a prolonged imbalance 
(dysregulation) or shift in the IL-6 circadian rhythm are consistent with reports of pronounced 
sleep problems and increased morbidity, disability, and mortality (Bovbjerg, 2003; Friedman et 
al., 2005; Mills et al., 2007).  
Animal studies have demonstrated evidence consistent with human studies, which 
hypothesize that IL-6 possesses sleep modulatory properties. Guan, Omori, Vgontzas, Bixler, 
and Fang (2003) induced total sleep deprivation in adult male rats, finding a 10% to 26% 
increase in IL-6 levels by the 6th hour of sleep loss compared to that of controls. While 
controlling for other stressors, Hu and colleagues (2003) found similar results in mice with 36 
hours of sleep deprivation. Hogan and investigators (2003) utilized exogenous administration of 
IL-6 in albino male rats, which evoked dose-dependent NREM alterations. Morrow and Opp 
(2005) also confirmed a general role in sleep physiology by using advanced IL-6 knockout mice, 
genetically altered for IL-6 gene deletion. These sleep-deprived mice lacking the expression of 
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IL-6 spent more time in REM sleep and took 6 hours longer to obtain the same amount of NREM 
sleep than their controls.  
In 1987, Dr. Norman’s group first suggested that changes in cytokine concentrations 
during HIV infection played a pivotal role in the alterations of sleep-wake behaviors that were 
observed. Several studies found the expression of somnogenic cytokines, like IL-6, greatly 
amplified due to immune dysfunction during the viral challenge and in phase with the altered 
sleep-wake rhythms (Babakhanian, 1995; Foster et al., 2008; Krueger et al., 1995; Kubicki e al., 
1989; Norman, Chediak, Kiel, & Cohn, 1990; White et al., 1995). Honda and group (1990) found 
mean IL-6 levels of 55.5 pg/mL in a group of asymptomatic HIV-seropositive carriers. This was 
significantly higher than the 9.5 pg/mL exhibited by healthy age-matched controls. Data from in 
vitro studies led them to propose the continuous stimulation of infected monocytes and 
macrophages as the likely source of elevated serum IL-6 levels. Breen and partners (1990) found 
circulating plasma levels of IL-6 in HIV-infected donors to be 16-fold higher (mean 1.3 U/mL) 
as compared to that of healthy donors (mean 0.08 U/mL, p < 0.005). In a twenty-four hour 
culture, with no exogenous stimulation from IL-6 activators, isolated donor cells exhibited a 10-
fold increase from HIV-infected donors (2.5 U/mL) compared with controls (0.22 U/mL, p < 
0.025). Furthermore, fractionation of the isolated blood into groups prior to the 24-hour culture 
helped to identify the cell-type responsible for the increased IL-6 secretions. The 
monocytes/macrophage fraction was found to account for the majority of the IL-6 secreted in 
vitro. Animal models confirmed cytokine dysregulation as instrumental in sleep pathology 
throughout the course of HIV infection. Opp and coworkers (1996) used exogenous 
administration of HIV-envelope glycoprotein 120 (gp120) in rats to induce altered synthesis and 
secretion of various somnogenic cytokines, and thus, alter sleep. Sleep-wake behaviors were 
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unremarkable at low doses (20ng of gp120). However, larger doses of 100ng and 500ng 
produced hallmark responses seen in elevated cytokine levels, including fragmented sleep, stage 
1 shifts, and increased NREM sleep (equivalent to SWS in human studies). Gemma and Opp 
(1999) replicated these findings in another rat study, except they established that the HIV-
envelope gp160 and gp41 could produce the characteristic sleep patterns associated with 
cytokine dysregulation.  
Honda’s group (1990) also noted that as HIV-disease progressed to symptomatic stages 
like AIDS-related complex (ARC) and AIDS, so did IL-6 levels (106.8 pg/mL and 283 pg/mL, 
respectively). Data suggested that IL-6 levels associated with the degree or stage of HIV-induced 
illness may be a consequence of an immune interaction that appears to favor immune 
pathogenesis, where infected mononuclear phagocytic cells (monocytes and macrophages) are 
continuously stimulated to secrete IL-6, produce large quantities of the HIV virus (viral 
replication), and serve as a reservoir for the virus. IL-6 and viral copies affect the function of T-
and B-cells, as well as many other cell types favoring immune abnormalities (Honda et al., 
1990). Since then, Foster and colleagues (2007) found greater cytokine dysregulation and 
significantly higher percentage of T-cell activation in HIV-infected children with higher viral 
loads >400 copies/mL (viremia) compared to those with undetectable viral loads <400 
copies/mL or controls. In a subsequent study led by Foster (2008), children with viremia 
demonstrated enhanced alterations in sleep patterns and an increased mean plasma IL-6/IL-1β 
ratio (1.3, ln) compared to controls (-1.7, ln, p = 0.003). Kinoshita and Taguchi (2008) provided 
a technical explanation of the mechanism underlying viral replication. They described IL-6 
transcription factor (NF-IL6), also known as an IL-6 promoter, as a natural inhibitor of 
APOBEC3G, an antiviral cytidine deaminase. The resulting inhibition of APOBEC3G, which 
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normally blocks HIV-1 reverse transcriptions, permits the uninhibited activation of T-cells, a 
crucial step in allowing HIV viral replication to proceed.  
Recent studies have been able to duplicate the association between IL-6 levels and CD4+ 
counts and viral burden (Bastard et al., 2012; Míguez, Rosenberg, Burbano-Levy, Carmona, & 
Malow, 2012). Bastard and researchers (2012) found 122 immunologically stable subjects 
(80.3% men) with an IL-6 range of 0.15-5.46 pg/mL and a median of 0.685pg/mL. IL-6 levels 
correlated with nadir CD4+ level and HIV viral load, the threshold value for increased IL-6 level 
was 31 HIV copies/mL. Míguez and colleagues (2012) contended that lower IL-6 levels were 
associated with smokers compared to nonsmokers, HAART-treated individuals compared to 
non-treated, and hazardous alcohol users compared to nonhazardous users. Gender differences 
were also noted with African American participants having lower levels of IL-6. Fumaz and 
coworkers (2012) noted a mean plasma IL-6 level of 7.0 pg/mL in 50 subjects (88% men), when 
they found a strong correlation between IL-6 and stress. Additional studies regarding IL-6 levels 
in HIV-infected individuals were related to BMI and obesity (Koethe et al., 2013), omega-3 fatty 
acid therapy in hypertriglyceridemic HIV patients (Metkus et al., 2013), Hepatitis C virus and 
liver fibrosis (Fuster et al., 2013), and lastly, McDonald and partners (2013) who emphasized 
that IL-6 levels are important predictors of all-cause mortality. 
In summary, research efforts that specifically seek to understand IL-6, an inherent 
biomarker of health and wellbeing, as a common variable between HIV-related sleep disruption, 
disease progression, and quality of life are lacking. Most had very small sample sizes and relied 
on single-point measurements of IL-6, which consequently undermines its periodicity in phase 
with sleep-wake rhythms. Additionally, many studies fail to mention consideration of potential 
confounders related to gender, body composition, and other biological or pathological 
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abnormalities. In an attempt to simplify the feedback loop hypothesized above, HIV infects the 
central nervous system and immune competent cells causing cytokine dysregulation. The 
dysregulation of somnogenic cytokines disrupts sleep-wake behaviors and promotes viral 
replication. The resulting sleep dysruption and increased viremia, not only affects daytime 
functioning, increased morbidity, and quality of life, but also leads right back to further cytokine 
dysregulation. Thus, the interplay between cause and consequence continues.  
Quality of Life. 
Quality of life has evolved into a critical outcome measure that gives researchers an 
indication of an individual’s subjective perception of their overall state of health and wellbeing. 
Health is an impliable factor of wellbeing, contributing not only to the quantity of life 
expectancy but also to the quality of life tolerability (Cella & Tulsky, 1990; O’Keefe & Wood, 
1996). Since 1946, the WHO has defined health as “a state of complete physical, mental, and 
social wellbeing and not merely the absence of disease or infirmity” (http://www.who.int/about/ 
definition/en/print.html). However, with no real consensus as to the precise meaning or 
conceptual boundaries for these terms, quality of life and wellbeing are often used 
interchangeably and synonymously with health. Traditionally, quality of life was thought of as “a 
vague and ethereal entity, something that many people talk about, but which nobody very clearly 
knows what to do about” (Campbell, Converse, & Rodgers, 1976). It has also been described as a 
fluid or dynamic multidimensional reflection of the internal satisfaction or happiness with how 
life is going compared to some aplombed conjecture of how life should be (Cella & Tulsky, 
1990; Lutgendorf et al., 1994). Health status, general functional abilities, income, freedom, 
environment are just a few important factors that may influence one’s quality of life (Briones et 
al., 1996; O’Keefe & Wood, 1996).  
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HIV is a chronic disease thwart with a relapsing and remitting nature, a hauntingly 
uncertain trajectory of life-threatening physical decline, a lifestyle full of stigma and redress, and 
an ever-increasing reliance on innovative healthcare and medical adeptness. Highly active 
antiretroviral therapy (HAART) and an improved ability to monitor the effectiveness of 
treatment with HIV viral loads and CD4+ cell counts has led to a significant decrease in the 
traditional clinical outcomes of HIV disease (Call et al., 2000). Subsequently, the emerging goal 
of HIV care not only seeks to postpone these fatal outcomes, but vies to balance the prolongation 
of life in a manner consistent with optimal productivity and normalizing quality of life as much 
as possible (Davis, 2004; Lutendorf et al., 1994); thus, shifting the focus of HIV care to more of 
a ‘patient-based’ set of outcome measures, particularly those related to adherence, tolerability, 
and quality of life (Call et al., 2000). The measurement of quality of life helps to weigh the 
burden incurred from the debilitating course of HIV and its associated sequelae, assess the 
effectiveness of various treatments, gauge the durability of the therapeutic net benefit against the 
risk of common side effects experienced, and track the perception of health and wellbeing over 
time (Hays et al., 2000; Revicki, Wu, & Murray, 1995).  
 Early on, researchers were able to establish that HIV/AIDS greatly affects one’s quality 
of life. In Philadelphia, 90 participants diagnosed with AIDS responded to a mail-in survey 
conducted by Ellerlman (1989). They reported a mean score of 6.8 on the standardized Spitzer’s 
Quality of Life Index, which was significantly lower than that reported by cancer (7.1) and other 
chronically ill patients (7.3). Lutgendorf and researchers (1994) found that even in asymptomatic 
HIV-positive men, just the knowledge and perceived implications of their serostatus was enough 
to permeate their awareness, behaviors, and sense of wellbeing. Asymptomatic disease, however, 
demonstrated less diminution in quality of life than later stages in the progression of disease 
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(Ragsdale & Morrow, 1990; O’Keefe & Wood, 1996; Lubeck & Fries, 1997). Many found a 
general trend, such that, as HIV disease progresses, health declines, associated symptoms arise, 
and quality of life becomes poorer (Bing et al., 2000; Hand et al., 2006; Hays et al., 2000; Kohli, 
Sane, Kumar, Paranjape, & Mehendale, 2005; Lubeck & Fries, 1992; Phillips, Sowell, Rush, & 
Murdaugh, 2001; Wu et al., 1991).  
 Investigators were first interested in establishing generic quality of life instruments as 
valid and reliable within the HIV population. Common instruments included, but were not 
limited to the Quality of Life Index, Quality of Well-being Scale, Sickness Impact Profile, and 
multiple versions of the Medical Outcomes Survey (MOS). As such outcome measures became 
more integrated within HIV research, various disease-specific and health-related quality of life 
measures were developed and validated, including the Medical Outcomes Survey disease-
specific modified version (MOS-HIV), the HIV/AIDS Targeted Quality of Life Instrument 
(HAT-QoL), and the Functional Assessment of HIV Quality of Life Instrument (FAHI). Both 
generic and disease-specific measures took a deeper look into specific biomarkers of disease 
severity, such as symptomology, HIV viral load, and CD4+ cell count, as surrogate outcome 
measures of quality of life (Call et al, 2000; Weinfurt, Willke, Glick, Freimuth, & Schulman, 
2000). In a sample of 2295 homosexual men, Bing and coworkers (2000) found that having even 
one HIV-related symptom was enough to significantly decrease quality of life scores per the SF-
36. Hays and partners (2000), with an even larger sample, further concluded that symptoms may 
provide more insight into the effects of HIV disease progression on wellbeing than clinical 
staging or CD4+ cell counts. This had significant ramifications related to HIV care, making early 
detection and prevention of the symptomatic phase of great importance. Gill and co-investigators 
(2002) focused on viral loads and CD4+ cell counts in response to HAART. Besides the usual 
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findings of lower viral loads and higher CD4+ cell counts being associated with superior quality 
of life, they added that viral loads needed to be suppressed to undetectable levels in order to see 
significant improvements. Even though HAART had its own problems with quality of life, they 
also found that those who were adherent in the long run were able to experience improvements 
that outweighed the side effects. Hudson, Kirksey, and Holzmer (2004) endorsed symptomology 
as contributing the most to the variance seen in quality of life measures in their sample. 
Burgoyne & Tan (2008) agreed that advances in HAART are responsible for the decreases in 
morbidity and mortality, yet adherence issues, tolerability, and toxicity have continued to erode 
quality of life. Quality of life scores being relatively stable suggested that, in spite of viral 
suppression and immunological repletion, the lived experiences of HIV-related symptoms and/or 
HAART-related side effects are actually most responsible for the variance in the quality of life.  
McDonnell and associates (2000) recognized a noticeable lack in research related to the 
quality of life in women living with HIV. A sample of 287 inner-city HIV+ women yielded a 
profile description of African American women (94%), mean age 33 years old, high school 
nongraduate (55%), never been married (63%), with heterosexual contact as the mode of 
transmission (46%).  Per MOS-HIV scores, this sample was consistent with that of other HIV-
positive female samples from previous validation studies. However, even after adjusting for 
symptomatic status, their scores were notably lower than that recorded from their higher 
socioeconomically profiled HIV-positive male counterparts whose mode of transmission was 
homosexual contact. Another study, which interviewed 3,778 HIV-positive adults for an ongoing 
CDC supplemental behavioral surveillance study, demonstrated that increased age, female, 
African American or Hispanic ethnicity, lower education, lower income, and no private health 
insurance were all significantly associated with lower quality of life scores (Campsmith, 
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Nakashima, & Davidson, 2003). Hays and partners (2000), however, had already explained that 
an association with socioeconomic status is not surprising, in that it is reflective of the potential 
role that accomplishment, productivity, and access to healthcare may play in the promotion of 
wellbeing. Kohli’s group (2005) reinforced the differences in sociodemographics with respect to 
quality of life in a mixed sample of 100 HIV-infected individuals from India. Lower societal 
status and poor health seeking behaviors among the women in India were suggested as the 
reasons for the observed differences seen in the quality of life scores.  
Many psychosocial variables have been associated with quality of life, especially given 
high rates of sexual and physical violence, inadequate social support, and the tremendous 
concerns regarding stigma, discrimination, and hopelessness (Andrinopoulos, et al., 2011; 
Gielen, McDonnell, Wu, O’Campo, & Faden, 2001). Sherbourne and staff (2000) reported 
subjects with probable mood disorders had significantly lower quality of life scores, and heavy 
drinking and drug use were not associated. Gielen and associates (2001) found that women with 
more social support resources and self-care behaviors, such as adequate sleep and exercise, 
reported better mental health and overall quality of life. Yang, Chen, Kuo, and Wang (2003) 
revealed that higher quality of life was associated with less mood disturbance, reduced physical-
symptom distress, and higher levels of social support. The mean QLI score for their sample in 
Taiwan was 18.50 (SD = 4.30, range = 5.67-29.36). In adolescent and young adult women 
studies, researchers recommended interventions that effectively decrease stigma and depression, 
increase social support and illness acceptance, and likely improve their wellbeing and quality of 
life (Andrinopoulos et al., 2011). Armon & Lichtenstein (2012) explored coping and found it 
associated with both the mental and physical subscales of the MOS-HIV. 
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A growing body of knowledge demonstrates that sleep impacts an individual’s general 
health and wellbeing. Many studies attest to the intrusive nature of HIV-related sleep disruption 
contributing to a waning quality of life and wellbeing (Cohen et al., 1996; Morin, 1993; Nokes et 
al., 1999; Nokes & Kendrew, 1996, 2001; Vosvick et al., 2004). Briones and fellows (1996) 
found that sleepiness accounted for 6% of the variance in the measurement of wellbeing in a 
generally healthy sample without severe chronic medical or psychiatric illnesses. Davis (2004) 
concurred, describing sleep disturbances as one of the most common clinical symptoms affecting 
the quality of life in HIV-positive patients. Dreher (2003) found that by simply decreasing the 
caffeine intake, the experimental group experienced a 35% sleep improvement and a subsequent 
7% improvement in perceived wellbeing. Interestingly, the sample, fairly stable Caucasian HIV-
positive males, consumed 2.4 times more caffeine (476mg/day) a day than that of the National 
US consumption average (200mg/day). This supported the fact that to a degree, sleep has an 
underlying effect on wellbeing in HIV disease. Phillips, Sowell, and researchers (2005) 
undertook an important descriptive study with a sample of 144 AA HIV-positive females 
recruited from 12 southern US clinics. In this sample, there was an increased prevalence of poor 
sleep quality, with poor sleepers reporting decreased quality of life. Asymptomatic poor sleepers 
scored lower on the mental component of the quality of life scale, and symptomatic poor sleepers 
scored lower on the physical component. Of importance, sleep quality explained more of the 
variance on quality of life in a regression model than the stage of illness. Sleep quality accounted 
for 20% of the variance in the mental component of the quality of life score, while stage of 
illness accounted for 14% of variance in the physical component. They concluded that improving 
sleep quality might improve quality of life, especially mental quality of life, which in turn means 
better adherence, healthier choices, improved self-care, and more health-promoting behaviors. 
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Phillips’ group (2006), in a subsequent study, presented evidence that spiritual wellbeing was not 
only tied into mental and physical health, but sleep quality as well. 
In summary, HIV-related sleep disturbances are undoubtedly associated with poor quality 
of life and a lower sense of wellbeing. There is a lack of coherence related to the various 
working definitions and the many measures of quality of life available, thus complicating the 
efforts of comparative analysis and drawing firm conclusions beyond that which was already 
stated. Quality of life has been measured using unidimensional, multidimensional, global, 
modular, generic, and disease-specific instruments. The choice of instrument may be affected by 
many factors, such as the lens though which one is viewing quality of life, form of data 
collection, investigator preference, and participant burden. Regardless of the many constraints 
and methodological issues to consider, interest in the area of quality of life in HIV research 
continues to escalate and has led to a proliferation of consequential studies. Perhaps future 
investigation into quality of life issues would benefit from the use of conceptual theories and 
mid-range theories as frameworks to actually guide the intricate methodological details of the 
research, instead of just making mention of the studies theoretical underpinnings. Theory-driven 
research may provide a much better structure from which to organize and synthesize conclusions. 
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CHAPTER 4 
METHODOLOGY 
Methods for measuring sleep disruption in asymptomatic HIV-seropositive AA women 
were initially assessed by this investigator via a small feasibility study (Protocol Number 
080907M1F), which was approved by the Wayne State University Human Investigation 
Committee (HIC) and completed as a master’s project in the winter semester, 2008. The 
feasibility study specifically looked for any technical and operational issues that might arise with 
such a biophysical protocol, as well as the level of difficulty or participant burden related to the 
population of interest. Findings of the feasibility study were used to revise and expand the 
methodology proposed in this dissertation project. After all the prerequisites for the dissertation 
project were met, a letter of amendment, revised informed consent form, and expanded protocol 
080907M1F were submitted to the HIC for approval. This amended the HIC approval from the 
master’s project NUR7998MRP029 to the dissertation project NUR9995DRP20. This chapter 
presents the study design, variables, protocol, and methods for the dissertation project. 
Research Design 
 A descriptive, correlational study design was used to examine the dynamics of HIV-
related sleep disruption and wellbeing experienced in asymptomatic HIV-seropositive African 
American women of childbearing age. This biophysical monitoring protocol had a cross-
sectional study period of four days. The variables of interest were organized within the 
framework of the Sleep Conservation Model substructed from Levine’s Conservation Model. 
The study utilized multiple quantitative techniques, including an objective device (wrist 
actigraph), chart abstraction, questionnaires, visual analogue scales, and biological specimens to 
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measure the variables of the sleep/wake rhythm, sleep quality, daytime sleepiness, the IL-6 
rhythm, and quality of life in this sample. 
Sample Inclusion/Exclusion Criteria 
A purposeful sample of twenty asymptomatic HIV-seropositive African American 
women of childbearing age, experiencing HIV-related sleep disruption was recruited for this 
preliminary study. To be eligible, the potential subjects had to meet the following criteria: 
• Gender: Female 
• Race: African American  
• Age: 18-40 years  
• Documentation of current asymptomatic phase of HIV-1 infection 
• Experiencing HIV-related sleep disruption 
Limited by design, the aforementioned eligibility criteria were set to control for any sleep 
differences due to gender, race, age, and progression of disease. To further ensure that the sleep 
disruption was related to the purpose of this study, potential participants presenting with any of 
the following, either by self-report or upon review of the medical records, were excluded from 
the study:  
• Diagnosis or symptoms of a primary sleep disorder (i.e. narcolepsy, primary 
insomnia, primary hypersomnia)  
• Diagnosis or symptoms of a secondary sleep disorder not related to HIV (severe 
pain, sleep apnea, restless leg syndrome) 
• Sleep disruption prior to HIV exposure 
• Formal treatment for sleep disorders of any kind 
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• Diagnosis of a cognitive impairment (mental retardation, dementia, memory 
impairment) 
• Diagnosis of a major inflammatory disease (rheumatoid arthritis, inflammatory 
heart disease, systemic lupus erythematous) 
• Pregnancy 
• BMI calculation > 30 
• Average pain severity rating > 7 
• Diagnosis of a major psychiatric disorder (panic disorder, post-traumatic stress 
disorder, major depression)  
• Night-shift work 
• Any condition or illness, which in the opinion of the investigator, would interfere 
with patient safety or compliance to the study protocol 
Setting 
Participants for this study were recruited from Wayne State University Physician Group 
Infectious Diseases Clinic (ID Clinic) located at 3750 Woodward Ave. Detroit, Michigan. At the 
time, the ID Clinic served a 73% African American demographic and 83% of the females were 
African American. The clinic was equipped to treat most infectious diseases, however, the 
primary focus was HIV care. Patients of the clinic were educated on various types of research; 
and many had participated in government sponsored network trials [Community Programs for 
Clinical Research on AIDS (CPCRA), International Network for Strategic Initiatives in Global 
HIV Trials (INSIGHT), and AIDS Clinical Trials Group (ACTG)], pharmaceutical studies 
(Pfizer, GlaxoSmithKline, and Boehringer Ingelheim), and various local provider-driven studies. 
This setting was also ideal in that, as an employee of the WSU ID Research Department, the 
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Principal Investigator (PI) was able to establish a comfortable and trusting work-relationship of 
eight years with staff and patients of the ID Clinic alike.  
Recruitment 
A list of potential participants was generated from an eligibility query of the ID Clinic’s 
HIV/AIDS Program database. The program database was originally designed in 1994 to provide 
an aggregate of demographic and clinical data for grant reporting purposes. Over time, the 
database grew in size and complexity, and was now stored on a secured WSU School of 
Medicine server, managed by the Medical School Information Services Group (MSIS). The 
database was able to measure and closely monitor outcome objectives in order to ensure 
continued excellence in patient care and service delivery, as well as meet grantor requirements 
for data reporting. The database included data fields for demographic information, encounter 
data, diagnoses, hospitalizations, laboratory results, vital statistics, psychosocial data, 
immunization history, medication history, genotypes, clinical trials, and special research. The 
query request prompted a database search for all subjects who met the gender, race, age, and 
category of disease requirements listed in the eligibility criteria of this study. A query report was 
provided to the investigator listing one hundred potential participants meeting the inclusion 
criteria along with other pertinent information such as medical record number, ID physician, last 
CD4+ cell count and draw date, and date of last clinic visit. Once participant interest was 
established and their primary ID physician had given consent for participation in the study, the 
patient was able to start the research process beginning with informed consent as described 
below. A unique personal identification number (PID) was then assigned to each informed 
participant for identification purposes of all study-related documents, including source 
documents, laboratory requisitions, and questionnaires. The PID ensured confidentiality of 
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protected health information. The PIDs for this study followed the pattern SC001, SC002, 
SC003, and so on.   
Informed Consent 
Following HIC approval, the informed consent form was reviewed in detail with each 
interested participant to ensure full disclosure of the nature, objectives, and procedures of the 
study, as well as any anticipated risk, although minimal risk was associated with the study. 
Special attention was given to the fact that participation in the study was voluntary; meaning one 
could withdraw from the study at any point. Ample time was set aside for questions and 
concerns. Once full awareness was confirmed, the investigator obtained documented consent 
from each participant prior to any study-related data collection. Consent was documented by the 
participant’s dated signature on a consent form along with the dated signature of the investigator 
conducting the consent discussion. A copy of the signed consent form was given to the 
participant. 
Study Variables and Measurements 
 This section discusses the variables used to sketch a sample profile, as well as each of the 
major study variables explored in this study. The study variables examined were the CD4+ cell 
count, HIV RNA viral load, sleep/wake rhythm, sleep quality, daytime sleepiness, the IL-6 
rhythm, and quality of life. A study definition for the study variables will be provided, along 
with a discussion of the instruments used to measure each of these variables. Copies of the 
instruments can be found in the appendices.  
Study Variables and Measurements  
Sample Profile 
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Demographic and Lifestyle Questionnaire. Distinctive characteristics of the participants 
were collected in order to provide a profile summary of the sample of interest. The sample 
profile includes a description of the general demographic profile, medical profile, lifestyle 
profile, and sleep environmental profile obtained via chart abstraction of the participant’s ID 
medical chart and the Demographic and Lifestyle Questionnaire. The Demographic and Lifestyle 
Questionnaire is an investigator-developed questionnaire that includes a combination of 30 
forced-choice and fill-in response items. General demographic characteristics include age, 
marital status, religious affiliation, level of education, employment status, and income range. The 
medical profile consists of a general medical profile, HIV profile, and ART profile. General 
medical variables include body mass index (BMI), average pain level, menstrual cycle phase, 
and medication allergies. HIV disease variables include date of HIV diagnosis, mode of 
transmission, lowest CD4+ cell count, and highest HIV RNA viral load. ART variables include 
total time on ART, current ART use, current ART regimen, and the CNS penetration 
effectiveness score (CPE) of the current ART regimen. The lifestyle variables include various 
dietary sways (caffeine intake, time of last meal and liquids for the day), recreational medication 
use (alcohol, tobacco, and marijuana), and exercise habits. Lastly, the sleep variables include 
data on various sleeping habits, use of sleep aids or medications, and environmental sleep 
settings and preferences. Each of these characteristics or behaviors have been linked with or 
known to modify sleep and/or plasma IL-6 levels in the literature, and thus, were accounted for 
in this study.  
CD4+ Cell Count/HIV Viral Load 
CD4+ Cell Count. The CD4+ cell count in this study is the amount of T-helper 
lymphocyte cells expressing a surface protein CD4, which activates and helps determine the type 
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of immune response the body will make against a particular pathogen. The CD4+ cell count is an 
indication of the strength of the immune system and was obtained by the most recent 
documentation of a T-cell lymphocyte subpopulation from the medical chart. The CD4+ cell 
count is expressed in cubic millimeters. Rationale for this measure was to account for the 
strength of the immune system in defending the body, which may influence the likelihood of 
experiencing opportunistic infections (candidiasis, pneumocystis carinii pneumonia, herpes 
zoster) and HIV symptomologies (unexplained diarrhea, seborrheic dermatitis, papular pruritic 
eruptions) that have been found to create annoyances, disrupting sleep. 
HIV RNA Viral Load. The HIV RNA viral load in this study is the amount of HIV viral 
copies or genetic material (RNA) present in the blood. The viral load is an indication of the 
strength of the HIV disease and was obtained by the most recent documentation of an 
ultrasensitive HIV-RNA by PCR from the medical chart. The HIV viral load is expressed in 
RNA copies per milliliter. Rationale for this measure was to account for the accretion of the 
virus in dismantling the body, which may influence the likelihood of experiencing HIV-
symptomologies and the dysregulation of IL-6, both of which have been found to distort and 
abrogate normal sleep.  
Sleep/Wake Rhythm 
The sleep/wake rhythm in this study is a circadian pattern of rest and activity of the body. 
Each 24-hour period of the sleep/wake rhythm was uniformly broken into two 12-hour segments, 
a sleep segment followed by a wake segment. Similar to Lee, Portillo, and Miramontes’ study 
(2001), specific start and stop times for the sleep/wake segments were pre-set given that the 
protocol did not utilize a sleep log or sleep diary (due to a history of poor compliance) to help 
identify individualized sleep/wake segments. The sleep segment also referred to as “down” time, 
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was defined as 2100 to 0859 hours. The wake segment also referred to as “up” time, was defined 
as 0900 to 2059 hours. The objective experience of the sleep/wake rhythm was measured by a 
physiologic recording device, the MicroMini-Motionlogger® wrist actigraph. A picture of the 
wrist actigraph can be found in the appendices.  
Wrist Actigraph. The MicroMini-Motionlogger® (Ambulatory Monitoring Inc., Ardsley, 
NY) is a small, waterproof, watch-like microprocessor that with minimal imposition is usually 
attached to the nondominant wrist to provide continuous, noninvasive monitoring of wrist 
motion. Per the Material Safety Data Sheet (MSDS) from Precision Control Design, Inc., this 
product is a non-significant risk device. However, temporary discomfort and mild irritation from 
skin contact are potential risks if the device is strapped too tight or does not fit properly. The 
actigraph sensor measures linear acceleration of wrist movement in one-minute intervals 
(epochs), translates the motion into a numeric representation (activity count), then aggregates 
and digitally stores the values at a constant interval or epoch, which can be displayed 
graphically. Muscle activity is usually frequent during wakeful hours and infrequent during 
sleep. So, the presence or absence of muscle activity is then used to estimate various objective 
sleep/wake behaviors. The actigraph requires a microinterface and connector to download the 
data into a computer, and it comes with automatic sleep-scoring software (Action 4 and Action 
W Software Programs, Ambulatory Monitoring Inc., Ardsley, NY) for prompt analysis. The 
software programs offer various algorithms useful in scoring sleep/wake behaviors. Actigraphic 
data has been supported with electroencephalogram and polysomnographic measures of sleep 
with adequate validity (r = 0.93-0.99), sensitivity (80%), specificity (90%), and reliability in 
various groups of research subjects (Ancoli-Israel, Clopton, Klauber, Fell, & Mason, 1997; Hauri 
& Wisbey, 1992; Jean-Louis, Kripke, Mason, Elliott, & Youngstedt, 2001; Walsh et al., 1991). 
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According to recommendations put forth by The American Academy of Sleep Medicine as a 
result of a comprehensive review of the literature, wrist actigraphy has been useful and reliable 
in the assessment of many sleep, daytime sleepiness, and circadian rhythm disorders (Littner et 
al., 2003). Data obtained from the actigraph was used to estimate specific objective sleep/wake 
behaviors including sleep/wake minutes, sleep/wake episodes, minutes before sleep onset, sleep 
percentage, sleep efficiency, sleep fragmentation index, activity mean, activity index, and 
acceleration index. An operational definition for each of the sleep/wake indices is provided in the 
appendices. 
Sleep Quality 
Sleep quality in this study is the subjective perception of the restorative and undisturbed 
nature of the person’s sleep pattern. The Pittsburgh Sleep Quality Index (PSQI) was used to 
measure the general perception of sleep quality and the Subjective Sleep Quality Questionnaire 
(SSQ) was used to measure a nightly pattern of sleep quality.  
Pittsburgh Sleep Quality Index (PSQI). The Pittsburgh Sleep Quality Index (PSQI) is a 
19-item self-report scale used to measure general sleep quality. The PSQI measures seven 
components of sleep experienced within the past month, including a subjective account of sleep 
quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleep 
medications, and daytime functioning (Buysse et al., 1989). The respondent is first asked specific 
questions related to their usual sleep habits, like “During the past month, what time have you 
usually gone to bed at night?” Then, they are asked to rate various situations on a four-point 
Likert-type scale. For example, “During the past month, how often have you had trouble sleeping 
because you cannot breathe comfortably?” In each case, a score of “0” indicates no difficulty, 
while a score of “3” indicates severe difficulty. The 19 items together combined to yield one 
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“global” sleep quality score, ranging from 0 to 21. Higher scores indicate a decline in sleep 
quality or poor sleepers. Although a global score of 5 or greater has been the standard cutoff, 
some investigators, in testing HIV subjects, felt that 7 was a more conservative and reliable 
cutoff point to be able to differentiate good sleepers from poor sleepers (Buysse et al., 1991; 
Phillips, Sowell, et al., 2005). This index is one of the most widely used sleep quality 
instruments in sleep research, and it has been supported by sleep log and polysomnography data. 
The PSQI demonstrates 89.6% sensitivity, 86.5% specificity, a reliability coefficient of 0.83 
(Cronbach), and a test-retest reliability of 0.85-0.87 (Backhaus, Junghanns, Broocks, Riemann & 
Hohagen, 2002; Buysse et al., 1989).    
Subjective Sleep Quality Questionnaire (SSQ). The Subjective Sleep Quality 
Questionnaire (SSQ) is a 14-item self-report measurement used to examine the daily rhythmicity 
of the subjective feeling of sleep quality. The SSQ asks for the respondent’s impression of the 
quality and effectiveness of their last night’s sleep. An example of one of the items is “I had 
enough sleep last night”.  The responses are based on a six-point Likert scale, ranging from 1 
(strongly agree) to 6 (strongly disagree). Psychometric properties of the SSQ include an internal 
consistency well above acceptable range (α = 0.86-0.92), a high correlation with a visual 
analogue sleep quality scale (r = 0.93), as well as being reflective of select objective sleep data 
obtained from wrist actigraphy (Nunnally, 1978; Smith & Davis, 2002). 
Daytime Sleepiness 
Daytime sleepiness in this study is the subjective perception of how alert or sleepy a 
person feels during waking hours. The Epworth Sleepiness Scale (ESS) was used to measure the 
general perception of daytime sleepiness and the Stanford Sleepiness Scale (SSS) was used to 
measure a daily pattern of daytime sleepiness.  
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Epworth Sleepiness Scale (ESS). The Epworth Sleepiness Scale (ESS) is an eight-item 
self-report questionnaire used to measure general daytime sleepiness. The ESS retrospectively 
assesses sleep propensity, or a subjective estimate of the behavioral likelihood of falling asleep 
based on the current lifestyle (Johns, 1991; Pilcher, Pury, & Muth, 2003). The respondent is 
asked to indicate how likely they are to doze off or fall asleep while engaged in eight different 
activities of varying levels of stimulation. Examples of the activities include watching TV, 
talking to someone, and riding as a passenger in a car. Responses are based on a Likert-type 
scale ranging from 0 (would never doze) to 3 (high chance of dozing). The total score may range 
from 0 to a maximum of 24; and while 0-10 qualifies as normal range, 10-12 is borderline 
abnormal and 12-24 is abnormal. The ESS is often used in sleep research, including HIV sleep 
research. ESS scores have a reported internal consistency of 0.88 and a test-retest reliability of 
0.82 (Johns, 1992). The ESS has been significantly correlated to standard methods for measuring 
daytime sleepiness, the Multiple Sleep Latency Test (MSLT) and polysomnography (Johns, 
1991; Fong, Ho, & Wing, 2005).  
Stanford Sleepiness Scale (SSS). The Stanford Sleepiness Scale (SSS) is a one-item real-
time self-report questionnaire used to determine the daily rhythmicity of the subjective feeling of 
daytime sleepiness (Hoddes, Dement, & Zarcone, 1971). The respondent is asked to “circle the 
statement which best describes your state of sleepiness right now.” The statements are based on a 
seven-point Likert-type scale, ranging from 1 (alert) to 7 (almost asleep), and describe the level 
of sleepiness at the specific time the scale is administered. The instructions include a reference 
point of > 3, indicative of a sleep debt or the need for more sleep. Also included is a note that 
times of high alertness are commonly 9am and 9pm, with 3pm being a time of low alertness. 
Quite sensitive to discrete changes in sleepiness (Hoddes, Zarcone, Smyth, Phillips, & Dement, 
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1973), the SSS has been used mostly in sleep deprivation, sleep fragmentation, and circadian 
phase studies. Pilcher, Pury, & Muth (2003), asserted that the SSS looked more at the subjective 
feeling or internal state of sleepiness (verses a physiological state or behavioral propensity), 
especially when it intercorrelated so strongly with other measures of internal states, like the 
Profile of Mood States (POMS) and a Sleepiness Visual Analogue Scale.  
IL-6 Rhythm 
The IL-6 rhythm in this study is a circadian pattern of plasma interleukin-6 levels within 
the body. The IL-6 rhythm is a construct of four time-specific plasma IL-6 levels, as measured 
by human IL-6 immunoassay, plotted on a graph. The times for the blood collections in this 
study were 0500, 0800, 1900, and 2100 hours + 10 minutes. These times were based on the 
biphasic nadirs and zeniths of healthy participants reported in the literature.  
Human IL-6 Immunoassay. The Quantikine HSTM Human IL-6 Immunoassay (R&D 
Systems, Inc., Minneapolis, MN, USA) is a highly sensitivity enzyme-linked immunosorbent 
assay (ELISA) specifically engineered for the measurement of human IL-6 protein levels. IL-6 
levels are expressed in pg/mL, and the highly sensitive assay has a mean minimum detectable 
dose of 0.039 pg/mL. The specificity of the assay recognizes recombinant and natural human 
interleukin-6. Both the inter-assay and intra-assay precision coefficients of variation are < 10%, 
and the recovery, linearity, and calibration evaluations of this assay are all favorable.  
Quality of Life 
Quality of life in this study is the subjective measure of the sense of wellbeing that stems 
from the level of satisfaction with the areas in life that are important to the person (Ferrans, 
1990). The Quality of Life Index (QLI) was used to measure the general perception of quality of 
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life, and the Quality of Life Visual Analogue Scale (VAS-Q) was used to measure a daily pattern 
of quality of life.  
Quality of Life Index (QLI). The Quality of Life Index (QLI) is a 66-item questionnaire 
used to measure the general sense of wellbeing that stems from the satisfaction or dissatisfaction 
with various areas in life that are considered important. Five aspects of life are assessed 
including overall quality of life, health/functioning, psychological/spiritual, social/economical, 
and family (Ferrans & Powers, 1985). Each is said to be interrelated with the other, yet may exert 
differing levels of influence on one’s life as a whole (Ferrans, 1990; Mellors, Riley, & Erlen, 
1997). Respondents are first asked to describe their satisfaction level with various circumstances, 
such as, “Your chances for a happy future” or “The amount of worries in your life”. Respondents 
are then asked to rate those same circumstances in level of importance to them. Responses for 
both satisfaction and importance are based on a six-point Likert-scale ranging from 1 (very 
unsatisfied/unimportant) to 6 (very satisfied/important). By using the importance ratings to 
weight the satisfaction responses, items of greater importance have a greater impact on the 
scores, reflecting the satisfaction levels of the aspects in life that the respondent values most. 
Scores range from 0 to 30, with higher scores representing higher satisfaction and importance. 
Internal consistency reliability (0.73-0.99), test-retest reliability (0.78-0.87), sensitivity, and 
validity are supported by numerous studies, including those with HIV samples (Dougherty, 
Dewhurst, Nichol, & Spertus, 1998; Ferrans & Powers, 1992; Yang et al., 2003).  
Quality of Life Visual Analogue Scale (VAS-Q). The Quality of Life Visual Analogue 
Scale (VAS-Q) is a quick one-item self-mark scale used to measure the daily rhythmicity of the 
perception of quality of life. Unlike scales with discrete jumps or forced categorizations (mild, 
moderate, and severe), visual analogue scales (VAS) measure a subjective phenomenon on a 
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continuous spectrum, across a continuum of values with minimum constraints (Crichton, 2001). 
A visual analogue scale consists of a 10cm horizontal line, anchored on each end by words 
describing the boundaries of the continuum (none and most extreme). The respondent is asked to 
place a mark that corresponds to the level of the variable they are experiencing. For example, on 
the VAS-Q, the perceived level of quality of life felt by a person can range anywhere from “the 
worst possible quality of life” to “the best possible quality of life”. VAS data is scored by 
measuring the distance of the mark, in centimeters, from the edge of the line on the left anchor 
(0cm). The simple VAS, which is sensitive to subjective changes (Hauser & Walsh, 2008), has 
proven to be an adequate, reliable, and valid measure of quality of life (de Boer et al., 2004; 
Haywood, Garratt, Dziedzic, & Dawes, 2002; Mrus et al., 2002; Nahm, Resnick, Shaughnessy, 
Michael, & Kopunek, 2006; Sherman, Eisen, Burwinkle, & Varni, 2006).  
Data Collection Procedures 
 All aspects of the study were completed in accordance with HIPPA and Wayne State 
University guidelines. An overview of the research activities for each study period is presented 
as a flowchart in the appendices. Study related activities involved three phases: phase 1 included 
screening and baseline procedures, phase 2 included monitoring procedures, and phase 3 
included specimen collection and end of study procedures. 
Phase 1 
Screening. Screening occurred at the initial study visit. The study was explained in detail, 
an informed consent signed, and a personal identification number assigned as previously 
described. Eligibility to participate in the study was determined per the inclusion/exclusion 
criteria of this protocol. Once eligibility was confirmed, the participant completed a medical 
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history and physical examination including height, weight, and vital signs. The physical exam 
was a safety measure conducted to verify safe participation in the study. 
Baseline. Baseline data collection also occurred at the initial study visit just prior to the 
dispensing of the monitoring phase study packet. At baseline, the participant completed all 
general measures for a total of four questionnaires, including the Demographic and Lifestyle 
Questionnaire, Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and 
Quality of Life Index (QLI). Their ID medical chart was reviewed to obtain the most recent 
CD4+ cell count and HIV RNA viral load as well as the historically lowest CD4+ cell count and 
highest HIV RNA viral load. Next, the participant received the monitoring study packet, which 
included a wrist actigraph, the daily questionnaires, and a written copy of the instructions and 
investigator’s contact information. Detailed instructions on the monitoring phase procedures of 
the study included a review of the daily questionnaires and the maintenance, care, and proper fit 
of the monitoring device. The investigator conducted a fit test to check the safety of the wrist 
actigraph, and allowed extra time for any further questions and clarifications of instructions that 
arose. For each participant, a new battery was inserted before the actigraph was placed on the 
interface unit for initialization to record motion. Based on the manufacturer’s recommendations 
for human motion studies, the actigraph was configured to Low Proportional Integrating 
Measure (LoPIM) as the mode of operation for this study. Once successful initialization was 
confirmed, the actigraph was placed on the non-dominant arm, and the participant instructed to 
avoid removal of the actigraph, even when showering, without first consulting with the 
investigator to troubleshoot any unforeseen difficulties.    
Phase 2 
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Monitoring. The monitoring period occurred for four consecutive days (a 96-hour period) 
with the participant wearing a wrist actigraph on their non-dominant arm. Within 30 minutes 
from waking up each day, the participant completed two daily questionnaires related to sleep 
quality and quality of life, the Subjective Sleep Quality Questionnaire (SSQ) and Quality of Life 
Visual Analogue Scale (VAS-Q). Then, at four specific times throughout each of the four days 
(1000, 1300, 1600, and 1900 hours), the participant completed a daily questionnaire on daytime 
sleepiness, the Stanford Sleepiness Scale (SSS).  
Phase 3 
Specimen Collections. On Day 4, or the last day of the monitoring period, the participant 
had four plasma IL-6 samples collected at 0500, 0800, 1900, and 2100 hours. During business 
hours, participants had the option of the plasma specimens being collected either at the 3750 
Woodward Ave UPG ID Clinic Laboratory or a home visit (i.e. participant’s place of residence). 
These options were discussed in detail and agreed upon at the initial visit in order to minimize 
the risk of feelings of invasion of privacy. Using proper phlebotomy techniques, the investigator 
obtained the specimens via venipuncture with an EDTA venous blood vacuum collection tube + 
10 minutes of the target draw times. The specimens were then processed locally according to 
manufacturer recommendations. The specimens underwent 15 minutes of centrifugation at 1000x 
g within 30 minutes of collection. The plasma was removed, transferred into aliquots, and then 
stored in a freezer at < -20 C° until they were ready for shipment to the Cytokine Core 
Laboratory in Baltimore, Maryland for analysis.  
End of Study. The end of study occurred after the 2100 hour plasma IL-6 specimen 
collection to close out the study protocol. The participant returned the study materials 
(monitoring device and the 24 monitoring questionnaires) to the investigator, was thanked for 
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their participation in the study, and received $100 compensation for their time and 
inconvenience.  
Data Management and Analysis 
Participant research files were kept and accessed in accordance with HIPPA and Wayne 
State University guidelines. Data gathered was entered into a computer file for analysis using 
SPSS Version 17.0. In order to verify accuracy of data entry, the items entered were manually 
checked by the investigator and then rechecked by a member of the ID research staff. Important 
to note, there was no missing data for this study. Statistical analysis was divided into three 
sections. The first section used descriptive statistics to provide a sample profile of the 
participants in the study. The second section used descriptive statistics to depict the 
immunological integrity of the participants in the study. The third section of the analysis 
employed a combination of descriptive statistics, graphical representation, correlation, partial 
correlation, and agreement analysis to address the research questions posed for the specific aims 
of this study. 
Sample Profile 
A profile of the sample population, gathered from the ID medical chart and the 
Demographic and Lifestyle Questionnaire, included general demographic, medical, lifestyle, and 
sleep environment characteristics. Data from continuous profile characteristics are presented in 
terms of mean, standard deviation, and range. Data from categorical profile characteristics are 
described as frequency and percentage distributions.  
Immunological Integrity 
 Current CD4+ cell count and HIV RNA viral load were obtained from the ID medical 
chart. Continuous data are presented in terms of mean, standard deviation, median, and range. 
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Categorical data are described as frequency and percentage distributions. In accordance with the 
model, Pearson’s correlation coefficient analysis was used to test for potentially significant 
relationships between the variables of immunological integrity and the sleep/wake rhythm, sleep 
quality, daytime sleepiness, and IL-6. Each of the relationships tested for significance are 
presented in the appendices. The level of significance for analyses was set at p < 0.05 (two-
tailed).  
Specific Aims 
Specific aim #1 end-point was to provide a clinical picture of the HIV-related sleep 
disruption experienced in asymptomatic HIV-seropositive African American women, as 
manifested by the variables of sleep homeodynamics (sleep/wake rhythm, sleep quality, daytime 
sleepiness, interleukin-6 rhythm). 
Sleep/Wake Rhythm. The sleep/wake rhythm was the objective experience of the 
circadian pattern of rest and activity of the body, as measured by the MicroMini-Motionlogger® 
wrist actigraph. Each participant was able to wear the actigraph for the entire length of the four-
day study without difficulty. The raw actigraphic data was downloaded via the interface unit, and 
visually inspected before analysis to screen for artifacts and malfunctioning. Due to the potential 
interference of the blood draws on Day 4, the data was trimmed to include only the first three 
consecutive 24-hour periods (72 hours) of the protocol, just meeting the minimum 
recommendation put forth by the American Academy of Sleep Medicine (Littner et al., 2003). 
The sleep segment or down time was custom marked as 2100 to 0859 hours and the wake 
segment or up was marked as 0900 to 2059 hours. To address research question 1(A), actigraphic 
data from the down time and up time segments, as well as the total 24-hour interval (from 2100 
to 2059 hours) for each day of the protocol, was analyzed and scored using the University of 
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California, San Diego (UCSD) sleep estimation algorithm available within Action W 2.6 scoring 
software by Ambulatory Monitoring Inc. (Ardsley, New York). Each participant’s scored data 
was then entered into SPSS Version 17.0 for group analysis. Sleep/Wake indices are presented in 
terms of mean, standard deviation, and range. The strength and direction of the significant 
correlations with current CD4+ cell count and HIV RNA viral load are presented in the results 
section. The level of significance for analyses was set at p < 0.05 (two-tailed).  
Sleep Quality. The Pittsburgh Sleep Quality Index  (PSQI) and the Subjective Sleep 
Quality Questionnaire (SSQ) were scored according to supplier instructions. Descriptive and 
graphical statistics were used to summarize the general and rhythmic measures of sleep quality. 
Circadian rhythm data were plotted graphically for visual inspection and are included in the 
results section. Pearson’s correlation coefficient analysis was used to calculate the reliability of 
the Sleep Quality Questionnaire (SSQ) of the protocol. The strength and direction of the 
correlations for reliability, as well as the significant correlations with current CD4+ cell count 
and HIV RNA viral load are presented in the results section. The level of significance for 
analyses was set at p < 0.05 (two-tailed).  
Daytime Sleepiness. The Epworth Sleepiness Scale (ESS) and the Stanford Sleepiness 
Scale (SSS) were scored according to supplier instructions. Descriptive and graphical statistics 
were used to summarize the general and rhythmic measures of daytime sleepiness. Circadian 
rhythm data were plotted graphically for visual inspection and are included in the results section. 
Pearson’s correlation coefficient analysis was used to calculate the reliability of the Stanford 
Sleepiness Scale (SSS) of the protocol. The strength and direction of the correlations for 
reliability, as well as the significant correlations with current CD4+ cell count and HIV RNA 
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viral load are presented in the results section. The level of significance for analyses was set at p < 
0.05 (two-tailed).  
Interleukin-6 Rhythm. Each plasma IL-6 level was assayed in duplicate at the Cytokine 
Core Laboratory in Baltimore, Maryland and the result expressed as a mean of the two values. 
The average IL-6 level was calculated by averaging the four time-specific plasma IL-6 results. 
Descriptive and graphical statistics were used to summarize the general and rhythmic measures 
of the IL-6 rhythm. Circadian rhythm data were plotted graphically for visual inspection and are 
included in the results section. The strength and direction of the significant correlations with 
current CD4+ cell count and HIV RNA viral load are presented in the results section. The level of 
significance for analyses was set at p < 0.05 (two-tailed).  
Specific aim #2 end-point was to provide a depiction of the sense of wellbeing in 
asymptomatic HIV-seropositive African American women experiencing HIV-related sleep 
disruption, as manifested by quality of life. The Quality of Life Index (QLI) was scored 
according to supplier instructions, and the Quality of Life Visual Analogue Scale (VAS-Q) was 
scored by measuring the distance of the “mark” from the left anchor in millimeters. Descriptive 
and graphical statistics were used to summarize the general and rhythmic measures of the quality 
of life. Circadian rhythm data were plotted graphically for visual inspection and are included in 
the results section. Pearson’s correlation coefficient analysis was used to calculate the reliability 
of the Quality of Life Visual Analogue Scale (VAS-Q) of the protocol. The strength and 
direction of the correlations for reliability are presented in the results section. The level of 
significance for analyses was set at p < 0.05 (two-tailed).  
Specific aim #3 end-point was to explore potential links between specified rhythmic 
variables of sleep homeodynamics and wellbeing in asymptomatic HIV-seropositive African 
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American women experiencing HIV-related sleep disruption. Partial correlation analysis was 
used to calculate the degree of association between actigraphic sleep efficiency and Quality of 
Life Visual Analogue Scale (VAS-Q), Subjective Sleep Quality Questionnaire (SSQ) and 
Quality of Life Visual Analogue Scale (VAS-Q), Stanford Sleepiness Scale (SSS) and Quality of 
Life Visual Analogue Scale (VAS-Q), and average IL-6 level and Quality of Life Visual 
Analogue Scale (VAS-Q), while accounting or adjusting for the effects of immunological 
integrity. The strength and direction of the partial correlation are presented in the results section. 
The level of significance was set at 0.05 (two-tailed).  
Specific aim #4 end-point was to explore if the Quality of Life Visual Analogue Scale 
(VAS-Q) provided an adequate representation of the sense of wellbeing in asymptomatic HIV-
seropositive African American women experiencing HIV-related sleep disruption as the Quality 
of Life Index (QLI). Bland-Altman agreement analysis was used to estimate the agreement or 
repeatability between the Quality of Life Index (QLI) and the Quality of Life Visual Analogue 
Scale (VAS-Q). Agreement results are presented in the results section. 
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CHAPTER 5 
RESULTS 
The purpose of this descriptive study was to examine the dynamics of HIV-related sleep 
disruption and wellbeing as experienced in asymptomatic HIV-seropositive AA women. The 
results of this inquiry are presented in this chapter.  
Sample Profile 
A database search, as described in Chapter 4, was performed to help identify potential 
participants fitting the criteria of an asymptomatic AA female, between the ages of 18 and 40, 
with a recent CD4+ cell count over 300. The query generated an initial list of 100 names, of 
which many were further excluded after additional inquiry into BMI (35%), ethnicity (5%), 
current pregnancy status (2%), and gender at birth (1%). After obtaining provider approval to 
approach the remaining potential participants, many were found to be unreachable due to 
outdated contact information (24%), while some were simply not interested (5%). The final 28 
potential participants were enrolled in the study on a first come first serve basis for a final 
sample total of 20 (n = 20). Each participant who signed an informed consent form completed 
the four-day protocol, and thus data for a total of 20 AA women of childbearing age were 
gathered for this exploratory study. 
General Demographic Profile 
Table 5.1 presents the general demographic characteristics of the sample. The mean age 
of the sample was 32.20 (SD = 5.03) years. Actual ages ranged from 20 to 39 years old, with two 
(10%) subjects between the ages of 18-25 years old, eight (40%) were between 26-33 years old, 
and 10 (50%) were between 34-40 years old. In terms of marital status, 14 (70%) of the subjects 
were single, never married, while three (15%) were married, one (5%) was separated, and two 
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(10%) were divorced. Nineteen, or 95% of the subjects, reported a Christian religious affiliation. 
In terms of educational level, while five (25%) reported completing less than high school, 13, or 
65% of the sample, attended some college, one (5%) earned a 2-year college degree, and one 
(5%) had a graduate level degree. Employment status was classified into four categories: 
unemployed, student, part-time employment, and full-time employment. Seven (35%) of the 
participants were unemployed, four (20%) were students, five (25%) were employed part-time, 
and four (20%) were employed full-time. To further describe those classified as unemployed, 
three (15%) had been without a job for more than one year while the other four (20%) were on 
disability and unable to work. About 15 (75%) of the participants reported a yearly income of 
less than $10,000. Lastly, the reported household size for the sample ranged from 1 to 7 
members with a mean of 3.60 (SD = 1.39) persons per household. 
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Table 5.1. General Demographic Profile (N=20) 
Characteristics Mean SD SE N % 
Age (years) 32.20 5.03 1.12 -- -- 
     Age 18-25 Yrs -- -- -- 2 10 
     Age 26-33 Yrs -- -- -- 8 40 
     Age 34-40 Yrs -- -- -- 10 50 
Marital Status      
     Single -- -- -- 14 70 
     Married -- -- -- 3 15 
     Separated -- -- -- 1 5 
     Divorced -- -- -- 2 10 
Religious Affiliation      
     Christian -- -- -- 19 95 
     Other/None -- -- -- 1 5 
Educational Level      
     Less than High School -- -- -- 5 25 
     Some College -- -- -- 13 65 
     2Yr College Degree -- -- -- 1 5 
     Graduate Level Degree -- -- -- 1 5 
Employment Status      
     Unemployed -- -- -- 7 35 
     Student -- -- -- 4 20 
     Part-Time -- -- -- 5 25 
     Full-Time -- -- -- 4 20 
Unemployed       
     More than 1Yr -- -- -- 3 15 
     Unable to Work -- -- -- 4 20 
Income Range      
     Less than $10,000 -- -- -- 15 75 
     $10-19,000 -- -- -- 2 10 
     $20-39,000 -- -- -- 2 10 
     $40-59,000 -- -- -- 1 5 
Household Size 3.60 1.39 0.31 -- -- 
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Medical Profile 
Table 5.2 presents the medical variables for the sample. Participants had a mean body 
mass index (BMI) of 25.93 (SD = 3.22, Mdn = 26.40) with an inclusive range of 19.60 to 29.80. 
The mean pain level on a scale of 0 to 10 was 1.83 (SD = 1.90, Mdn = 1.00); inclusive range 0 to 
5. In terms of the menstrual cycle phase of the participants while in the study, nine (45%) were in 
the follicular phase, five (25%) were in the luteal phase, four (20%) experienced a mix of both 
follicular and luteal phases during the four-day protocol, and two (10%) were unable to be 
determined due to a hysterectomy and complications from an IUD placement. Four (20%) 
participants reported having medication allergies to various pain medications, antibiotics, and 
other OTC and prescription drugs.   
Table 5.2. Medical Profile (N=20) 
Characteristics Mean SD SE Median Minimum Maximum N % 
BMI 25.93 3.22 0.72 26.40 19.60 29.80 -- -- 
Pain Level 1.83 1.90 0.42 1.00 0.00 5.00 -- -- 
Menstrual Cycle Phase         
     Follicular Phase -- -- -- -- -- -- 9 45 
     Luteal Phase -- -- -- -- -- -- 5 25 
     Both Follicualr/Luteal -- -- -- -- -- -- 4 20 
     Unable to Determine -- -- -- -- -- -- 2 10 
Medication Allergies -- -- -- -- -- -- 4 20 
 
In reference to HIV disease, data collection included length of time since diagnosis, mode 
of transmission, history of the lowest CD4+ cell count, history of the highest HIV RNA viral 
load, total length of time on antiretroviral therapy (ART), current ART use, current ART 
regimen, and CNS penetration effectiveness (CPE) of the current ART regimen. Table 5.3 
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presents the HIV medical variables for the sample. The length of time since HIV diagnosis 
ranged from 8 to 309 months with a group mean of 92.12 (SD = 82.77) months. To express time 
since diagnosis in terms of years, 5% (n = 1) had been living with HIV less than 1 year, while 
35% (n = 7) reported 1 to 5 years, 40% (n = 8) 5 to 10 years, and 20% (n = 4) more than 10 
years. Eighteen, or 90% of participants contracted HIV from heterosexual contact; the remaining 
two (10%) experienced a mother-to-infant transmission at birth (MTIT). In terms of immune 
status history, 3 (15%) participants had a CD4 lower than 250 cells/mm3 at some point in the 
history of their disease progression. The group’s lowest CD4 mean was 356.40 (SD = 155.35) 
cells/mm3. With regard to viral status, 16 (80%) participants had a HIV viral load higher than 
1000 copies/mL at some point in the progression of their disease with a mean of 43,678.85 (SD = 
70,278.39) copies/mL for the group’s highest viral load.  
Table 5.3. HIV Profile (N=20) 
Characteristics Mean SD SE Median Minimum Maximum N % 
Time since HIV Diagnosis (months) 92.12 82.77 18.51 64.40 8.00 309.00 -- -- 
HIV Diagnosis Range         
     Less than 1 Yr -- -- -- -- -- -- 1 5 
     1 – 5 Yrs  -- -- -- -- -- -- 7 35 
     5 – 10 Yrs -- -- -- -- -- -- 8 40 
     More than 10 Yrs -- -- -- -- -- -- 4 20 
Transmission Mode         
     Birth (MTIT) -- -- -- -- -- -- 2 10 
     Heterosexual Contact -- -- -- -- -- -- 18 90 
Lowest CD4 (cells/mm3) 356.40 155.35 34.74 310.00 91 703 -- -- 
     Lowest CD4 under 250  -- -- -- -- -- -- 3 15 
Highest VL (copies/mL) 43678.85 70278.39 15714.73 11270.00 80 299000 -- -- 
     Highest VL over 1000 -- -- -- -- -- -- 16 80 
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In terms of treatment, ART characteristics for the sample are presented in Table 5.4. The 
mean time on ART was 67.25 months (SD = 92.07) with an inclusive range of 0 to 312 months. 
Expressed in years, 20% (n = 4) were ART-naïve, 35% (n = 7) had taken HIV medications less 
than 1 year, 15% (n = 3) 1 to 5 years, 20% (n = 4) 5 to 10 years, and 10% (n = 2) more than 10 
years. Of the ART-experienced participants, 12 (60%) were on a current ART regimen at the 
time of study. The most common regimens were Norvir-boosted Reyataz with Truvada (ATV/R 
+ TRU, n = 4, 20%), followed by Norvir-boosted Reyataz with Epzicom (ATV/R + EPZ, n = 2, 
10%) and Norvir-boosted Prezista with Truvada (DRV/R + TRU, n = 2, 10%). Other regimens 
included Kaletra with Epzicom (LPV + EPZ, n = 1, 5%), Viramune with Epzicom (NVP + EPZ, 
n = 1, 5%), Raltegravir plus Reyataz with Truvada (RAL + ATV + TRU, n = 1, 5%), and Atripla 
(n = 1, 5%). In order of increasing effectiveness, the cumulative CNS penetration effectiveness 
scores (CPE) of the current ART regimens were six (n = 4, 20%), seven (n = 5, 25%), eight (n = 
1, 5%), and nine (n = 2, 10%). Those who were not currently on an ART regimen were given a 
CPE score of zero (n = 8, 40%).  
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Table 5.4. ART Profile (N=20) 
Characteristics Mean SD SE Minimum Maximum N % 
Time on ART (months) 67.25 92.07 20.59 0.00 312.00 -- -- 
ART Range (years)        
     ART Naïve -- -- -- -- -- 4 20 
     Less than 1 Yr -- -- -- -- -- 7 35 
     1 – 5 Yrs -- -- -- -- -- 3 15 
     5 – 10 Yrs -- -- -- -- -- 4 20 
     More than 10 Yrs -- -- -- -- -- 2 10 
Current ART Use -- -- -- -- -- 12 60 
Current ART Regimen        
     ART Naïve (CPE0) -- -- -- -- -- 4 20 
     ART Hx Only (CPE0) -- -- -- -- -- 4 20 
     ATV/R + TRU (CPE6) -- -- -- -- -- 4 20 
     ATV/R + EPZ (CPE7) -- -- -- -- -- 2 10 
     DRV/R + TRU (CPE7) -- -- -- -- -- 2 10 
     LPV + EPZ (CPE8) -- -- -- -- -- 1 5 
     NVP + EPZ (CPE9) -- -- -- -- -- 1 5 
     RAL + ATV + TRU (CPE9) -- -- -- -- -- 1 5 
     ATRIPLA (CPE7) -- -- -- -- -- 1 5 
CNS Penetration Effectiveness (CPE)        
     0 -- -- -- -- -- 8 40 
     6 -- -- -- -- -- 4 20 
     7 -- -- -- -- -- 5 25 
     8 -- -- -- -- -- 1 5 
     9 -- -- -- -- -- 2 10 
 
Lifestyle Profile 
Lifestyle tendencies of the participants are presented in Table 5.5. Nine (45%) 
participants had used tobacco in the last four weeks prior to study participation. Those who 
smoked, smoked anywhere from 2 to 20 cigarettes per day (M = 7.89, SD = 5.75), for 3 to 22 
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years (M = 13.89, SD = 6.39). Seven (35%) of the 20 participants were frequently exposed to 
second-hand smoke in the household, five (25%) of who did not smoke themselves. In terms of 
alcohol use, 13 (65%) participants had consumed alcohol in the last four weeks. Two (10%) 
participants reported daily alcohol use, ranging from one to five drinks per day (M = 3.00, SD = 
2.83), while five (25%) reported weekly use ranging from two to three drinks per week (M = 
2.20, SD = 0.45), and the remaining six (30%) participants, reported 2 to 12 drinks per month (M 
= 3.83, SD = 4.02). In terms of caffeine intake, 90% (n = 18) of respondents had consumed one 
to six multi-serving size cups per day of various caffeinated beverages, such as coffee, tea, or 
soda in the last four weeks (M = 3.17, SD = 1.86). In reference to illicit substances, six (30%) 
participants disclosed marijuana use within the last four weeks. Fourteen (70%) of the 
participants reported eating their last meal of the day by mid-evening (6-8pm), five (25%) 
reported eating by late-evening (9-11pm), and one (5%) ate after midnight. Sixty percent (n = 
12) of participants reported consuming their last liquids for the day right at bedtime. Finally, 
three (15%) of the participants reported regular exercise in the last four weeks. One (5%) of the 
three exercised at least once a week, while the other two (10%) reported exercising several times 
a week.  
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Table 5.5. Lifestyle Profile (N=20) 
Characteristics N % Mean SD SE 
Tobacco Use 9 45 -- -- -- 
     Cigarettes/Day -- -- 7.89 5.75 1.29 
     Years Smoked (years) -- -- 13.89 6.39 1.43 
Second-Hand Smoke 7 35 -- -- -- 
Alcohol Use 13 65 -- -- -- 
     Drinks/Day -- -- 3.00 2.83 0.63 
     Drinks/Week -- -- 2.20 0.45 0.10 
     Drinks/Month -- -- 3.83 4.02 0.90 
Caffeine Intake 18 90 -- -- -- 
     Large Cups/Day -- -- 3.17 1.86 0.42 
Marijuana Use 6 30 -- -- -- 
Last Meal      
     Mid Evening 14 70 -- -- -- 
     Late Evening  5 25 -- -- -- 
     Midnight or Later  1 5 -- -- -- 
     Bedtime Liquids  12 60 -- -- -- 
Exercise 3 15 -- -- -- 
     Once a Week 1 5 -- -- -- 
     Several Times a Week 2 10 -- -- -- 
 
Sleep Environment Profile 
 The sleep environment conditions of the sample are presented in Table 5.6. As observed, 
18 (90%) of the participants expressed that they actually enjoyed sleeping. None of the 
participants reported the use of sleeping aids or sleep medications in the last 4 weeks. Common 
idiosyncrasies noted to disrupt sleep were snoring (15%), teeth grinding (15%), sleep-talking 
(15%), bad dreams (15%), and sinus trouble during the night (25%). One hundred percent (n = 
20) of the participants conveyed the need to sleep in a dark room. And while 16 (80%) of 
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participants stated that they preferred to sleep in a quiet environment, 65% (n = 13) admitted that 
they normally slept with the television on, and 15% (n = 3) slept with music. One (5%) 
participant expressed the need to read before going to sleep. As far as mattress comfort level, 14 
(70%) of the respondents thought that their mattress was just right, whereas 4 (20%) found their 
mattress too hard and 2 (10%) reported their mattress too soft. Fifty-five percent (n = 11) of 
participants slept alone, while 30% (n = 6) reported an adult bed partner, and 15% (n = 3) had a 
child sleeping in the same bed and/or bedroom with them on a regular basis. Four (20%) 
participants described their bedroom as a multipurpose room used for more than just sleeping.   
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Table 5.6. Sleep Environment Profile (N=20) 
Characteristics N % 
Likes to Sleep 18 90 
Sleep Aids/Medication Use 0 0 
Snores 3 15 
Teeth Grinding 3 15 
Sleep-Talking 3 15 
Bad Dreams 3 15 
Sinus Trouble: Nighttime 5 25 
Bedroom Lighting: Dark 20 100 
Bedroom Noise: Quiet 16 80 
Sleeps with TV 13 65 
Sleeps with Music 3 15 
Reads to Sleep 1 5 
Mattress Comfort level   
     Just Right (Comfortable) 14 70 
     Too Hard (Uncomfortable) 4 20 
     Too Soft (Uncomfortable) 2 10 
Sleeps Alone 11 55 
Bed/Bedroom Partner   
     Adult Bed/Bedroom Partner 6 30 
     Child Bed/Bedroom Partner 3 15 
Multipurpose Bedroom 4 20 
 
Immunological Integrity 
 Immunological integrity was represented in this study by current CD4+ cell count and 
HIV RNA viral load, which were abstracted from the participant’s ID medical chart. Results 
were obtained from blood collections within 12.36 months prior to enrollment into the study (M 
= 3.28 months, SD = 2.84) and are presented in Table 5.7. Current CD4+ cell counts ranged 
anywhere from 252 to 1080 cells/mm3 with 45% (n = 9) over 500 cells/mm3. The group mean 
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was 605.80 (SD = 264.58, Mdn = 483.00) cells/mm3 while the median was 483 cells/mm3. 
Current viral loads ranged from 40 to 75,900 copies/mL with 65% (n = 13) under 1000 
copies/mL and 45% (n = 9) undetectable or less than 48 viral copies/mL. The group mean was 
6,660.35 (SD = 18441.40, Mdn = 118.00) copies/mL while the median was 118 copies/mL.  
Table 5.7. Immunological Integrity Profile (N=20) 
Characteristics Mean SD SE Median Minimum Maximum N % 
Time Since Labs (months) 3.28 2.84 0.64 2.55 0.33 12.36 -- -- 
Current CD4 (cells/mm3) 605.80 264.58 59.16 483.00 252 1080 -- -- 
     Current CD4 over 500 -- -- -- -- -- -- 9 45 
Current VL (copies/mL) 6660.35 18441.40 4123.62 118.00 40 75900 -- -- 
     Current VL under 1000 -- -- -- -- -- -- 13 65 
     Current VL under 48 -- -- -- -- -- -- 9 45 
 
Specific Study Aims 
Data were gathered over a period of four days for each subject in an effort to answer the 
research questions of the specific aims posed in the present study. However, due to the potential 
interference imposed by the time-specified blood draws on Day 4 of the protocol, the following 
analyses only include the first three days of data collection.  
Specific Aim 1 
Specific aim one was to describe the sleep homeodynamics of HIV-related sleep 
disruption in asymptomatic HIV-seropositive African American women, as evidenced by 
sleep/wake rhythm, sleep quality, daytime sleepiness, and interleukin-6 rhythm.  
Research Question 1(A): What are the characteristics of the sleep/wake rhythm? 
Sleep Segment. Descriptive statistics of the sleep segment (down time) are presented in 
Table 5.8 and the 3-day rhythm graphs of specific variables in the sleep segment are presented in 
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Figure 5.1, 5.2, 5.3, and 5.4. The sleep segment spanned a total period of 720 minutes (12 hours), 
from 2100 hours to 0900 hours each of the three days included in the analysis. The mean total 
minutes scored as sleep, during down time, was 384.10 (SD = 99.62) minutes or 6.4 hours (SD = 
1.67). Participants slept anywhere from 2.45 hours to 9.70 hours across the 3 nights, with 45% of 
the sample averaging less than 6 hours of sleep per night, 35% averaging 6 to 8 hours, and 25% 
over 8 hours. The mean number of minutes from 2100 hours to the start of the first continuous 
block of at least 20 minutes of scored sleep (down minutes before sleep onset) was 219.03 (SD = 
114.80) minutes or 3.7 hours. And although most participants fell asleep sometime after 
midnight each night, four (6.7%) of the nights a participant initiated sleep onset prior to 2100 
hours. Participants experienced an average of 18.25 (SD = 6.55) down wake episodes 
(awakenings) per night, and the mean total minutes, scored as wake, during down time, was 
336.88 (SD = 99.63) minutes or 5.6 hours. Accordingly, the calculated mean down sleep 
percentage was 53.28 (SD = 13.28) percent, the mean down sleep efficiency was 81.27 (SD = 
8.90) percent, and the mean down sleep fragmentation index was 5.08 (SD = 1.94). Current 
CD4+ cell count and HIV RNA viral load did not correlate significantly with any of the down 
segment indices in this protocol.    
Wake Segment. Descriptive statistics of the wake segment (up time) are presented in 
Table 5.8 and the 3-day rhythm graphs of specific variables in the wake segment are presented in 
Figure 5.5, 5.6, 5.7, and 5.8. The wake segment spanned a total period of 720 minutes (12 hours), 
from 0900 hours to 2100 hours following each of the three sleep segments included in the 
analysis. Inspection of the raw actigraphic data revealed that three participants remained awake 
and active all three of the days in this study. In fact, 15 out of the 60 nights (25%) analyzed, 
participant’s nocturnal sleep period ran past the 0900 hours marker into the wake segment. 
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Nonetheless, the mean total minutes scored as wake, during up time, for the sample was 645.55 
(SD = 55.54) minutes or 10.76 hours (SD = 0.93). The percentage of time awake during this 
period ranged from 77.69% to 99.77%, with an average of 89.66% + 7.71%. The mean activity 
score for the wake segment was 11402.77 (SD = 4350.05), while the mean total minutes scored 
as sleep, during this time was 75.32 (SD = 55.41) minutes or 1.25 hours. On average, the 
participants experienced 9.20 (SD = 6.50) up sleep episodes (naps) per day, and such naps lasting 
longer than 30 minutes were observed in 11 (55%) of the 20 women. Accordingly, the calculated 
mean up sleep percentage was 10.45% (SD = 7.69), mean up activity index was 99.17 (SD = 
1.04), and mean up acceleration index was 0.07 (SD = 0.09). Current CD4+ cell count was 
significantly correlated with up wake minutes (r = 0.61, p = 0.005), up sleep minutes (r = -0.61, p 
= 0.005), and up sleep percentage (r = -0.61, p = 0.005); however, HIV RNA viral load did not 
correlate significantly with any of the up segment indices in this protocol.  
Twenty-four Hour Rhythm. The 24-hour rhythm measures of total sleep/wake minutes are 
also presented in Table 5.8.  
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Table 5.8. Descriptive Statistics for Sleep/Wake Rhythm (N = 20) 
Variables Mean SD SE Minimum Maximum N % 
Sleep prior to Down Time (Nights) -- -- -- -- -- 4/60 6.7 
Down Sleep Minutes  384.10 99.62 22.28 192.67 536.67 -- -- 
     Slept < 6 Hours per night -- -- -- -- -- 9 45 
     Slept 6-8 Hours per night -- -- -- -- -- 7 35 
     Slept > 8 Hours per night -- -- -- -- -- 4 20 
Down Minutes before Sleep Onset  219.03 114.80 25.67 35.00 439.67 -- -- 
Down Wake Episodes (Awakenings) 18.25 6.55 1.46 10.00 30.33 -- -- 
Down Wake Minutes 336.88 99.63 22.28 184.33 528.33 -- -- 
Down Sleep Percentage  53.28 13.82 3.09 26.72 74.43 -- -- 
Down Sleep Efficiency  81.27 8.90 1.99 59.69 96.40 -- -- 
Down Sleep Fragmentation Index 5.08 1.94 0.43 2.12 8.64 -- -- 
Sleep thru Up Time (Nights) -- -- -- -- -- 15/60 25 
Up Wake Minutes  645.55 55.54 12.42 559.33 718.33 -- -- 
Up Activity Mean  11402.77 4350.05 972.70 5913.16 21031.22 -- -- 
Up Sleep Episodes (Naps) 9.20 6.50 1.45 1.00 25.00 -- -- 
Up Sleep Minutes  75.32 55.41 12.39 2.67 161.67 -- -- 
     Naps > 30 minutes -- -- -- -- -- 11 55 
Up Sleep Percentage 10.45 7.69 1.72 0.37 22.42 -- -- 
Up Activity Index  99.17 1.04 0.23 97.09 100.00 -- -- 
Up Acceleration Index  0.07 0.09 0.02 -0.11 0.28 -- -- 
24-Hour Total Sleep Time  459.02 97.85 21.88 303.67 643.33 -- -- 
24-Hour Total Wake Time  980.98 97.85 21.88 796.67 1136.33 -- -- 
 
 
	  	  
	  
95 
	  	  	  	  	  	  	  	  	  	  	  	   	  
            
Figure 5.1-4. 3-Day Rhythm of the Sleep Segment as measured by Down Sleep Minutes, Down 
Wake Episodes, Down Sleep Efficiency, and Down Sleep Percentage 
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Figure 5.5-8. 3-Day Rhythm of the Wake Segment as measured by Up Wake Minutes, Up Sleep 
Episodes, Up Activity Mean, and Up Sleep Percentage     	  
Research Question 1(B): What is the perception of sleep quality? 
Table 5.9 and Figures 5.9 and 5.10 present the sample’s overall perception of sleep 
quality, as measured by the well-known Pittsburgh Sleep Quality Index (PSQI), and the daily 
rhythm of perceived sleep quality, as measured by the Subjective Sleep Quality Questionnaire 
(SSQ).  
Pittsburgh Sleep Quality Index (PSQI). The PSQI was completed at baseline to obtain a 
global sleep quality score in order to distinguish the good sleepers from the poor sleepers. Using 
a conservative cutoff score of seven modified for HIV samples (Phillips, Sowell, et al., 2005), 
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100% (n = 20) were either at or above the cutoff. The study yielded PSQI scores that ranged 
from 7 to 15, and the sample mean was 9.80 (SD = 2.44; Cronbach’s alpha 0.547). Current CD4+ 
cell count and HIV RNA viral load did not correlate significantly with the Pittsburgh Sleep 
Quality Index in this protocol. 
Subjective Sleep Quality Questionnaire (SSQ). The SSQ is a 14-item Likert-based scale 
that was completed within 30 minutes of awakening in order to give a subjective account of the 
previous night’s quality of sleep. With higher scores reflective of a good night’s rest, the sample 
showed a progressive decline throughout the protocol. The Day 1 mean was 3.87 (SD = 1.19; 
Cronbach’s alpha 0.911), the Day 2 mean was 3.82 (SD = 1.25; Cronbach’s alpha 0.929), and the 
Day 3 mean was 3.76 (SD = 0.94; Cronbach’s alpha 0.835). Overall 3-day scores ranged from 
2.02 to 5.36, and while the group mean was 3.82 (SD = 0.97), four (20%) participants scored 
below the tools mean of 3. The reliability correlations presented in Table 5.10 were significant 
between Day 1 and Day 2 SSQ measures (r = 0.567, p = 0.009) and Day 2 and Day 3 measures (r 
= 0.823, p = 0.000), but not Day 1 and Day 3 measures (r = 0.427, p = 0.061). Current CD4+ cell 
count and HIV RNA viral load did not correlate significantly with the Subjective Sleep Quality 
Questionnaire in this protocol. 
Table 5.9. Descriptive Statistics for Sleep Quality Variables (N = 20) 
Variables Mean SD SE Minimum Maximum N % 
PSQI 9.80 2.44 0.55 7 15 -- -- 
     PSQI > 7 -- -- -- -- -- 20 100 
SSQ Day 1 3.87 1.19 0.27 1.57 5.71 -- -- 
SSQ Day 2 3.82 1.25 0.28 2.00 5.86 -- -- 
SSQ Day 3 3.76 0.94 0.21 1.71 5.43 -- -- 
SSQ for 3 Days 3.82 0.97 0.22 2.02 5.36 -- -- 
     SSQ < 3 -- -- -- -- -- 4 20 
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Figure 5.9. Histograms of Sleep Quality Variables as measured by PSQI and Mean SSQ 
Table 5.10. Reliability of Subjective Sleep Quality Questionnaire 
  SSQ Day 1 SSQ Day2 SSQ Day3 
Pearson Correlation 1 0.567** 0.427 
Sig. (2-tailed)  0.009 0.061 
SSQ Day1 
N 20 20 20 
Pearson Correlation 0.567** 1 0.823** 
Sig. (2-tailed) 0.009  0.000 
SSQ Day2 
N 20 20 20 
Pearson Correlation 0.427 0.823** 1 
Sig. (2-tailed) 0.061 0.000  
SSQ Day3 
N 20 20 20 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Figure 5.10. 3-Day Rhythm of Sleep Quality as measured by SSQ 
Research Question 1(C): What is the perception of daytime sleepiness? 
  Table 5.11 and Figures 5.11 and 5.12 present the overall perception of daytime 
sleepiness, as measured by the Epworth Sleepiness Scale (ESS), and a daily rhythm of perceived 
daytime sleepiness, as measured by the Stanford Sleepiness Scale (SSS).  
Epworth Sleepiness Scale (ESS). The ESS was completed at baseline to obtain a general 
sense of daytime sleepiness through estimates of how likely the subject could fall asleep in 
various settings (Johns, 1991; Pilcher, Pury, & Muth, 2003). ESS scores ranged from 1 to 17 
with a sample mean of 8.90 (SD = 4.38; Cronbach’s alpha 0.755). As observed in Figure 10, 
eight (40%) participants scored in the abnormal range with a 10 or above. Current CD4+ cell 
count and HIV RNA viral load did not correlate significantly with the Epworth Sleepiness Scale 
in this protocol. 
Stanford Sleepiness Scale (SSS). Data from the SSS were gathered four times throughout 
each of the three days to determine the rhythmicity of the daytime sleepiness experienced 
throughout the protocol (Hoddes et al., 1971). Figure 11 depicts a daily rhythm by time and then 
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by day. Observed by time, the 1000-hour group mean was 2.50 (SD = 1.57), the 1300-hour mean 
was 1.97 (SD = 1.01), the 1600-hour mean was 2.75 (SD = 1.28), and the 2100h-hour mean was 
3.30 (SD = 1.80). When observed by day, the group SSS score for Day 1 yielded a mean of 2.68 
(SD = 1.12), Day 2 was 2.76 (SD = 1.29), and Day 3 was 2.45 (SD = 1.02). The 3-day 
cumulative scores ranged from 1.42 to 4.67, and although the group mean was 2.63 (SD = 0.94), 
five (25%) participants score above the tools cut-off indicating the need for more sleep. The 
reliability correlations presented in Table 5.12 were significant between Day 1 and Day 2 SSS 
measures (r = 0.544, p = 0.013) and Day 2 and Day 3 measures (r = 0.580, p = 0.007), but not 
Day 1 and Day 3 measures (r = 0.403, p = 0.078). Current CD4+ cell count and HIV RNA viral 
load did not correlate significantly with the Stanford Sleepiness Scale in this protocol. 
Table 5.11. Descriptive Statistics for Daytime Sleepiness Variables (N = 20) 
Variables Mean SD SE Minimum Maximum N % 
ESS 8.90 4.38 0.98 1.00 17.00 -- -- 
     ESS > 10 -- -- -- -- -- 8 40 
SSS 1000  2.50 1.57 0.35 1.00 6.67 -- -- 
SSS 1300  1.97 1.01 0.23 1.00 4.67 -- -- 
SSS 1600  2.75 1.28 0.29 1.00 6.00 -- -- 
SSS 1900 3.30 1.80 0.40 1.00 6.33 -- -- 
SSS Day 1 2.68 1.12 0.25 1.00 4.50 -- -- 
SSS Day2  2.76 1.29 0.29 1.00 5.00 -- -- 
SSS Day 3  2.45 1.02 0.23 1.25 4.50 -- -- 
SSS for 3 Days 2.63 0.94 0.21 1.42 4.67 -- -- 
     SSS > 3 -- -- -- -- -- 5 25 
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Figure 5.11. Histogram of Daytime Sleepiness Variables 
 
Table 5.12. Reliability of Stanford Sleepiness Scale 
  SSS Day 1 SSS Day2 SSS Day3 
Pearson Correlation 1 0.544* 0.403 
Sig. (2-tailed)  0.013 0.078 
SSS Day1 
N 20 20 20 
Pearson Correlation 0.544* 1 0.580** 
Sig. (2-tailed) 0.013  0.007 
SSS Day2 
N 20 20 20 
Pearson Correlation 0.403 0.580** 1 
Sig. (2-tailed) 0.078 0.007  
SSS Day3 
N 20 20 20 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Figure 5.12. Daily Rhythm and 3-Day Rhythm of Daytime Sleepiness as measured by SSS.  
Research Question 1(D): What are the characteristics of the interleukin-6 rhythm? 
 The IL-6 rhythm was comprised of four time-specific plasma IL-6 levels over a 24-hour 
period based on the published peak (0500 and 1900 hours) and trough (0800 and 2100 hours) 
times. Data for the four IL-6 levels and the resulting circadian pattern are presented in Table 5.13 
and Figure 5.13. The sample’s 0500-hour results ranged from 0.50 to 8.46 pg/mL, and the mean 
was 2.46 (SD = 1.93). The 0800-hour results ranged from 0.27 to 9.23 pg/mL, the mean was 2.15 
(SD = 1.91). The 1900-hour results ranged from 0.37 to 8.79 pg/mL, the mean was 1.67 (SD = 
1.81). The 2100-hour results ranged from 0.34 to 8.89 pg/mL, the mean was 1.85 (SD = 1.85). 
After plotting the four IL-6 levels for each participant, four (20%) were found to follow a similar 
biphasic circadian pattern noted in the literature with the 0500 and 1900 hour levels higher than 
the 0800 and 2100 hour levels. Meanwhile, four (20%) participants followed an exact opposite 
biphasic pattern with 0500 and 1900 hour levels lower than the 0800 and 2100-hour levels. Three 
of the 20 (15%) started off with a high 0500-hour level with each subsequent value lower than 
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the previous level. The remaining nine (45%) participants had a mixture of other various patterns 
of peaks and troughs.  
Finally, an average of the four plasma IL-6 levels was calculated for each of the 
participants; the results are also presented in Table 13 and Figure 12. Average IL-6 levels ranged 
from 0.45 to 8.84 pg/mL, and the mean for the group was 2.03 (SD = 1.81). Current CD4+ cell 
count and HIV RNA viral load did not correlate significantly with average IL-6 level in this 
protocol.  
Table 5.13. Descriptive Statistics for IL-6 Rhythm (N = 20) 
Variables Mean SD SE Minimum Maximum 
Plasma IL-6 0500 2.46 1.93 0.43 0.50 8.46 
Plasma IL-6 0800 2.15 1.91 0.43 0.27 9.23 
Plasma IL-6 1900 1.67 1.81 0.40 0.37 8.79 
Plasma IL-6 2100 1.85 1.85 0.41 0.34 8.89 
Average IL6 Level 2.03 1.81 0.40 0.45 8.84 
          
Figure 5.13. Circadian IL-6 Rhythm and Frequency Histogram of the Average IL-6 Level. 
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Specific Aim 2 
Specific aim two was to describe wellbeing in asymptomatic HIV-seropositive African 
American women experiencing HIV-related sleep disruption, as evidenced by quality of life. 
Research Question 2: What is the perception of quality of life? 
To address research question 2, the Quality of Life Index (QLI) was used to gain an 
overall general perception of quality of life, while the Quality of Life Visual Analogue Scale 
(VAS-Q) was used to obtain a daily rhythm of quality of life. Results are presented in Table 5.14 
and Figures 5.14 and 5.15.  
Quality of Life Index (QLI). The QLI is a 66-item scale, which was administered at 
baseline to measure the sense of wellbeing stemming from the satisfaction or dissatisfaction with 
various areas in life that are considered important. Out of a possible 30 points, scores ranged 
from 7.16 to 28.31, and the sample’s mean was 21.28 (SD = 5.14; Cronbach’s alpha 0.890). 
Twelve (60%) participants scored above 20 on the index, expressing satisfaction with their 
quality of life, while only two (10%) scored below 15.  
Quality of Life Visual Analogue Scale (VAS-Q). The VAS-Q, on the other hand, is a 1-
item scale administered within 30 minutes of awakening each morning to measure the 
rhythmicity of the daily perception of quality of life on a scale from 0 (worst possible quality of 
life) to 10 (best possible quality of life). As observed in Figure 14, the mean score on Day 1 was 
6.36 (SD = 2.12) with a range from 2.25 to 9.80, the Day 2 mean score was 6.28 (SD = 2.33), 
range 0.20 to 10, and the Day 3 mean score was 6.31 (SD = 2.17), range 2.35 to 10. Collectively, 
the 3-day mean VAS-Q score was 6.32 (SD = 1.89), range 2.82 to 9.18, with 25% (n=5) of the 
participants scoring below the tool’s mean of 5. The reliability correlations presented in Table 
5.15 were significant between Day 2 and Day 3 VAS-Q measures (r = 0.774, p = 0.000) and Day 
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1 and Day 3 measures (r = 0.654, p = 0.002), but not Day 1 and Day 2 measures (r = 0.373, p = 
0.105).  
Table 5.14. Descriptive Statistics for Quality for Life Variables (N = 20) 
Variables Mean SD SE Minimum Maximum N % 
QLI 21.28 5.14 1.15 7.16 28.31 -- -- 
     QLI < 15 -- -- -- -- -- 2 10 
VAS-Q Day 1 6.36 2.12 0.47 2.25 9.80 -- -- 
VAS-Q Day 2 6.28 2.33 0.52 0.20 10.00 -- -- 
VAS-Q Day 3 6.31 2.17 0.49 2.35 10.00 -- -- 
VAS-Q for 3 Days  6.32 1.89 0.42 2.82 9.18 -- -- 
     VAS-Q < 5 -- -- -- -- -- 5 25 
 
 
 
 
 
 
 
 
 
 
Table 5.15. Reliability of Quality of Life Visual Analogue Scale 
  
VAS-Q Day 1 VAS-Q Day2 VAS-Q Day3 
Pearson Correlation 1 0.373 0.654** 
Sig. (2-tailed)  0.105 0.002 
VAS-Q 
Day1 
N 20 20 20 
Pearson Correlation 0.373 1 0.774** 
Sig. (2-tailed) 0.105  0.000 
VAS-Q 
Day2 
N 20 20 20 
Pearson Correlation 0.645** 0.774** 1 
Sig. (2-tailed) 0.002 0.000  
VAS-Q 
Day3 
N 20 20 20 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Figure 5.14. Histogram of Quality of Life Variables  
 
 
Figure 5.15. 3-Day Rhythm of Quality of Life as measured by VAS-Q  
Specific Aim 3 
Specific aim three was to determine the relationship between selected variables of sleep 
homeodynamics and wellbeing in asymptomatic HIV-seropositive African American women 
experiencing HIV-related sleep disruption.  
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In order to address specific aim 3, partial correlation analysis was used to assess the 
degree of association between down sleep efficiency of the sleep/wake rhythm, subjective sleep 
quality, subjective daytime sleepiness, and the average IL-6 level of the IL-6 rhythm and 
wellbeing, while accounting for or adjusting for the effects of the immunological integrity study 
variables, current CD4+ cell count and current HIV RNA viral load. The results of the partial 
correlation analysis are presented with a level of significance set at 0.05 (two-tailed) in Table 
5.16. Summary graphs of the study variable rhythms monitored across days and the rhythms 
monitored across 24 hours are presented in the appendix, respectively.    
Research Question 3(A): What is the strength and direction of the correlation between the 
sleep/wake rhythm and wellbeing, as measured by mean actigraphic down sleep efficiency and 
the Quality of Life Visual Analogue Scale? 
The correlation between mean actigraphic down sleep efficiency and mean Quality of 
Life Visual Analogue Scale was r = -0.050, p = 0.842. This is a weak negative relationship with 
no statistical significance between objective sleep efficiency of the sleep/wake rhythm and 
wellbeing when adjusting for the effects of immunological integrity.  
Research Question 3(B): What is the strength and direction of the correlation between sleep 
quality and wellbeing, as measured by the Subjective Sleep Quality Questionnaire and the 
Quality of Life Visual Analogue Scale? 
The correlation between mean Subjective Sleep Quality Questionnaire and mean Quality 
of Life Visual Analogue Scale was r = 0.415, p = 0.087. This is a weak positive relationship with 
no statistical significance between subjective sleep quality and wellbeing when adjusting for the 
effects of immunological integrity.  
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Research Question 3(C): What is the strength and direction of the correlation between daytime 
sleepiness and wellbeing, as measured by the Stanford Sleepiness Scale and the Quality of Life 
Visual Analogue Scale? 
 The correlation between mean Stanford Sleepiness Scale and mean Quality of Life Visual 
Analogue Scale was r = 0.023, p = 0.927. This is a weak positive relationship with no statistical 
significance between subjective daytime sleepiness and wellbeing when adjusting for the effects 
of immunological integrity.  
Research Question 3(D): What is the strength and direction of the correlation between the 
interleukin-6 rhythm and wellbeing, as measured by the average interleukin-6 level and the 
Quality of Life Visual Analogue Scale? 
  The correlation between average IL-6 and mean Quality of Life Visual Analogue Scale 
was r = -0.296, p = 0.233. This is a weak negative relationship with no statistical significance 
between IL-6 and wellbeing when adjusting for the effects of immunological integrity.  
Table 5.16. Partial Correlation Analysis 
Variable Scores 
Quality of Life Visual 
Analogue Scale (VAS-Q) 
Correlation - 0.50 
Significance (2-tailed) 0.842 
Down Sleep Efficiency (DSE) 
Df 16 
Correlation 0.415 
Significance (2-tailed) 0.087 
Subjective Sleep Quality 
Questionnaire Score (SSQ) 
Df 16 
Correlation 0.023 
Significance (2-tailed) 0.927 
Stanford Sleepiness Scale Score 
(SSS) 
Df 16 
Correlation - 0.296 
Significance (2-tailed) 0.233 
Average Interluekin-6 Level (IL-6) 
Df 16 
Control Variables: CD4 (cells/mm3) and VL (copies/mL)  
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Specific Aim 4 
Specific aim four was to determine the agreement or repeatability between the quality of 
life measurements in asymptomatic HIV-seropositive African American women experiencing 
HIV-related sleep disruption. 
Research Question 4: What is the agreement between the Quality of Life Index and the Quality 
of Life Visual Analogue Scale? 
In order to address specific aim 4, Bland-Altman agreement analysis was used to 
determine the agreement between the Quality of Life Index (QLI) and each of the days of 
Quality of Life Visual Analogue Scale (VAS-Q).   
Agreement Analysis: Quality of Life Index and Quality of Life Visual Analogue Scale Day 1 
A 95% confidence interval calculated a lower limit of agreement -2.358 to -1.002 and an 
upper limit of agreement 1.002 to 2.358 in QLI and QOL Day 1 scores. Thus, the 95% 
confidence interval for either the lower and upper limit of agreement was as wide as 1.36 
standard deviations under a standard normal curve. This width is less than 2 standard deviations, 
and thus, the intervals were small enough to imply good agreement between the two methods. 
Descriptive statistics of the differences in QLI and QOL Day 1 scores is presented in Table 5.17 
and a scatter plot in Figure 5.16.  
Table 5.17. Agreement Analysis: QLI vs. QOL Day1 
Descriptive Statistics 
 N Mean Std. Deviation 
 Statistic Statistic Std. Error Statistic 
DIFFQLIQOL1 20 14.9180 0.91503 4.09216 
ZDIFFQLIQOL1 20 0.0000 0.18740 0.83808 
Valid N (listwise) 20    	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Figure 5.16. Agreement Scatter plot QLI vs. VAS-Q Day 1  
Agreement Analysis: Quality of Life Index and Quality of Life Visual Analogue Scale Day 2 
A 95% confidence interval calculated a lower limit of agreement -3.300 to -1.400 and an 
upper limit of agreement 1.400 to 3.300 in QLI and QOL Day 2 scores. Thus, the 95% 
confidence interval for either the lower and upper limit of agreement was as wide as 1.90 
standard deviations under a standard normal curve. This width is less than 2 standard deviations, 
and thus, the intervals were small enough to imply good agreement between the two methods. 
Descriptive statistics of the differences in QLI and QOL Day 2 scores is presented in Table 5.18 
and a scatter plot in Figure 5.17.  
Table 5.18. Agreement Analysis: QLI vs. QOL Day2 
Descriptive Statistics 
 N Mean Std. Deviation 
 Statistic Statistic Std. Error Statistic 
DIFFQLIQOL2 20 15.0030 1.10385 4.93659 
ZDIFFQLIQOL2 20 0.0000 0.26242 1.17356 
Valid N (listwise) 20    
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Figure 5.17. Agreement Scatter plot QLI vs. VAS-Q Day 2  
Agreement Analysis: Quality of Life Index and Quality of Life Visual Analogue Scale Day 3 
A 95% confidence interval calculated a lower limit of agreement -2.514 to -1.066 and an 
upper limit of agreement 1.066 to 2.514 in QLI and QOL Day 3 scores. Thus, the 95% 
confidence interval for either the lower and upper limit of agreement was as wide as 1.45 
standard deviations under a standard normal curve. This width is less than 2 standard deviations, 
and thus, the intervals were small enough to imply good agreement between the two methods. 
Descriptive statistics of the differences in QLI and QOL Day 3 scores is presented in Table 5.19 
and a scatter plot in Figure 5.18.  
Table 5.19 Agreement Analysis: QLI vs. QOL Day3 
Descriptive Statistics 
 N Mean Std. Deviation 
 Statistic Statistic Std. Error Statistic 
DIFFQLIQOL3 20 14.9755 0.94119 4.20912 
ZDIFFQLIQOL3 20 0.0000 0.19987 0.89383 
Valid N (listwise) 20    
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Figure 5.18. Agreement Scatter plot QLI vs. VAS-Q Day 3  
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CHAPTER 6 
DISCUSSION 
 A preliminary investigation of HIV-related sleep disruption and quality of life among 
asymptomatic HIV-seropositive African American women of childbearing age was understudied. 
The specific aims of this study were to describe the homeodynamics of sleep and wellbeing in 
one of the fastest growing HIV populations today, as well as identify any significant 
relationships that may exist between them. This chapter presents a discussion of the research 
findings of this clinically significant sample. Study limitations, conclusions, and implication for 
practice, theory, and future research are also addressed.  
Sample Profile 
Twenty asymptomatic HIV-seropositive African American women receiving care from 
an infectious diseases clinic in the Detroit Metropolitan Area were recruited to participate in this 
study. The majority of participants in this purposeful sample were single, between the ages of 34 
and 39 years, with a Christian religious affiliation, and an average household size of three to four 
people. Most had an income of less than $10,000 per year and little exposure to higher education. 
These findings are consistent with regional HIV demographic results, as poverty in single 
female-headed households is a major contributor of the HIV/AIDs disparities seen among 
African American women (CDC, 2010).  
The sample measured slightly overweight with both the mean and median BMI over 25, 
which is the standard cut-off put forth by the WHO (http://apps.who.int/bmi/index.jsp?introPage 
=intro_3.html). Pain levels were minimal with the sample mean and median greater than one and 
two deviations lower than the tool’s mean, respectively. Almost half (45%) of the sample was in 
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the follicular phase of their menstrual cycle during the 4-day protocol, and medication allergies 
to one or more OTC and/or prescription medications were reported in 20% of the participants.  
Regarding their disease-specific medical history, the majority of the women reported 
contracting HIV through heterosexual transmission more than five years ago. Characteristic of 
asymptomatic disease, past immunologic stability was verified with only a few participants 
having had a CD4+ cell count lower than 250 cells/mm3 in the history of their disease 
progression. Most participants had had a prior viral load greater than 1000 copies/mL; and while 
some had never been on HIV medications before, the majority of the women had less than a one- 
year history of ART experience. Over half (60%) of the sample was on a current ART regimen, 
with Norvir-boosted Reyataz plus Truvada being the most common regimen.  
Less than half of the women disclosed current marijuana (30%) and tobacco (45%) use 
within the last four weeks prior to study participation. The average tobacco user smoked up to 
eight cigarettes a day for almost 14 years; while a little more than a third (35%) of the women 
were exposed to second-hand smoke in their households. More than half reported consuming 
high caffeine (90%) and alcoholic (65%) beverages regularly within the last four weeks. The 
average caffeine intake, consistent with the high caffeine consumption reported in previous HIV-
studies (Dreher, 2003), was just over three large (multi-serving size) cups per day. Most 
participants reported eating their last meal of the day between 6pm and 8pm, and their last 
liquids for the day right at bedtime. Very few reported any exercise on a regular basis.  
The majority of the sample conveyed that they truly liked to sleep; they also expressed a 
preference of sleeping in a dark, quiet environment. Over half reported sleeping alone (55%), on 
a comfortable mattress (70%), with the television on (65%), and in a room dedicated solely as a 
bedroom (80%). And while some reported sleep-related problems such as snoring, teeth 
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grinding, sleep-talking, bad dreams, and sinus trouble at night; each participant denied the use of 
any sleeping aids or sleep medications.  
Immunological Integrity 
Controlled by design, the women demonstrated current signs of stable immune system 
functioning with a relatively low risk for related symptomologies and opportunistic infections. 
This was evidenced by almost half (45%) of the sample having a current CD4+ cell count above 
500 cells/mm3 (within normal range) and no vulnerable cell counts below 250 cells/mm3. The 
sample also presented with a relatively low viral burden to enforce the acerbic effects of HIV on 
the immune system. This was evidenced by a median current viral load of 118 copies/mL. The 
sample mean was not used due to two outliers that were well over 10,000 copies/mL, 
nevertheless, almost half of the sample had an undetectable current viral load under 48 
copies/mL. In this study, CD4+ cell count had a significant association with the wake segment, 
which will be discussed further in the wake segment section below.     
Specific Aim 1 
The end-point for specific aim 1 was to provide a clinical picture of the HIV-related sleep 
disruption experienced in asymptomatic HIV-seropositive African American women, as 
manifested by the variables of sleep homeodynamics (sleep/wake rhythm, sleep quality, daytime 
sleepiness, and IL-6 rhythm). They are as follows: 
Sleep/Wake Rhythm  
Sleep Segment. Analysis of 72 continuous hours of actigraphic data showed that, as a 
group, participants slept an average of 6.4 + 1.7 hours during the night, with 45% averaging less 
than 6 hours a night. The women usually did not fall asleep until sometime after midnight, and 
the number of nighttime arousals recorded by the actigraph averaged 18.25 + 6.55 times per 
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night. The group’s sleep fragmentation index was calculated at 5.08 + 1.94; whilst the average 
sleep efficiency (81.27%) was less than the ideal 85%.  
The current study corroborated prior findings from Lee, Portillo, and Miramontes’ (2001) 
sample of 100 HIV-positive women, 59% of which were African American. They reported an 
average of 6.5 hours of sleep per night, 75% sleep efficiency, and an average number of 
awakenings of 18.7 times upon actigraphic investigation. Thirty of these original women (60% 
African American) reconfirmed the results in a subsequent intervention study, with a pre-
intervention total sleep time of 6.4 hours, 72.7% sleep efficiency, and an average of 20.6 number 
of awakenings a night (Hudson et al., 2008).  
Wake Segment. During the 12-hour daytime segments, participants were awake and 
active an average of 10.8 + 0.9 hours, however, they were likely to doze off or nap 
approximately 9 times throughout the day for a mean total of 1.3 + 0.9 hours. As a result, the 
daytime sleep percentage was 10.8% + 7.5% and the mean activity score was 11402.77. The 
activity index and acceleration index were calculated at 99.17% and 0.07%, respectively. The 
length of daytime wakefulness was positively associated with current CD4+ count in that those 
with a weak immune system were found to be awake less during the day.  
Hudson, Portillo, and Lee (2008) noted similar pre-intervention daytime sleep percentage 
findings (10.0 + 11.5%) in the sample of the 30 women mentioned above. They described those 
over 4% as being “nappers”. Perhaps the most significant finding of this current study is that 
immune status was linked to the subject’s objective daytime experience (wake segment 
variables). Which is in contrast to Lee and researchers (2001, 2012), who found CD4+ cell counts 
related to objective nocturnal variables. They reported CD4+ counts inversely associated with the 
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number of nighttime awakenings (2001), and significantly lower CD4+ counts in short sleepers 
who slept < 6 hours per night (2012).  
Sleep Quality 
Given the fact that 100% of the current sample scored between 7 and 15 on the PSQI (M 
= 9.80, SD = 2.44), the general subjective experience of sleep quality in this sample was very 
poor. Using a conservative cutoff point of 7 to identify poor sleepers, this study strongly supports 
the indication that asymptomatic HIV-seropositive African American women often suffer from 
substantial sleep disruption. Although daily mean SSQ scores somewhat declined throughout the 
course of the study, this sample demonstrated a relatively stable rhythm of subjective sleep 
quality slightly above the tool’s mean.  
Prevalence rates of poor sleep quality up to 100% have been corroborated by several 
studies (Hand et al., 2003; Phillips et al., 2006; Robbins et al., 2004); and although more recent 
PSQI scores have been a bit lower than the present group, results are consistent with that found 
in HIV-sleep studies (Lee et al., 2001; Nokes & Kendrew, 2001; Salahuddin et al., 2009).  
Daytime Sleepiness 
The study yielded a general daytime sleepiness score of 8.90 (SD = 4.38) on the ESS, 
which is indicative of normal to mild sleepiness for the tool. However, 8 (40%) women in this 
pilot study scored a 10 or above on the scale, indicating a pathological propensity to fall asleep at 
inappropriate times during the day. Observed by time, mean SSS scores yielded a rhythm with its 
lowest level of drowsiness noted at 1pm followed by a progressive increase in drowsiness 
throughout the day. Making the sample’s optimal level of alertness in the afternoon, right before 
most individuals are getting ready to experience their drowsiest time of the day (3pm). The 7pm 
score was the only score to reach above the tool’s cutoff point of 3, indicating that the group was 
	  	  
	  
118 
more likely to demonstrate symptoms of sleep debt in the evening. Interestingly, discrepancies 
were noted between actigraphy data and SSS scores, and will be further discussed in the studies 
limitation section. Observed by day, mean SSS scores had a narrow range and were all less than 
the cutoff, indicating that the overall daily average of drowsiness was stable and within normal 
limits over each of the three days analyzed in this protocol.  
The fact that the women experienced and perceived such disrupted sleep patterns during 
the night, yet did not perceive an excessively abnormal amount of daytime sleepiness is a 
particularly interesting finding. It might easily be explained by looking at the sample’s 24-hour 
total sleep time, which calculates to about 7.66 hours of sleep per 24-hour day. This data 
suggests that the participants were able to make up, in the daytime, whatever sleep they lacked 
during the night, getting a little more than seven and a half hours of sleep total per day.  
IL-6 Rhythm 
Human IL-6 Immunoassay. Although four time-specific plasma IL-6 levels cannot 
provide an accurate depiction of a comprehensive IL-6 circadian rhythm, the goal was to get a 
sense of whether the sample’s rhythm matched the peaks and troughs described as “normal” in 
the literature. Observed by time, mean plasma IL-6 levels demonstrated a slight progressive 
decline until the last time point, which showed a minor increase. These findings were atypical, 
yet expected due to HIV-related dysregulation described in the literature. Further examination 
revealed that only 4 (20%) of the 20 participants had a diurnal-like plotting as described by 
Alesci (2005) and Vgontzas (1999, 2005). Perhaps the most unexpected finding in this study, 
however, was that the average IL-6 level for the group was 2.03 pg/mL.  
Current IL-6 levels were quite a bit lower than that found in Honda’s study (1990) of 18 
asymptomatic HIV-seropositive individuals (M = 55.5 pg/mL). Then again, more recent studies 
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have noted levels similar to that of the current sample (Bastard et al., 2012; Fumaz et al., 2012). 
It is also possible that the racial/ethnic variations found by Míguez and researchers (2012) may 
explain the low levels in this current African American sample.  
Specific Aim 2 
The end-point for specific aim 2 was to provide a depiction of the sense of wellbeing in 
asymptomatic HIV-seropositive African American women experiencing HIV-related sleep 
disruption, as manifested by quality of life. 
Quality of Life 
Consistent with other asymptomatic samples like Mellors and associates (1997), the 
general perception of quality of life in this preliminary work was well above the tool’s mean for 
satisfaction and importance (sample mean = 21.28, SD = 5.14). In fact, only 2 (10%) participants 
scored below the tool’s mean of 15, while 12 (60%) participants scored higher than one standard 
deviation above the tool’s mean. Comparatively, the group mean was also higher than Yang’s 
(2003) sample mean of 18.50 (SD = 4.30). The sample also demonstrated a consistent and stable 
daily rhythm of subjective quality of life above the tool’s mean.  
Specific Aim 3 
The end-point for specific aim 3 was to explore potential links between specific variables 
of sleep homeodynamics and wellbeing while accounting for the effects of immunological 
integrity in asymptomatic HIV-seropositive African American women experiencing HIV-related 
sleep disruption. Due to lack of significance, no partial correlation was found between 
actigraphic down sleep efficiency (DSE) and the Quality of Life Visual Analogue Scale (VAS-
Q). Thus, objective sleep was not associated with the daily perception of quality of life in this 
sample. Due to lack of significance, no partial correlation was found between the Subjective 
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Sleep Quality Questionnaire (SSQ) and the Quality of Life Visual Analogue Scale (VAS-Q). 
Thus, daily subjective sleep quality was not associated with the daily perception of quality of life 
in this sample. Due to lack of significance, no partial correlation was found between the Stanford 
Sleepiness Scale (SSS) and the Quality of Life Visual Analogue Scale (VAS-Q). Thus, daily 
subjective daytime sleepiness was not associated with the daily perception of quality of life in 
this sample. Due to lack of significance, no partial correlation was found between the average 
IL-6 level (IL-6) and the Quality of Life Visual Analogue Scale (VAS-Q). Thus, cytokine level 
was not associated with the daily perception of quality of life in this sample.  
So, no significant associations were found between any of the specified study variables 
and the daily perception of quality of life using partial correlation analysis accounting for the 
effects of immunological integrity. Additionally, no significant associations were found between 
any of the specified study variables and the daily perception of quality of life using simple linear 
correlation analyses either. Yet, the women perceived a positive sense of quality of life. One 
could speculate that the sample was not large enough to be able to demonstrate significant 
correlations between the variables. It may also be that the variables chosen to represent the 
constructs need to be reevaluated, or at least tested. 
Specific Aim 4 
The end-point for specific aim 4 was to explore whether a 1-item quality of life 
instrument provided a comparable representation of the sense of wellbeing as a 66-item quality 
of life instrument in asymptomatic HIV-seropositive African American women experiencing 
HIV-related sleep disruption. Due to adequate interval widths, an agreement was found between 
the Quality of Life Index (QLI) and the Quality of Life Visual Analogue Scale (VAS-Q). Thus, 
in hopes of decreasing assessment burdens in this population, the short questionnaire may be 
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used with confidence in place of the long questionnaire. It is very important to be mindful of the 
assessment burden of research studies involving this particular population, especially when 
seeking thoughtful and accurate data.  
Study Limitations 
This preliminary study implemented a cross-sectional, descriptive correlation design to 
gather baseline data regarding HIV-related sleep disruption experienced by an underrepresented 
subpopulation of those living with HIV. Although appropriate, utilization of such a low-level 
study design is not without restrictions. Cross-sectional studies are limited in that they do not 
permit one to draw conclusions regarding causal relationships between variables of interest or 
confirm the direction for causality of the relationships observed. They are also limited when 
considering the notion of change over time. Cross-sectional studies provide only a snapshot, and 
thus sacrifice issues related to chronicity, recurrence, progression of disease, or even long-term 
clinical significance. Therefore, data from the current study should be interpreted cautiously. 
The exploratory nature of this study design involves significance testing of multiple 
correlations, which introduces the potential for a false discovery rate as described by John D. 
Storey (2003). A false discovery rate is the proportion of relationships that falsely appear 
statistically significant due to random error or some artifact of random variation. This study did 
not control or adjust for this multiple comparisons hazard, and must then acknowledge that when 
enough relationships are tested, a certain portion of them will falsely appear as statistically 
significant. Therefore, statistically significant relationships in this study should also be 
interpreted cautiously.  
The sample for the present study was limited in size by design to 20 participants, thus it 
lacked statistical power and generalizability of the findings is limited. Nonetheless, the number 
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of participants is consistent with other pilot studies in the literature seeking to describe 
phenomena, while looking for trends that may warrant further investigation. The number of 
participants is also consistent with that of published sleep studies, HIV-sleep research, 
dissertation projects, and other exploratory endeavors of a biophysical nature, seeking new 
knowledge and potential significance to science. Obviously, a larger sample would be more 
advantageous; however, for a number of reasons, including time and resources, most studies of 
this nature are conducted using small samples. 
The sample was also limited by design to asymptomatic HIV-seropositive AA women, 
between the ages of 18 and 40 years, being seen at the ID clinic in Detroit, MI. Consequently, the 
results of such a convenience sample may be biased and not generalizable to any other HIV-
seropositive AA women, specifically those with symptomatic disease, those seeking treatment 
from private-practice clinics, or those vulnerable to not seeking treatment at all. The fact that the 
entire sample was recruited from one healthcare clinic indicates that these women may somehow 
be distinct in their circumstances and not truly representative of the overall subpopulation. A 
randomly selected sample may have strengthened the design of the study; however, this is not 
usually possible, especially when looking to explore a specific phenomenon. A relevant 
comparison group of comparable HIV-seronegative African American women might have also 
been used to strengthen the design of the study; however, the goal of this preliminary effort was 
to gain as much baseline data as possible related to the phenomenon of interest.  
Despite the intricate theoretical underpinnings used in the development of this study, the 
variables chosen to represent the constructs of sleep homeodynamics, immunological integrity, 
and wellbeing may not be comprehensive. This is a potential threat to the construct validity of 
this study. However, the flexibility of the conceptual framework allowed room for scholarly 
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interpretation and a selection of variables that held significance in the literature. The variables 
chosen in this study were found to have consequence in both the sleep and the HIV literature. 
Due to funding constraints, CD4+ cell count and HIV RNA viral load values were 
obtained via chart abstraction from the most recent blood collection documented in the 
participant’s medical chart. These values were from a single time-point prior to recruitment and 
data collection, and thus, may not be reflective of the values at the time of the study. The average 
timing of blood collection for the sample was approximately 3 months prior to enrollment into 
the study, which is congruent with the standard of care for monitoring immune function every 3-
4 months. Additionally, with the chronic nature of the asymptomatic phase, it is common 
practice in HIV studies with a limited budget to assume that the CD4+ cell count and the HIV 
RNA viral load will not vary significantly within that short period of time.    
Although the use of wrist actigraphy is becoming an increasingly popular method for 
estimating sleep and sleep patterns, it is limited in that it is only able to measure movement and 
not actual sleep or wake itself. From the movement, sleep-wake inferences are made with an 
understanding of the inability to discern true sleep from quiet rest. Actigraphy is also limited in 
that it requires correlation with a sleep log in order to obtain a true calculation of some sleep 
measures, such as sleep latency. Without a sleep log, it is impossible to calculate sleep latency 
since the time that the participant actually laid down or went to bed is unknown. As a result, 
sleep latency in this study was substituted with minutes before sleep onset (total minutes after 
2100 hours until the first continuous block of at least 20 minutes of scored sleep). Another 
possible limitation this study faced is that it did not by design restrict the 72 hours of continuous 
monitoring to weekdays only, which might have caused some variability within the study. 
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However, no significant statistical difference was found between those whose protocol 
monitoring period included weekend days and those whose did not.   
Lastly, cognitive bias was a potential threat to the integrity of this study. This happens if 
participants fail to provide accurate answers to self-report questionnaires. Accuracy often 
depends on, but is not limited to the interpretation of the instrument, the speed with which it is 
completed (back filling verses real-time answers), and the participant’s estimation or recall 
abilities, especially after a substantial amount of time has passed. Misinformation of true 
experiences may also be provided if the respondents are in denial, feel embarrassed of the truth, 
or if they complete the instruments based on how they perceive the researcher wants them to 
respond (Kerlinger & Lee, 2000). In effort to strengthen the results of the study, each 
questionnaire was reviewed with the subject, as well as written instructions and contact 
information for the investigator provided in the event that the participant had any questions. The 
goal of creating a true clinical picture, a reflection uniquely theirs (an underrepresented 
subpopulation) was used to reinforce the importance of timely and accurate self-reporting. Yet, 
some inconsistencies between the objective actigraphic assessments and the daily subjective 
Stanford Sleepiness Scale (SSS) were found. For example, a participant might have self-reported 
feeling wide-awake and active on the 1pm SSS, yet the corresponding actigraphic data from that 
day’s wake segment clearly demonstrates minutes scored as sleep around that same particular 
time point.  
Despite serious constraints, the current research was exploratory in nature, and the 
significance of the contributions it has provided is principal.  
Conclusion 
	  	  
	  
125 
In general, this sample consisted of poor, uneducated, slightly overweight, single African 
American women in their 30’s; that had contracted HIV from heterosexual contact more than 
five years ago. Most of the women slept alone, usually with the television on, and reported a 
moderately high caffeine intake to keep them going throughout the day. Furthermore, they were 
immunologically stable; with CD4+ counts associated with wake variables.  
The women’s objective sleep experience demonstrated severe sleep disruption and 
disorganized sleep patterns with almost half of the night spent awake. Their self-reported 
experience of sleep quality, both general and daily pattern, was consistent with that of substantial 
sleep disruption. The daily sleep quality pattern, however, did seem to be a bit less obtrusive. 
The women’s objective measurement of daytime function correspondingly showed to be 
disrupted as well; with frequent dozing throughout the day verifying the inadequacy of their 
nocturnal sleep. Interestingly enough, their self-reported experience of daytime sleepiness, both 
general and daily pattern, was within normal limits. While IL-6 levels confirmed a rhythm-like 
nature, such levels were not consistent with the normal peaks and troughs of the diurnal pattern 
described in the literature. In fact, average IL-6 levels were much lower than that found in 
normal controls and other asymptomatic HIV-seropositive samples.   
General quality of life, in agreement with the daily pattern of quality of life, indicated a 
positive sense of general wellbeing in this sample. However, the daily pattern of quality of life 
measure was not associated with the daily pattern of sleep efficiency, subjective sleep quality, 
daytime sleepiness, or IL-6 levels when controlling for CD4+ cell count and HIV RNA viral 
load. So, despite the severe disruption in sleep homeodynamics, the young women’s sense of 
wellbeing remained intact. This finding supports Levine’s Conservation Theory, which 
postulates that other factors (ie. personal and social) may be at play, helping to maintain 
	  	  
	  
126 
successful adaptation and conserve (or keep together) wholeness even in the face of disruption. 
The data also suggests that it is plausible that the total sleep time that the women were able to 
obtained during a full 24-hour period was adequate enough to sustain their sense of wellbeing.  
Implications for Practice  
Implications for practice reflect the study findings related to sleep disruption in 
asymptomatic HIV-seropositive African American women of childbearing age. There were 
several clinically meaningful findings in this study that hold significant implications for HIV 
healthcare practitioners. A major finding in this study was the overwhelming presence of 
disrupted sleep/wake patterns in this sample. This supports the fact that HIV-related sleep 
disruption is a frequently encountered problem, even in asymptomatic HIV disease, yet none of 
these women were being treated for such disruptions to ensure that quality of life remains intact. 
The lack of diagnosis and treatment of short sleepers and nappers suggests inadequate screening 
practices, undeveloped treatment modalities, and/or insufficient communication with HIV care 
providers. Therefore, it is imperative to implement routine assessments focused on sleep 
disruption as part of every patient’s holistic nursing assessment in HIV care, and document as 
such. Initial emphasis should be placed on environmental and sleep hygiene factors, given their 
potential impact on sleep duration and sleep fragmentation. Instruments, similar to the ones used 
in this study, may be incorporated at different phases in the comprehensive health maintenance 
plan with protocols designed to include appropriate referrals and treatment modalities.  
The study also assessed a host of demographic, psychosocial, and behavioral 
characteristics that have been associated with sleep/wake patterns in the literature. Clinicians 
must be able to appreciate the complexity of the multidimensional nature of the disparities that 
African American women living with HIV face. Findings also reinforce the importance of 
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routine comprehensive assessments for potential vulnerabilities. Such factors may or may not be 
assessed at a regular clinical appointment, however, such inquiry should be as routine as 
obtaining laboratory evaluations. That way, patient education regarding risk-taking behaviors 
and lifestyle modification strategies can be tailored to fit the patient’s needs as they arise. 
The completion of study instruments led many patients to truly reflect upon their life 
circumstances and sleep/wake experiences since their HIV diagnosis, thereby opening 
communication with the clinical researcher. This type of introspection needs to be facilitated in 
clinical practice. Thus, study findings support the importance of early patient education 
regarding potential changes in sleep/wake patterns, how to communicate concerns with their 
provider, along with practice interventions aimed to support healthy sleep hygiene specific to this 
population.  
Contributions to Nursing Science 
 Published sleep literature fails to depict much advancement in nursing science through 
the examination of explicit exemplars guided by conceptual nursing frameworks. This small-
scale research effort was the first to systematically explore the objective and subjective, as well 
as the general and daily experience of HIV-related sleep disruption from within the ontological 
grounding of a specific philosophical nursing perspective. The conceptual framework of 
Levine’s Conservation Model was the foundation used to substruct a middle-range theory, the 
Sleep Conservation Model, from which the empirical structure and defining limits of this study 
were delineated. Utilization of such a substantive model not only provides the scientific rationale 
for the dynamics of the human health experience being studied and the essential dimensions for 
scholarly research rooted in the nursing discipline; but it also facilitates the synthesis of 
relationships between theory, measurement, and data interpretation phases of the research 
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process (Grant, Kinney, & Davis, 1993; Moody, 1990). Findings from this investigation supports 
the integration of Levine’s Conservation Model as a useful disciplinary research perspective, 
which has great potential to generate nursing knowledge needed to continue to promote societal 
priorities of health and wellbeing. Therefore, this study was able to fill a gap in nursing science 
by establishing an underlying validity in the application of Levine’s Conservation Model in the 
area of sleep research. 
Published literature also fails to depict much advancement in nursing science through the 
use of Levine’s Conservation Model within the context of specific underrepresented populations. 
This pilot study serves as a preliminary investigation for the utilization of the Conservation 
Model as an organizing framework to explore the complexities of asymptomatic HIV-
seropositive African American women as they relate to HIV-related sleep disruption. Mapping 
the diverse pathways of key biological and psychosociobehavioral measures specific to a 
population provides the very foundation needed for the formulation of innovative health-
promoting interventions specific to that population. Findings from this inquiry support the need 
for the systematic assessment of unique inherited and acquired vulnerabilities that may 
contribute to HIV-related sleep disruption in asymptomatic HIV-seropositive African American 
women of childbearing age. Therefore, this study was able to fill a gap in nursing science by 
establishing an underlying validity in the utilization of Levine’s Conservation Model with an 
underrepresented population in the midst of great disparity. 
Recommendations for Future Research 
Given the complexity of the phenomenon, uniqueness of the population, and vastness of 
the theory, prospects for continued research are numerous. Recommendations for future research 
to extend the preliminary work reported here are discussed in this section. 
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Much more work lies ahead before scientists can truly understand all the dynamics of 
HIV-related sleep disruption. Larger cross-sectional and longitudinal studies are needed to 
expound upon and refine the variables of sleep homeodynamics and wellbeing in asymptomatic 
HIV-seropositive African American women. Researchers need to continue to search for 
significant trends and relationships among the sleep/wake rhythm, sleep quality, daytime 
sleepiness, the IL-6 rhythm, and quality of life in this population. Future studies into the potential 
roles and predictive nature of various confounding variables may prove beneficial, in helping to 
identify those at high-risk for this sleeping disorder. Comparison protocols with matched-control 
groups may help with drawing conclusions in such observational studies where the researcher 
has little or no control. Sleep logs will need to be incorporated into the protocol for publication 
goals. Further investigation into the suboptimal IL-6 levels is warranted, and efficacies of 
culturally suitable interventions to treat this disorder and strategies that foster better sleep 
hygiene have not yet been tested.  
The exploration of cultural differences is imperative, especially given the multiple 
disparities that influence African American women. For example, on the QLI, this group of 
African American women seemed to place very low importance on satisfaction with their 
immediate family and/or significant other, yet quality of life scores were generally high. It would 
be prudent to explore whether this truly is a culturally-driven difference or just unique to this 
group of women. Greater understanding will help when trying to tailor interventions specific to 
this population. Sleep homeodynamics should also be explored within a family context. Findings 
from this present study suggest that it is likely that social and family dynamics are essential in 
understanding the various cultural elements affecting sleep in this population.  
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The development of the Sleep Conservation Model is still in its early phases, so future 
studies, which utilize path analysis or structural equation modeling (SEM), will not only allow 
for the testing of the model, but its refinement as well. SEM is beneficial in that it is a statistical 
technique, which allows for the analysis of complex models with multiple relationships to be 
tested simultaneously. It also allows for numerous indicators of the theoretical constructs and 
incorporates measurement error in the variables. So, all the relationships between the variables of 
sleep homeodynamics and wellbeing, as well as those of immunological integrity, psychological 
integrity, and relational integrity will be good-fit tested simultaneously. Further attention will be 
given to the refinement of the model. This is possible through the model generating techniques of 
SEM that permits new relationships to emerge from the data. The goal is to end up with a 
testable and parsimonious middle-range theory substructed from Levine’s Conservation Model 
framework. 
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APPENDIX C 
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APPENDIX L 
CORRELATIONS FOR THE VARIABLES OF IMMUNOLOGICAL INTEGRITY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*. Correlation is significant at the 0.05 level (2-tailed). 
**.Correlation is significant at the 0.01 level (2-tailed). 
 
 
 
 
Correlations for Immunological Integrity (N = 20) 
Variables 
 
CD4 
(cells/mm3) 
VL 
(RNA copies) 
Pearson Correlation .180 .278 Down Sleep Minutes 
Sig. (2-tailed) .448 .236 
Pearson Correlation -.213 -.077 Down Minutes Before Sleep Onset 
Sig. (2-tailed) .368 .747 
Pearson Correlation -.111 .311 Down Wake Episodes 
Sig. (2-tailed) .643 .183 
Pearson Correlation -.179 -.278 Down Wake Minutes 
Sig. (2-tailed) .449 .236 
Pearson Correlation .180 .278 Down Sleep Percentage 
Sig. (2-tailed) .449 .236 
Pearson Correlation .138 .276 Down Sleep Efficiency 
Sig. (2-tailed) .562 .238 
Pearson Correlation -.203 .011 Down Sleep Fragmentation Index 
Sig. (2-tailed) .391 .963 
Pearson Correlation .607** -.156 Up Wake Minutes 
Sig. (2-tailed) .005 .510 
Pearson Correlation .045 -.241 Up Activity Mean 
Sig. (2-tailed) .852 .306 
Pearson Correlation -.385 .388 Up Sleep Episodes 
Sig. (2-tailed) .094 .091 
Pearson Correlation -.605** .157 Up Sleep Minutes 
Sig. (2-tailed) .005 .509 
Pearson Correlation -.605** .157 Up Sleep Percentage 
Sig. (2-tailed) .005 .509 
Pearson Correlation .218 -.036 Up Activity Index 
Sig. (2-tailed) .355 .879 
Pearson Correlation -.383 .108 Up Acceleration Index 
Sig. (2-tailed) .096 .652 
Pearson Correlation .22 -.376 Pittsburgh Sleep Quality Index 
Sig. (2-tailed) .334 .102 
Pearson Correlation -.074 .242 Subjective Sleep Quality Questionnaire 
Sig. (2-tailed) .756 .303 
Pearson Correlation -.214 -.025 Epworth Sleepiness Scale 
Sig. (2-tailed) .366 .916 
Pearson Correlation .000 -.224 Stanford Sleepiness Scale 
Sig. (2-tailed) .998 .341 
Pearson Correlation .303 -.141 IL-6 Level 
Sig. (2-tailed) .195 .553 
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APPENDIX M 
SUMMARY GRAPHS FOR STUDY VARIABLE RHYTHMS 
 
Summary for the Daily Rhythms 
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BACKGROUND: HIV-related sleep disruption is a common complaint of persons with 
HIV infection. With the demographical shifts, African American women have now emerged as 
one of the fastest growing HIV populations today, yet they remain a vulnerable and 
underrepresented population in the sleep literature.  
OBJECTIVE: The purpose of this pilot study was to explore the dynamics of HIV-related 
sleep disruption and wellbeing in asymptomatic HIV-seropositive AA women of childbearing 
age within the context of a holistic, theoretical substruction from Myra Levine’s Conservation 
Model (1967). The rationale for the proposed study was to provide a foundation of both the 
objective and subjective experience of HIV-related sleep disruption, which as a stressor can 
affect wellbeing.  
METHODS: A descriptive correlational design was used to examine the immunological 
integrity, sleep/wake rhythm, sleep quality, daytime sleepiness, IL-6 rhythm, and quality of life 
in 20 asymptomatic HIV-seropositive African American women receiving care at Wayne State 
University Physicians Group Infectious Diseases Clinic in Detroit, MI. In this 4-day protocol, 
measures included CD4+ cell count, HIV RNA viral load, wrist actigraphy, Pittsburgh Sleep 
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Quality Index, Subjective Sleep Quality Questionnaire, Epworth Sleepiness Scale, Stanford 
Sleepiness Scale, plasma IL-6, Quality of Life Index, and Quality of Life Visual Analogue Scale. 
RESULTS: Both the objective and subjective experience of sleep demonstrated severe 
sleep disruption and disorganized sleep patterns. Nearly half (45%) of the sample slept < 6 hours 
per night, usually not falling asleep until sometime after 12 midnight. Objective daytime 
functioning was also disrupted with frequent dozing (> 9 sleep episodes) noted throughout the 
day. Self-reported daytime sleepiness was inconsistent with the objective assessment and was 
within normal limits. The sample’s mean IL-6 level was 2.03 pg/mL, which is much lower than 
that reported in other asymptomatic samples or normal controls. Quality of life measures 
indicated a positive sense of wellbeing, but the daily pattern of quality of life was not associated 
with the daily pattern of sleep efficiency, subjective sleep quality, daytime sleepiness, or IL6 
levels when controlling for CD4+ cell count and HIV RNA viral load. And lastly, the 1-item 
quality of life scale showed agreement with the 66-item quality of life index using Bland-Altman 
agreement analysis, which may help in decreasing participant burden in clinical trials enrolling 
this population.  
CONCLUSION: This sample suffered from severe HIV-related sleep disruption, as 
evidenced by an average sleep time of 6.4 hours per night and frequent dozing throughout the 
day. Despite this disruption, the sample perceived a positive sense of quality of life. These results 
provide further evidence that future studies exploring efforts to improve sleep and daytime 
functioning in asymptomatic HIV-seropositive African American women are essential in order to 
maintain quality of life and wellbeing in this population.  
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